Professional Documents
Culture Documents
www.kalbe.co.id
IDX: KLBF
Daftar Isi
Table of Contents
4 Strategi & Pencapaian 2011
2011 Strategy & Achievement
6 Kinerja 2011
2011 Performance
8 Ikhtisar Keuangan
Financial Highlights
10 Ikhtisar Saham
Stock Highlights
12
40
Profil
Perusahaan
Company
Profile
Laporan Manajemen
Management Report
42 Informasi Perseroan
Corporate Information
44 Sekilas Kalbe Farma
Kalbe Farma at a Glance
46 Divisi Usaha
Business Divisions
48 Struktur Organisasi
Organization Structure
49 Struktur Kepemilikan
Perseroan dan Entitas Anak
Shareholding Structure of the
Company and Subsidiaries
50 Visi, Misi, Motto dan Nilai
Vision, Mission, Motto and
Values
52 Dewan Komisaris
Board of Commissioners
54 Direksi
Board of Directors
56 Komite Audit
Audit Committee
57 Komite Nominasi
Nomination Committee
106
112
116
Tinjauan Industri
Industrial Review
Tinjauan Usaha
Business Review
Divisi Obat Resep
Prescription Pharmaceuticals
Division
Divisi Produk Kesehatan
Consumer Health Division
Divisi Nutrisi
Nutritionals Division
Divisi Distribusi dan Logistik
Distribution and Logistics Division
93
Seluruh gambar inspirasi dan tradisi Indonesia adalah karya Deniek G. Sukarya
All Indonesian inspirational and traditions images are copyrights Deniek G. Sukarya
57 Komite Remunerasi
Remuneration Committee
58 Komite GCG
GCG Committee
60 Komite Risiko Usaha
Business Risk Committee
61 Kepala Unit Audit Internal
Head of Internal Audit Unit
61 Sekretaris Perusahaan
Corporate Secretary
62 Sumber Daya Manusia
Human Resources
78 Informasi Pemegang Saham
Shareholders Information
80 Entitas Anak
Subsidiaries
82 Daftar Prinsipal
Principals List
84 Prestasi dan Penghargaan
Recognition and Awards
86 Jejak Langkah
Milestones
88 Peristiwa Penting 2011
Event Highlights 2011
142
144
151
159
160
Tinjauan Keuangan
Financial Review
Laporan Laba Rugi Komprehensif
Konsolidasian
Consolidated Comprehensive
Statements of Income
Laporan Posisi Keuangan
Konsolidasian
Consolidated Statements of
Financial Position
Likuiditas dan Struktur
Permodalan
Liquidity and Capital Structure
Laporan Arus Kas
Statements of Cash Flow
106
238
Tanggung Jawab
Sosial Perusahaan
Corporate Social
Responsibility
162
163
163
163
164
164
Pemasaran
Marketing
Produksi
Manufacturing
Investasi Barang Modal
Capital Expenditure
Ikatan Material untuk
Investasi Barang Modal
Material Ties for Investment of
Capital Goods
Kebijakan Dividen
Dividend Policy
Realisasi Penggunaan Dana Hasil
Penawaran Umum
Usage of Proceeds from
Rights Issue
165
165
165
166
167
208
209
214
215
215
221
222
223
224
226
226
226
227
228
230
231
Audit Eksternal
External Audit
Manajemen Risiko
Risk Management
Kepatuhan
Compliance
Aksi Korporasi
Corporate Actions
Sekretaris Perusahaan
Corporate Secretary
Akses Informasi dan Data Perseroan
Access to Information and
Company Data
Kebijakan Teknologi Informasi
Information Technology Policy
Opsi Saham
Stock Option
Perkara Litigasi
Litigation
Benturan Kepentingan
Conflict of Interest
Pemberian Dana untuk
Kegiatan Sosial Politik
Funding for Political and Social
Activities
Komitmen pada Konsumen
Commitment to Consumers
Etika
Ethics
Whistleblowing System
Whistleblowing System
Implementasi GCG di Anak
Perusahaan
GCG Implementation in Company's
Subsidiaries
Pengembangan GCG di Tahun 2012
GCG Development in Year 2012
263
Laporan Keuangan
Konsolidasian 2011
2011 Consolidated
Financial Statements
Perjalanan
Menuju Kehidupan
yang Lebih Baik
Journey Towards a Better Life
45 tahun perjalanan Kalbe, bukanlah perjalanan yang singkat.
Kalbe terus tumbuh dan berkembang dalam
mewarnai dan memaknai kesehatan bangsa Indonesia.
Kalbe terus melangkah maju menuju era baru, melakukan upaya perubahan,
sebuah transformasi menuju pertumbuhan jangka panjang yang berkesinambungan.
Dengan didukung inovasi dan kompetensi sumber daya kami,
Kalbe bercita-cita menjadi perusahaan kesehatan terkemuka,
dengan pertumbuhan yang berkesinambungan dan memberikan makna bagi masyarakat
INOVASI UNTUK
KEHIDUPAN
YANG LEBIH BAIK
45KALBE
INNOVATION FOR BETTER LIFE
tahun
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Strategi &
Pencapaian 2011
2011 Strategy & Achievement
Produksi
Production
160
158
133
120
120
108
80
40
0
2008
2009
2010
2011
54%
Peningkatan jumlah
inisiatif perbaikan
Increase in number of
improvement initiatives
Performance
Highlights
Management
Report
Kinerja
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
2011
Performance
6.7 %
Rp 10.91
7.4 %
Rp 5.55
15.2 %
Rp 1.48
15.2 %
Rp 158
Penjualan Bersih
Net Sales
Laba Kotor
Gross Profit
Laba Bersih
Net Income
Triliun Trillion
Triliun Trillion
Triliun Trillion
Divisi Nutrisi
Nutritionals Division
Rp 2.78
Rp 1.84
Rp 2.42
Rp 3.87
Triliun Trillion
Triliun Trillion
Triliun Trillion
Triliun Trillion
7.7 %
8.3 %
5.5 %
6.0 %
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Ikhtisar Keuangan
Financial Highlights
Angka-angka pada seluruh tabel dan grafik dalam Laporan Tahunan ini menggunakan notasi Bahasa Inggris
Numerical notations in all tables and graphs in this Annual Report are in English
Dalam juta Rupiah, kecuali dinyatakan lain
In million of Rupiah, unless otherwise stated
2011
2010
2009
2008
2007
2006
2005
10,911,860
10,226,789
9,087,347
7,877,366
7,004,910
6,071,550
5,870,939
5,360,687
5,060,404
4,575,407
4,073,726
3,453,279
2,972,908
2,907,625
Laba Kotor
Gross Profit
5,551,173
5,166,386
4,511,940
3,803,640
3,551,631
3,098,642
2,963,314
1,987,259
1,770,435
1,471,072
1,178,022
1,158,667
1,090,081
1,015,565
Laba Bersih
Net Income
1,482,237
1,286,330
929,004
706,822
705,694
676,582
626,117
1,539,721
1,346,098
n/a
n/a
n/a
n/a
n/a
9,375
9,374
9,577
9,755
10,090
10,156
10,156
158
137
97
72
70
67
62
*Penyajian Laba Komprehensif Tahun Berjalan berdasarkan Pernyataan Standar Akuntansi Keuangan (PSAK) No. 1 (Revisi 2009) yang mulai diterapkan tanggal 1 Januari 2011
*Presentation of Comprehensive Income for the Year based on the Statement of Financial Accounting Standards (PSAK) No. 1 (Revised 2009) adopted on January 1, 2011
Neraca
Balance Sheets
Aktiva Lancar
Current Assets
5,956,123
5,037,270
4,701,893
4,168,055
3,760,008
3,321,278
3,559,836
113,871
5,316
62,596
124,748
175,833
259,701
882,993
Jumlah Aktiva
Total Assets
8,274,554
7,032,497
6,482,447
5,703,832
5,138,212
4,624,619
4,633,399
Kewajiban Lancar
Current Liabilities
1,630,589
1,146,489
1,574,137
1,250,372
754,629
658,760
903,516
140,706
25,344
340,678
405,504
314,118
378,590
1,019,747
Jumlah Kewajiban
Total Liabilities
1,758,619
1,260,361
1,691,512
1,358,990
1,121,188
1,080,171
1,821,584
4,325,535
3,890,781
3,127,755
2,917,683
3,005,379
2,662,518
2,656,320
Jumlah Ekuitas*
Total Equity*
6,214,818
5,373,784
4,310,438
3,622,399
3,386,862
2,994,817
2,333,172
Jumlah Pinjaman
Total Debts
*Sesuai dengan PSAK No.1 (Revisi 2009) Kepentingan Non-pengendali pada tanggal 31 Desember 2010 dan 2009 telah direklasifikasi sebagai bagian dari Ekuitas
*Based on PSAK No.1 (Revised 2009) Non-controlling Interest as of December 31, 2010 and 2009 have been reclassified as part of the Equity
50.87
50.52
49.65
48.29
50.70
51.04
50.47
17.91
18.29
14.33
12.39
13.73
14.63
13.51
23.85
23.94
21.55
19.51
20.84
22.59
26.84
365.27
439.36
298.70
333.35
498.26
504.17
394.00
2.26
0.47
7.88
11.19
9.27
12.64
43.71
1.7
0.36
5.24
7.11
6.11
8.19
22.01
Rasio Lancar
Current Ratio
10,912
5,166
9,087
1,286
4,512
7,877
5,871
1,482
5,551
10,227
6,072
7,005
2,963 3,099
3,552
3,804
929
626
158
137
677
706
707
26.84
22.59
20.84
21.55
23.94 23.85
43.71
19.51
97
62
67
70
72
12.64
9.27
11.19
7.88
0.47
2.26
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Ikhtisar Saham
Stock Highlights
4.000
80,000,000
3.000
60,000,000
2000
40,000,000
1000
20,000,000
0
Jan
Feb
Mar
Apr
10
May
Jun
Jul
Aug
Sept
Oct
Nov
Dec
Tertinggi
Highest
(Rp)
Terendah
Lowest
(Rp)
Penutupan
Closing
(Rp)
January
3,375
2,450
2,825
23,025,476
February
3,000
2,700
2,925
8,389,778
March
3,400
2,875
3,400
16,645,652
April
3,725
3,350
3,575
15,359,950
May
3,600
3,225
3,575
14,318,167
June
3,575
3,225
3,375
9,035,800
July
3,700
3,400
3,475
16,552,119
August
3,550
2,900
3,475
9,409,289
September
3,725
2,650
3,250
11,861,750
October
3,550
2,975
3,475
8,165,452
November
3,600
3,300
3,525
5,716,568
December
3,600
3,300
3,400
4,670,095
Terendah
Lowest
(Rp)
Penutupan
Closing
(Rp)
Tertinggi
Highest
(Rp)
2010
Terendah
Lowest
(Rp)
Penutupan
Closing
(Rp)
2011
Volume Rata-rata
Transaksi Harian
Average Daily
Trading Volume (Unit)
2010
2011
Triwulan Pertama
1,900
1,290
1,870
3,400
2,450
3,400
37,439,644
16,409,694
First Quarter
Triwulan Kedua
2,150
1,620
2,100
3,725
3,225
3,375
50,780,976
12,927,811
Second Quarter
Triwulan Ketiga
2,725
2,000
2,550
3,725
2,650
3,250
24,712,100
12,726,767
Third Quarter
Triwulan Keempat
4,100
2,500
3,250
3,600
2,975
3,400
30,939,056
6,176,734
Fourth Quarter
Jumlah (Rp)
Amount (Rp)
Rp 300,000,000,000
11
12
Perjalanan
Berlanjut
demi Menciptakan
Nilai Kehidupan
The Journey Continues to Create
Value of Peoples Lives
Laporan Manajemen
Management Report
13
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
15.2%
14
Johannes Setijono
Presiden Komisaris
President Commissioner
15
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
16
Respected Shareholders,
17
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
18
19
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
20
21
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Grateful Appreciation
Thus ends the Board of Commissioners Report on the
implementation of supervisory programs throughout
2011. On behalf of the Board of Commissioners, we
express our appreciation to both shareholders and
stakeholders, who have entrusted and supported
Kalbe. To the Board of Directors and all employees,
we deliver the highest appreciation for their hard work,
tenacity and spirit in facing such a challenging year.
Johannes Setijono
Presiden Komisaris
President Commissioner
22
1 Johannes Setijono
Presiden Komisaris
President Commissioner
6
2
Santoso Oen
Wahjudi Prakarsa
Ferdinand Aryanto
Komisaris
Commissioner
Komisaris
Commissioner
Komisaris Independen
Independent Commissioner
Komisaris
Commissioner
Komisaris Independen
Independent Commissioner
23
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
108 hari
Siklus Operasional Bersih Net Operating Cycle
24
Presiden Direktur
President Director
25
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
26
Respected Shareholders,
Kinerja Perusahaan
Kinerja Kalbe tahun 2011 secara umum mencapai hasil
yang cukup baik. Hal ini dapat terlihat dari pencapaian
kinerja penjualan dan laba Perseroan yang meningkat
dibandingkan dari realisasi tahun 2010, walaupun secara
internal berada di bawah target anggaran tahun 2011.
Company Performance
Kalbes performance in 2011 marked good overall
results. This is evident from the increase in Company
sales and profitability compared to 2010, despite
failing to achieve the internal target set for year 2011.
27
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
28
29
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
30
Kendala
Sebagai pemain dalam industri farmasi dan
kesehatan, salah satu kendala utama yang dihadapi
Perseroan adalah tidak tersedianya bahan baku
produk farmasi, produk kesehatan dan nutrisi dari
dalam negeri. Industri farmasi, produk kesehatan dan
nutrisi Indonesia memiliki ketergantungan yang sangat
tinggi terhadap pasokan bahan baku dari impor, dan
karenanya menjadi rentan terhadap fluktuasi nilai
tukar Rupiah dan perubahan harga komoditas dunia.
Kendala lainnya yang dihadapi adalah terkait kondisi
infrastruktur transportasi yang kurang memadai, yang
menjadi tantangan tersendiri dalam mendistribusikan
produk Perseroan ke seluruh wilayah Indonesia.
Challenges
As a player in the pharmaceuticals and health industry,
one of the main challenges faced by the Company is
the lack of any domestic source for most raw materials
for pharmaceuticals, consumer health and nutritional
products. Historically, the Indonesian pharmaceutical,
consumer health and nutritionals industry has been
highly dependant on imported raw materials, and is
therefore vulnerable to the fluctuation of the Rupiah
exchange rate and other changes in global commodity
prices. Another challenge is related to the nations
somewhat marginal infrastructure condition, which
presents an additional challenge in distributing the
Companys products throughout Indonesia.
31
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
32
Prospek Usaha
Kondisi ekonomi Indonesia di tahun 2011 secara
keseluruhan cukup kondusif, dengan mencatat
pertumbuhan sekitar 6,5% dan diprediksi akan
terus bertumbuh positif di tahun 2012. Peningkatan
pertumbuhan ekonomi tersebut ditopang oleh
peningkatan pertumbuhan daya beli masyarakat
serta kegiatan investasi dan peningkatan ekspor
yang sejalan dengan akan semakin pulihnya ekonomi
negara-negara maju tujuan ekspor Indonesia.
Business Prospects
Indonesian economic conditions in 2011 were
generally positive, with a 6.5% growth rate, and this
is predicted to hold through 2012. Economic growth is
supported by the steady increase in purchasing power
of consumers and investment activities, as well as by
export growth, related to the recovery of developed
countries as export destinations for Indonesian goods.
Pelayanan Prima
Sebagai perusahaan yang bergerak di bidang kesehatan,
Kalbe senantiasa memberikan upaya terbaiknya dalam
rangka pemenuhan kebutuhan obat-obatan dengan
kualitas yang memenuhi standard CPOB.
Service Excellence
As a company in the health sector, Kalbe strives to
exert its best efforts to meet needs for good-quality
drugs, ones that satisfy the GMP standard.
Corporate Governance
Kalbe is fully committed to implement corporate
governance at all levels of the organization, based on
GCG regulations and requirements. To optimize GCG
33
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
34
Manajemen Risiko
Manajemen menyadari bahwa kondisi lingkungan
eksternal dan internal Perusahaan mengalami
perkembangan pesat yang diikuti dengan semakin
kompleksnya risiko kegiatan usaha sehingga
meningkatkan kebutuhan praktek GCG yang baik dan
penerapan manajemen risiko yang handal.
Risk Management
The Management realizes that the Companys external
and internal environment shift rapidly, accompanied
by increasingly complex business activity risk, thereby
heightening the need for sound GCG practices and for
excellent risk management.
35
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Laporan Direksi
Report from the Board of Directors
Grateful Appreciation
On behalf of the Board of Directors, we extend
our gratitude to the Shareholders and Board of
Commissioners of Kalbe for their wise guidance and
thoughtful counsel. We express our appreciation to
consumers, business partners and other stakeholders
for their contribution, supporting Kalbe in retaining its
reputation as an outstanding pharmaceuticals and
healthcare company.
36
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Ongkie Tedjasurja
Herman Widjaja
Vidjongtius
Presiden Direktur
President Director
Direktur
Director
Direktur
Director
Direktur
Director
Direktur
Director
37
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tanggung Jawab
Pelaporan Tahunan
Responsibility for Annual Reporting
Laporan Tahunan ini, berikut laporan keuangan dan informasi terkait lainnya, merupakan tanggung jawab
Manajemen Kalbe dan telah disetujui oleh seluruh anggota Dewan Komisaris dan Direksi dengan membubuhkan
tanda tangannya masing-masing di bawah ini:
Dewan Komisaris
Board of Commissioners
Johannes Setijono
Presiden Komisaris
President Commissioner
Santoso Oen
Komisaris
Commissioner
Ferdinand Aryanto
Komisaris
Commissioner
Wahjudi Prakarsa
Komisaris Independen
Independent Commissioner
This Annual Report and the accompanying financial statements and related financial information are the
responsibility of the Management of Kalbe and have been approved by members of the Board of Commissioners
and the Board of Directors whose signatures appear below:
Direksi
Board of Directors
Herman Widjaja
Direktur
Director
Vidjongtius
Direktur
Director
Ongkie Tedjasurja
Direktur
Director
40
Kontribusi
Kinerja demi
Mempertahankan
Pertumbuhan
Positif
Sound Contribution to
Maintain Positive Growth
Profil Perseroan
Company Profile
41
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Informasi Perseroan
Corporate Information
Nama Perusahaan Name of Company
PT Kalbe Farma Tbk
Tanggal Pendirian Establishment Date
10 September 1966
Bidang Usaha Line of Business
Farmasi dan Kesehatan
Pharmaceuticals and Healthcare
Dasar Hukum Pendirian Legal Basis
Akta No.3, tanggal 10 September 1966, dibuat dihadapan Raden Imam Soesatyo
Prawirokoesoemo, Wakil Notaris di Jakarta
Deed No.3, dated September 10, 1966, drawn up before Raden Imam Soesatyo
Prawirokoesoemo, a Deputy Notary in Jakarta
Kepemilikan (per 31 Desember 2011) Ownership (as of December 31, 2011)*
PT Gira Sole Prima
10.17%
PT Santa Seha Sanadi
9.62%
PT Diptanala Bahana
9.49%
PT Lucasta Murni Cemerlang
9.47%
PT Ladang Ira Panen
9.22%
PT Bina Arta Charisma
8.66%
Publik Public
43.37%
100.00%
Total
* Tidak termasuk saham yang dibeli kembali
Excluding treasury stock
Pabrik Factory
Kawasan Industri Delta Silikon
Jl. M.H. Thamrin Blok A3 - 1
Lippo Cikarang, Bekasi 17550,
Indonesia
Tel. (62-21) 8990 7333 - 37
Fax. (62-21) 8990 7360
42
Divisi Divisions
Divisi Obat Resep
Divisi Produk Kesehatan
Divisi Nutrisi
Divisi Distribusi & Logistik
43
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Sekilas
Kalbe Farma
Kalbe Farma at a Glance
Kalbe didirikan pada tahun 1966. Pada tahun 1991, Kalbe terdaftar di Bursa Efek Indonesia sebagai perusahaan
publik. Kalbe telah jauh berkembang dari awal mulanya sebagai usaha farmasi yang dikelola di sebuah garasi di
wilayah Jakarta Utara. Saat ini Kalbe telah menjadi perusahaan produk kesehatan publik terbesar di Asia Tenggara
yang memiliki nilai kapitalisasi pasar sebesar USD 3,9 miliar dan omset penjualan Rp 10,91 triliun pada akhir tahun
2011.
Kalbe memiliki fokus bisnis pada 4 divisi, yaitu divisi obat resep, divisi produk kesehatan, divisi nutrisi serta divisi
distribusi dan logistik. Saat ini Kalbe didukung lebih dari 15.000 karyawan termasuk 4.000 tenaga pemasaran dan
penjualan yang tersebar di seluruh wilayah Indonesia, sehingga Kalbe mampu menjangkau 70% dokter umum,
90% dokter spesialis, 100% rumah sakit, 100% apotek untuk pasar obat-obat resep serta 80% untuk pasar
produk kesehatan dan nutrisi.
Inovasi adalah semangat yang menjiwai setiap tahap pertumbuhan Kalbe sebagai perusahaan farmasi terbesar
di Indonesia. Riset dan pengembangan produk-produk baru yang inovatif, bernilai tinggi, dan sesuai dengan
kebutuhan masyarakat dengan prospek yang baik di masa mendatang terus dilakukan. Menyadari kondisi
geografis Indonesia sebagai negara kepulauan yang sangat luas, Kalbe terus meningkatkan kapasitas dan kualitas
layanan distribusinya. Perbaikan berkesinambungan dalam integrasi rantai pasokan menjadi salah satu perhatian
utama Kalbe untuk meningkatkan efisiensi dan arus kas Perseroan.
Setelah melampaui 4 dasawarsa pertumbuhan, Kalbe telah bertransformasi dari produsen obat-obatan menjadi
penyedia solusi layanan kesehatan yang menyeluruh melalui penyediaan solusi kesehatan yang lengkap mulai
dari produk obat-obatan, nutrisi, suplemen, makanan dan minuman kesehatan hingga alat-alat kesehatan termasuk
pelayanan kesehatan primer. Bentuk pelayanan komprehensif atau holistik kepada konsumen yang telah dirintis,
Kalbe diyakini dapat mempertahankan dan meningkatkan daya saing Kalbe di tengah kompetisi yang semakin
ketat dalam rangka memperkuat keunggulan kompetitif Kalbe di masa depan. Adalah menjadi target kami untuk
membangun Global Brand yang memiliki potensi penjualan yang tinggi di setiap unit bisnis untuk mendorong
pertumbuhan kinerja.
Mampu terus tumbuh secara berkesinambungan melalui sinergi antar unit bisnis menjadi harapan Kalbe dalam
rangka mendukung terwujudnya misi Perseroan yaitu meningkatkan kesehatan untuk kehidupan yang lebih baik.
Dengan dukungan sumber daya manusia yang berkualitas serta upaya perbaikan dalam berbagai proses bisnis
secara berkesinambungan, Kalbe optimis akan mampu mencapai visi Perseroan menjadi perusahaan produk
kesehatan Indonesia terbaik yang didukung oleh inovasi, merek yang kuat dan manajemen yang prima.
44
13
Kalbe was incorporated in 1966. In 1991, Kalbe was listed on the Indonesia Stock Exchange as a public company.
Kalbe has significantly grown from its humble beginnings as a pharmaceuticals business run from a garage in
North Jakarta. Today Kalbe has become the largest publicly-listed pharmaceuticals company in Southeast Asia,
with a market capitalization of USD 3.9 billion and a sales turnover of Rp 10.91 trillion as of the end of 2011.
Kalbe has focused its business on four divisions: prescription pharmaceuticals, consumer health products,
nutritionals and distribution and logistics. Supported by over 15,000 employees, inclusive of 4,000 sales and
marketing professionals covering the entire Indonesian archipelago, Kalbe maintains coverage of more than 70%
of general practitioners, 90% of specialists, 100% of hospitals, 100% of pharmacies across Indonesia for the
prescription pharmaceuticals market and 80% for the consumer health and nutritionals markets.
Innovation remains as the spirit that characterizes every stage of growth for Kalbe, as it has metamorphosed into
the largest pharmaceutical company in Indonesia. Research and development for new products that are innovative,
high-value, and appropriately addressing the needs of society with good prospects in the future continues to
take place. In recognition of the reality that Indonesia is a vast archipelago, Kalbe continues to increase both the
capacity and quality of its distribution services. Continuous improvement of its supply chain integration is among
the main concerns of Kalbe in improving efficiency and cash flows of the Company.
After 4 decades of growth, Kalbe has transformed itself from a pharmaceuticals manufacturer into a provider of
"comprehensive healthcare solutions", through offering a range of comprehensive health care solution products
that goes from pharmaceuticals, nutrition, supplements, health foods and beverages to medical devices, including
primary healthcare services. Through conducting comprehensive (or holistic) care for consumers, Kalbe is able to
maintain and enhance its business competitiveness amid increasingly fierce competition, fortifying its competitive
advantage for the future. It is our target to build global brands with high sales potential in every business unit, to
support performance growth.
Maintaining sustainable growth through business unit synergy is Kalbes hope in the journey to realize the
Companys mission to improve health for a better life. With the support of quality human resources and through
continuous improvement efforts in various business processes, Kalbe is optimistic that it will be able to achieve
the Companys vision to be the best Indonesian healthcare company, driven by innovation, strong brands and
excellent management.
45
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Divisi Usaha
Business Divisions
46
Kalbes Consumer Health Division offers over-thecounter drugs with therapeutic benefits, consumer
products with health benefits, including supplements
and other preventive products, along with energy
drinks and healthy ready-to-drink products. Kalbes
over-the-counter portfolio category covers more
than 6 therapeutical classes with strong brands,
commanding a dominant market share, over recent
decades.
Divisi Nutrisi
Nutritionals Division
Divisi Nutrisi Kalbe mempunyai rangkaian produkproduk nutrisi yang lengkap untuk seluruh lapisan
usia konsumen, mulai dari bayi, balita, anak-anak
hingga pra-remaja, dewasa, ibu hamil dan menyusui,
hingga usia senja, serta produk-produk nutrisi untuk
konsumen dengan kebutuhan khusus.
47
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Struktur Organisasi
Organization Structure
Board of Commissioners
President Commissioner
Commissioner
Independent Commissioner
: Johannes Setijono
: Santoso Oen
Jozef Darmawan Angkasa
Ferdinand Aryanto
: Wahjudi Prakarsa
Farid Anfasa Moeloek
Board of Directors
President Director
Vice President Director
Director
Corporate Function
Audit Committee
Farid Anfasa Moeloek
Nomination Committee
Johannes Setijono
Remuneration Committee
Johannes Setijono
Business Risk Committee
Johannes Setijono
GCG Committee
Vidjongtius
Pharmaceuticals
Global Marketing Office
Corporate Management
System &
Business Development
Corporate Information
Technology & System
Corporate Strategic
Investments
Consumer Health
Nutritionals
Corporate Legal
Corporate Finance,
Accounting & Tax
Biopharma
Eye Care
Medical Devices
Corporate Communication
and CSR
Health Services
International
48
81.64%
Dankos Farma
99.975%
0.025%
Bintang Toedjoe
99.90%
Innogene Kalbiotech
Pte. Ltd
0.10%
93.34%
0.40%
99.60%
Finusolprima Farma
99.994%
75%
Kalbe
25%
0.006%
Bifarma Adiluhung
0.004%
99.996%
0.003%
100%
Sanghiang Perkasa
99.997%
Kalbe Morinaga
Indonesia
70%
Asiawide Kalbe
Philippines, Inc.
Kalbe International
Pte. Ltd.
50%
100%
99.6%
0.4%
30%
0.001%
99.999%
EPMT
91.75%
Farmasi
Pharmaceuticals
Makanan Kesehatan
Nutritionals
Penjualan dan Distribusi
Sale and Distribution
Perusahaan Terbuka
Listed Company
0.1%
Global Chemindo
Megatrading
0.1%
99.9%
99.9%
Renalmed Tiara
Utama
98.75%
49
Performance
Highlights
Management
Report
Company
Profile
Visi Vision
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Misi Mission
Motto
Visi dan Misi Perseroan telah disetujui oleh Dewan Komisaris dan Direksi
The Company's Vision and Mission have been approved by the Board of Commissioners and the Board of Directors
50
Nilai Values
Panca Sradha KALBE
1. Saling percaya adalah perekat di antara kami
Kami memberi kesempatan yang sama kepada setiap individu untuk mengembangkan
potensinya agar menjadi insan yang handal melalui budaya belajar dan perbaikan yang
berkesinambungan.
Sebagai bagian dari kehidupan, kami berperan serta memelihara keragaman dan
keharmonisan dengan melakukan usaha-usaha yang bermanfaat bagi sesama hingga
generasi mendatang.
51
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Dewan Komisaris
Board of Commissioners
Johannes Setijono
Presiden Komisaris
President Commissioner
Santoso Oen
Komisaris
Commissioner
52
Ferdinand
FerdinandAriyanto
Aryanto
Komisaris
Komisaris
Commissioner
Commissioner
Wahjudi
WahjudiPrakarsa
Prakarsa
Komisaris
KomisarisIndependen
Independen
Independent
IndependentCommissioner
Commissioner
Farid
FaridAnfasa
AnfasaMoeloek
Moeloek
Komisaris
KomisarisIndependen
Independen
Independent
IndependentCommissioner
Commissioner
Beberapa
penghargaan
yang
pernah
didapatkannya antara lain adalah Penghargaan Adi
Satya Utama dari Ikatan Dokter Indonesia (1996),
Bintang Republik Indonesia Maha Putra Adriprana
(1999), Satyalancana Karya Satya Republik
Indonesia XXX (2002), Penghargaan Bina Ekatama
dari Perkumpulan Keluarga Berencana Indonesia
(2002), dan Penghargaan Prof Mohtar Award dalam
Bidang Ilmiah dan Riset dari Ikatan Ahli Kesehatan
Masyarakat Indonesia (2007).
53
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Direksi
Board of Directors
54
Budi Dharma
Wreksoatmodjo
Herman
Widjaja
Direktur
Director
Direktur Perseroan sejak tahun 2005.
Warga Negara Indonesia. Lahir di Bojonegoro pada
tanggal 3 Januari 1954.
Berkuliah di Fakultas Farmasi Universitas Surabaya
hingga tahun 1977.
Beliau bergabung dengan Grup Kalbe pada tahun
1985 sebagai Sales Manager Ethical PT Dankos
Laboratories Tbk. Pada tahun 1988 beliau diangkat
sebagai Marketing Manager Ethical, lalu menjabat
sebagai Direktur PT Bintang Toedjoe pada tahun
1991 hingga tahun 1992. Sejak tahun 1996 hingga
tahun 2002, menjabat sebagai Presiden Direktur
dan setelah itu sebagai Komisaris PT Bintang
Toedjoe. Sejak tahun 1992 hingga tahun 1996
beliau menduduki jabatan sebagai Direktur dan
kemudian menjabat sebagai Presiden Direktur PT
Dankos Laboratories Tbk sejak tahun 2002 hingga
penggabungan usaha pada tahun 2005.
Hingga akhir tahun 2011, beliau menjabat sebagai
Presiden Komisaris PT Finusolprima Farma
Internasional, Presiden Komisaris PT Enseval
Putera Megatrading Tbk., Presiden Komisaris PT
Hexpharm Jaya Laboratories, Presiden Komisaris
PT Dankos Farma, dan Komisaris PT Renalmed
Tiara Utama.
Director of the Company since 2005.
An Indonesian citizen, born in Bojonegoro on
January 3, 1954. Studied at the Faculty of Pharmacy,
Surabaya University until 1977.
He joined Kalbe Group in 1985 as Sales Manager for
the Ethical Division at PT Dankos Laboratories Tbk.,
and in 1988 was appointed as Marketing Manager
for the Ethical Division. He served as a Director
of PT Bintang Toedjoe from 1991 to 1992, as
President Director from 1996 to 2002 and was then
appointed a Commissioner. From 1992 to 1996, he
was a Director of PT Dankos Laboratories Tbk and
then served as President Director from 2002 until
the merger in 2005.
Up to the end of 2011, he served President
Commissioner of PT Finusolprima Farma
Internasional, President Commissioner of PT
Enseval Putera Megatrading Tbk., President
Commissioner of PT Hexpharm Jaya Laboratories,
President Commissioner of PT Dankos Farma, and
Commissioner of PT Renalmed Tiara Utama.
Vidjongtius
Direktur
Director
Ongkie
Ongkie Tedjasurja
Tedjasurja
Direktur
Direktur
Director
Director
55
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Komite Audit
Audit Committee
Ichsan Gunawan
Anggota Komite Audit
Member of Audit Committee
56
Dianawati Sugiarto
Anggota Komite Audit
Member of Audit Committee
Komite Nominasi
Nomination Committee
Johannes Setijono
Ketua Komite Nominasi
Chairman of Nomination Committee
Johannes Setijono
Ketua Komite Remunerasi
Chairman of Remuneration Committee
Komite Remunerasi
Remuneration Committee
57
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Komite GCG
GCG Committee
Vidjongtius
Ketua Komite GCG
Chairman of GCG Committee
58
Joyce V. Handajani
Anggota Komite GCG |
Member of GCG Committee
Febiana Rinasari
Anggota Komite GCG |
Member of GCG Committee
59
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
60
Johannes Setijono
Ketua Komite Risiko Usaha
Chairman of Business Risk Committee
Vidjongtius
Anggota Komite Risiko Usaha
Member of Business Risk Committee
Consolidated
Financial
Statements
Kurniawan Tedjo
Kepala Unit Audit Internal
Head of Internal Audit Unit
Kepala Unit Audit Internal sejak 29 Maret 2007.
Sekretaris Perusahaan
Corporate Secretary
Vidjongtius
Sekretaris Perusahaan
Corporate Secretary
Sekretaris Perusahaan sejak 2008.
Corporate Secretary since 2008.
Riwayat hidup dapat dilihat pada bagian riwayat
hidup Direksi.
For a complete biography please refer to Board of
Directors biography section.
61
Performance
Highlights
Management
Report
Company
Profile
Mengembangkan
kader pemimpin
untuk pertumbuhan
berkelanjutan
Grooming leader
candidates for
sustainable growth
Rp
20.1
Miliar Billion
54.1
Peningkatan Jumlah
Inisiatif Perbaikan
Increase in the Number of
Improvement Initiatives
62
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
63
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
2011
16,701
26,092
248
293
QCP
79
114
A3R
1,233
1,583
PPS
TOTAL
64
2010
190
348
18,451
28,430
65
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Pengembangan SDM
Kalbe menyadari bahwa pertumbuhan bisnis
yang berkelanjutan hanya dapat dicapai dengan
pengembangan dan peningkatan kualitas SDM agar
mampu menjadi aset bagi Perseroan. Pengembangan
SDM di Kalbe menerapkan pendekatan Leader
creates Leaders yaitu setiap atasan harus mampu
mencetak calon pemimpin yang kompeten sesuai
dengan kebutuhan Perseroan. Proses pengembangan
SDM dilakukan melalui mekanisme People Review oleh
atasan dan Direktur terkait yang dilaksanakan setiap
tahun untuk mengevaluasi kinerja dan potensi masingmasing individu. Berdasarkan hasil People Review
setiap atasan membuat program pengembangan SDM
yang dapat berupa mutasi, rotasi, promosi jabatan,
penugasan serta pelatihan. Agar proses kaderisasi
berlangsung secara berkesinambungan. setiap atasan
wajib melakukan proses mentoring, coaching dan
counselling terhadap karyawan yang dibimbingnya.
Program pengembangan SDM dievaluasi setiap tahun
melalui sistem manajemen kinerja yang bertujuan
menyelaraskan target Perseroan dengan target
individu.
66
67
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
1,849 2,075
587 625
2010 2011
2010 2011
111
2010 2011
Officer/Supervisor
106
2010 2011
Manajer
Manager
Jajaran Eksekutif
Executive
3,468 3,454
3,757 3,727
1,633
1,723
593
126
82
2010 2011
68
261
355
176
2010 2011
2010 2011
2010 2011
SD
Elementary
SMA
Senior High School
SMP
Junior High School
Diploma
Diploma
2010 2011
2010 2011
S1
Undergraduate
13
11
2010 2011
S2
Post Graduate
S3
Doctorate
5,199 5,176
2,853 2,789
773
1,005
778
792
10
2010 2011
2010 2011
18 25 tahun
year
2010 2011
26 35 tahun
year
2010 2011
36 45 tahun
year
2010 2011
45 55 tahun
year
>55 tahun
year
9,613 9,766
5,533
2010 2011
5,024
2010 2011
Tetap
Permanent
Tidak Tetap
Non Permanent
69
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
No.
Tanggal
Date
Program
Programme
Pembicara
Speaker
Pembicara
Speaker
Tempat
Places
June 27 - 28
External
July
Internal
Anak Perusahaan
September 20
Internal
December 14
Didik Suwardi
External
December 20
Perhitungan Aktuaria
Taufik
External
April 14
Safety Assessment
Metty Susanti
Internal
July 18
Internal
October 28
Regulatory Forum
Internal
November 25
Internal
Corporate HRD
10
March 31
External
11
November 23
EPMT Team
Internal
EPMT - Jakarta
February 27
Mida Suharseno
Internal
13
July 19
Yvone Astri
Internal
14
July 29
Yuniar Linda
Internal
70
15
January 13
Irawati Setiady
Internal
16
February 11
Prawiro Wijaya
External
17
March 10-12
Julian Foe
External
MDC Gadog
No.
Tanggal
Date
Program
Programme
Pembicara
Speaker
Pembicara
Speaker
Tempat
Places
18
April 08
Julian Foe
External
19
April 29
Internal
20
June 10
Pre Agusta
Internal
21
July 12
A. Teguh Nugroho
Internal
22
August 08
Strategic Direction
External
23
September 15
Wira Halim
Internal
24
December 09
Internal
March 31 Apr 01
Leo J. Susanto
External
26
July 25
External
27
August 25
Internal
28
September 19
Internal
External
August 10
71
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Kepemimpinan
Leadership Competence
1
February 23-25
New Me Program
Bandung
February 28-March 01
Jakarta
April 04-14
Prasetya Mulya
Jakarta
May 2-13
Jakarta
September 14-16
Primasi
Sentul Bogor
Kompetensi Fungsional
Functional Competence
1
February 21-23
Jakarta
March 21-22
Training Essbase
Jakarta
March 31 April 01
Wimconsult
Jakarta
May 10-11
Building Image
Jakarta
May 23-27
Jakarta
June 27-28
Jakarta
December 15-16
Targeted Selection
Jakarta
Kompetensi Dasar
Basic Competence
72
February 22-25
People Sight
Bogor
April 02-15
People Sight
Puncak
May 03
Conim A3 Report
Jakarta
June 16-17
Heartspeaks
Jakarta
July 04-05
Internal
Jakarta
July 07-08
Internal
Bogor
September 06-09
People Sight
Jakarta
November 03-04
Infinite
Jakarta
December 01-02
Bogor
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Kepemimpinan
Leadership Competence
1
May 07-July 23
Dale Carnegie
Jakarta
June 16-September 22
Dale Carnegie
Jakarta
October 04-05
Leadership Foundations
Dunamis
Jakarta
November 22-24
Jakarta
Kompetensi Fungsional
Functional Competence
1
January 03-07
Iverson Technology
Jakarta
January 25-27
Project Management
Jakarta
January 26-June 01
Jakarta
January 24-February 04
Jakarta
January 25-26
Jakarta
January 27-28
Jakarta
February 21-25
Iverson Technology
Jakarta
February 03-09
Audit Kecurangan
Sukabumi
February 18
Jakarta
10
February 28-March 02
PT Viatama
Jakarta
11
February 09-11
Yogyakarta
12
March 16-18
Bintan
13
March 07-08
Jakarta
14
March 18-20
Universitas Udayana
Denpasar
15
April 05-06
GML Management
Jakarta
16
April 18-21
Batam
Singapore
17
April 20-21
Jakarta
18
April 08-10
Lancet Oncology
Hongkong
19
April 18-19
Jakarta
73
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Fungsional
Functional Competence
74
21
April 13
Jakarta
22
May 05
Virtual Consulting
Jakarta
23
May 23-24
Salvo Global
Singapore
24
May 24
PB Taxand
Jakarta
25
May 24-24
Prasetya Mulya
Jakarta
26
May 24-26
Manajemen Proyek
PPM Manajemen
Jakarta
27
May 30-31
Jakarta
28
May 30-31
Jakarta
29
May 09-10
Yogyakarta
30
May 06-07
Lean Logistic
LOGIC
Bandung
31
May 12
Jakarta
32
May 14-15
Universitas Brawijaya
Malang
33
June 08-10
Singapore
34
June 11July 03
Jakarta
35
June 24-25
Jakarta
36
July 02-03
Jakarta
37
July 09 October 22
Jakarta
38
July 11-15
Bandung
39
July 10-13
Kuala Lumpur,
Malaysia
40
July 13
Jakarta
41
21-Jul
Jakarta
42
July 13 & 20
PPM Manajemen
Jakarta
43
July 27-29
Jakarta
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Fungsional
Functional Competence
44
July 27
Jakarta
45
July 19-21
Jakarta
46
August 05
Jakarta
47
August 09
Prima Target
Jakarta
48
August 11
Kontan
Jakarta
49
September 19-30
Jakarta
50
September 22
International Tax
Jakarta
51
September 27-28
Singapore
52
September 27-28
Intipesan
Nusa Dua
Bali
53
September 28
Jakarta
54
September 13
December 15
Prasetya Mulya
Jakarta
55
September 19-21
Phacilitate Limited
Singapore
56
September 22-23
Surabaya
57
October 10-14
Iverson Technology
Jakarta
58
October 13
International Tax
Jakarta
59
October 14-15
Value Consult
Jakarta
60
October 27-28
Bina Management
Jakarta
61
October 24-28
Iverson Technology
Jakarta
62
October 29
Up Train International
Jakarta
63
October 14-15
Jakarta
64
October 13
Inventory Management
Jakarta
65
November 02-03
Building Management
Intipesan
Jakarta
66
November 04
PT Mitra Pajakku
Jakarta
67
November 10-11
PT NBO Indonesia
Jakarta
68
November 15-17
Marketing Management
PPM Manajemen
Jakarta
69
November 21-25
Iverson Technology
Jakarta
75
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Fungsional
Functional Competence
76
70
November 28-30
Iverson Technology
Jakarta
71
November 30
PT Tomifapajow Konsultama
Jakarta
72
November
30-December 01
Jakarta
73
November 29
Markplus
Jakarta
74
November 24-25
Trimitra Consultants
Jakarta
75
November 28
-December 08
Jakarta
76
November 28 December 09
Jakarta
77
November 09-10
EGA Briefings
Jakarta
78
November 10-11
Jakarta
79
November 16
Aplikasi Perkantoran
Jakarta
80
December 13-15
Manajemen Pajak
PPM Manajemen
Jakarta
81
December 12-23
Sukabumi
82
December 12-23
Sukabumi
83
December 19-20
Iverson Technology
Jakarta
84
December 01-02
PT Dimension
Jakarta
85
December 12-16
Iverson Technology
Jakarta
86
December 13-15
Jakarta
87
December 07-08
Jakarta
88
December 14-15
Lexmundus
Jakarta
89
December 13
Jakarta
90
December 12-13
Formasi
Jakarta
91
December 07
Jakarta
92
December 13-15
Manajemen Pajak
PPM Manajemen
Jakarta
93
December 02
Jakarta
No.
Tanggal Pelatihan
Date
Program
Programme
Penyelenggara
Institution
Tempat
Place
Kompetensi Dasar
Basic Competence
1
January 17-21
Jakarta
February 09-11
Jakarta
March 21-25
PPM Manajemen
Jakarta
July 13-15
Dunamis
Bogor
August 19
Jakarta
October 11-13
Prasetya Mulya
Jakarta
October 25
Dunamis
Jakarta
October 22December 10
English First
Cibubur
December 13-14
ValueConsult
Jakarta
10
December 06-07
PPM Manajemen
Jakarta
11
December 12-16
PPM Manajemen
Jakarta
77
Management
Report
Performance
Highlights
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
2010
953,574,577
10.17
953,574,577
10.17
901,929,368
9.62
901,929,368
9.62
PT Diptanala Bahana
889,594,088
9.49
889,594,088
9.49
887,979,088
9.47
887,979,088
9.47
864,590,588
9.22
864,590,588
9.22
812,163,308
8.66
812,999,808
8.67
4,065,193,405
43.37
4,064,356,905
43.36
780,990,000
780,990,000
10,156,014,422
100.00
10,156,014,422
100.00
Publik | Public
Saham yang Diperoleh Kembali | Treasury Stocks
TOTAL
Posisi
Position
Jumlah Saham
Number of Share
Persentase
Percentage
Santoso Oen
Komisaris | Commissioner
Komisaris | Commissioner
Ferdinand Aryanto
Komisaris | Commissioner
Wahjudi Prakarsa
2,124,500
0.02%
Direksi | Directors
Bernadette Ruth Irawati Setiady
Herman Widjaja
Direktur | Director
Direktur | Director
Vidjongtius
Direktur | Director
Ongkie Tedjasurja
Direktur | Director
37%
36%
2010
2011
63%
64%
Lokal | Domestic
Asing | Foreign
78
Status Pemilik
Jumlah Saham
Number of Shares
Pemodal Nasional
Owner Status
Domestic Investor
Perorangan*
79,831,433
0.85%
Individuals*
Koperasi
3,040,000
0.03%
Cooperatives
Yayasan
2,179,646
0.02%
Foundations
140,631,605
1.50%
Pension Funds
55,656,689
0.59%
Insurances
545,100
0.01%
Bankings
5,580,183,618
59.52%
Lembaga Keuangan
70,666,349
0.75%
Financial Institutions
Reksadana
99,618,908
1.06%
Mutual Funds
6,032,353,348
64.34%
2,641,461
0.03%
Individuals
3,340,029,613
35.63%
Dana Pensiun
Asuransi
Bank
Perseroan Terbatas**
Foreign Investor
Perorangan
Badan Usaha Asing
Total Pemodal Asing
3,342,671,074
35.66%
9,375,024,422
100.00%
780,990,000
Treasury Stocks
10,156,014,422
TOTAL
* termasuk Dewan Komisaris, Direksi, dan karyawan | including Board of Commissioners, Directors and Employees
** termasuk Pemegang Saham Pengendali | including Controlling Shareholders
Jumlah Saham
Number of Shares
20,000,000
30,000,000
50,000,000
8,000,000
75,600,000
32,400,000
216,000,000
1,728,000,000
1,900,800,000
4,060,800,000
2,034,414,422
79
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Entitas Anak
Subsidiaries
Nama Anak
Perusahaan
Subsidiary Name
80
Kegiatan Usaha
Line of Business
Mulai Beroperasi
Komersial
Commencement
of Commercial
Operations
Kepemilikan
Efektifl
Effective
Ownership
PT Bifarma Adiluhung
Farmasi
Pharmaceuticals
1997
100.00%
PT Bintang Toedjoe
Farmasi
Pharmaceuticals
1949
100.00%
PT Dankos Farma
Farmasi
Pharmaceuticals
2006
100.00%
PT Finusolprima Farma
Internasional
Farmasi
Pharmaceuticals
1981
100.00%
PT Hexpharm Jaya
Laboratories
Farmasi
Pharmaceuticals
1995
100.00%
Innogene Kalbiotech
Pte. Ltd.
Farmasi
Pharmaceuticals
2004
93.34%
Farmasi
Pharmaceuticals
2009
30.00%
Farmasi
Pharmaceuticals
2006
81.64%
PT Saka Farma
Laboratories
Farmasi
Pharmaceuticals
1997
100.00%
PT Kalbe Morinaga
Indonesia
Makanan Kesehatan
Health Foods
2007
70.00%
PT Sanghiang Perkasa
Makanan Kesehatan
Health Foods
1982
100.00%
Nama Anak
Perusahaan
Subsidiary Name
Kegiatan Usaha
Line of Business
Mulai Beroperasi
Komersial
Commencement
of Commercial
Operations
Kepemilikan
Efektifl
Effective
Ownership
PT Enseval Putera
Megatrading Tbk
Distributor Obat-obatan
Pharmaceutical
Distributor
1993
91.75%
Distributor Obat-obatan
Pharmaceutical
Distributor
1980
91.75%
PT Enseval Medika
Prima
Distributor Peralatan
Kesehatan
Distribution of Medical
Instruments
2008
91.75%
PT Global Chemindo
Megatrading
2008
91.75%
PT Millenia Dharma
Insani
Apotek, Perdagangan
Produk Farmasi dan
Klinik
Pelayanan Kesehatan
Pharmacy, Trading of
Pharmaceutical Products
and Healthcare Clinics
2003
91.75%
PT Renalmed Tiara
Utama
Perdagangan Peralatan
Kesehatan dan Barang
Habis Pakai
Trading of Medical
Instruments and
Consumable Products
2008
90.60%
Pengembangan,
Produksi, Pemasaran
dan Distribusi
Produk Kesehatan Mata
Development,
Production, Marketing
and Distribution
of Eye Health Products
2008
100.00%
Kalbe International
Pte. Ltd.
Pemasaran Produk
Kesehatan dan Farmasi
Wholesale of Medical
and Pharmaceutical
Products
2007
100.00%
Asiawide Kalbe
Philippines, Inc.
Pemasaran Minuman
Energi Siap Saji
Marketing of Energy
Drink in RTD Format
2010
50.00%
81
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Daftar Prinsipal
Principals List
prescriptionS
Eppendorf Ag
Epos
PT Interbat
Eracita Astamida
PT Nufarindo
Tsena Inovindo
Finusolprima
Tyco Healthcare/Covidien
Fukuda Sangyo
Unomedical
PT Interbat
Pt Sna Medika
Gottfried Vomel Kg
Pt Roche Indonesia
PT Abbott Indonesia
Intersience
PT Aquasolve Sanaria
J.S. Research
Pt 3M Indonesia
Kavo Gendex
Kimura
PT Beiersdorf Indonesia
Cv Metz Indonesia
PT Loreal Indonesia
Megadyne
Advanced Nutraceutical
PT Impers Pratama
Mg Electric
Minrad
PT Tata Nutrisana
PT Ikapharmindo Putramas
Nakamura Medical
Azelis Uk Ltd.
Industry Co.,Ltd
Medical Devices
Naturo Biotech
Biocon
Biotech Marine
Pnn Memokart
Bellco
General Co.
Sfri
Cardinal Carefusion
Sgm Biotech
Chemline Healthcare,Wicka
Chemo Sa.
Dental Ez Incorporation
Group Srl
Demetech Corp
Internasional )
82
Raw Materials
Merck Kgaa
Eka Chemicals Ab
Minerva
Monix Indonesia
Nb Entrepreneurs
H. FinzelbergS Nachfolge
Nutrasweet Indonesia
Vitasweet Co.,Ltd.
Henan Linhua
Wockhardt Ltd
Quat-Chem Limited
Hilmar Ingredients
Ikeda Corporation
Ipca Laboratories.Co.,Ltd
Shenyang Biotic
Co., Ltd
PharmaceuticalJj Degussa
Siddarth International
Chemical
Chemicals
Skyopen Medipharma
Chemical
Sungai Budi
Supriya Lifescience
Lonza Ltd.
Lupin Limited
Technoble Co,Ltd
83
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
84
Indonesia
Original
Brands
2011, from SWA for Entrostop,
Cerebrofort, and Cerebrovit.
Best
Role
of
Stakeholders
2011 from Indonesia Institute
for Corporate Directorship dan
Business Review
85
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Jejak Langkah
Milestones
Pendirian
Perseroan
dengan nama
PT Kalbe Farma
Incorporation of
the Company
under the name
PT Kalbe Farma
1966
1977
Akuisisi
PT Dankos
Laboratories
Acquisition
of PT Dankos
Laboratories
86
Pengalihan
bisnis distribusi
kepada PT
Enseval
sesuai dengan
ketentuan
peraturan
pemerintah
PT Igar
Jaya dan
PT Dankos
Laboratories
melakukan
Penawaran
Umum
Perdana
Spin-off the
distribution
business to
PT Enseval to
comply with
government
regulation
PT Igar
Jaya and
PT Dankos
Laboratories
conducted
their Initial
Public
Offering
1981
1985
1989
1991
Akuisisi PT
Bintang
Toedjoe dan
PT Hexpharm
Jaya
Acquisition
of PT Bintang
Toedjoe and
PT Hexpharm
Jaya
PT Kalbe Farma
melakukan
Penawaran Umum
Perdana
PT Kalbe Farma
conducted its
Initial Public
Offering
Akuisisi PT
Sanghiang
Perkasa dan
konsolidasi bisnis
nutrisi ke dalam
anak perusahaan
ini
Acquisition of
PT Sanghiang
Perkasa and
consolidation
of nutritional
business into this
subsidiary
1993
1995
1994
Memulai bisnis
minuman energi
dengan peluncuran
Extra Joss
PT Enseval Putera
Megatrading
melakukan
Penawaran Umum
Perdana
Entry into energy
drink market with
the launching of
Extra Joss
PT Enseval Putera
Megatrading
conducted its initial
Public Offering
1997
Penjualan sisa 50%
kepemilikan pada
PT Helios Arnotts
Indonesia
Penjualan divisi
pengemasan
gelas kepada
Schott Glasswerke
Beteiligungs GmbH
Akuisisi merek
Woods
Akuisisi 80% saham
PT Saka Farma
Laboratories
Divestment of
remaining 50%
ownership in PT
Helios Arnotts
Indonesia
Divestment of
glass packaging
division to Schott
Glasswerke
Beteiligungs GmbH
Acquisition of
Woods brand
Acquisition of
80% ownership
in PT Saka Farma
Laboratories
Konsolidasi
Grup Kalbe
Consolidation
of Kalbe Group
2005
2007
2006
Memperluas cakupan regional
Membangun merek dan
infrastruktur global
Meningkatkan fokus bisnis
melalui penggabungan usaha
dan akuisisi
Meningkatkan pengembangan
penemuan obat
Membangun jaringan dan
kemitraan global
Expand regional footprint
Build global brands and
infrastructure
Scale up through mergers and
acquisitions
Intensify proprietary drug
development
Establish global partnerships
and networks
2009
2010
2008
Pendirian PT Renalmed
Tiara Utama yang
bergerak di bidang
perdagangan peralatan
kesehatan
Perolehan izin edar
TheraCIM di Indonesia
dan Filipina
Peresmian outlet
pertama Klinik
Mitrasana di Cikarang
Establishment of PT
Renalmed Tiara Utama
which is engaged in
trading of medical
devices
TheraCIM secured its
registration approval
in Indonesia and the
Philippines
Inauguration of the
first outlet of Mitrasana
Clinic in Cikarang
Pembentukan Perusahaan
Joint Venture di Filipina
Divestasi 58,10% kepemilikan
dalam PT Kageo Igar Jaya
Tbk yang merupakan Divisi
Kemasan Perseroan
Establishing a Joint Venture
Company in the Philippines
Divestment 58.10% stake
in PT Kageo Igar Jaya Tbk,
the Companys Packaging
Division
87
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Mei May
5
Maret March
10
30
11
31
88
Juni June
18
25
89
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
September September
9
10-11
Agustus August
4
90
29
Oktober October
5
17
November November
4
Desember December
13
91
92
94-99
Tinjauan Industri
Industrial Review
Pengelolaan Usaha
yang Terarah
Menuju Pertumbuhan
Berkelanjutan
Sound Management to Empower
Sustainable Growth
93
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Tinjauan Industri
Industrial Review
Potensi
pertumbuhan
positif didukung
kondisi makro
ekonomi yang
kondusif
Strong growth
potential supported
by conducive
macro economic
environment
94
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Ekonomi
Perekonomian global pada tahun 2011 ditandai
dengan perlambatan kegiatan ekonomi dan
ketidakpastian akibat dampak krisis keuangan
Amerika Serikat dan zona Eropa, serta bencana
tsunami yang melanda Jepang. Namun
demikian, Amerika Serikat dan Jepang tercatat
menunjukkan tingkat pertumbuhan yang lebih
baik dibandingkan ekspektasi sebelumnya.
Pertumbuhan ekonomi global tahun 2012
diperkirakan melemah ke kisaran 3.25% dengan
adanya unsur ketidakpastian terkait penyelesaian
masalah hutang zona Eropa. (sumber: IMF)
Economic Review
The global economy in 2011 was marked by a
slowdown in economic activity and uncertainties
from the impact of financial crises in the US and
Euro zones, as well as the effects of the tsunami
on Japan. Nevertheless, both the US and Japan
recorded an improved economic growth rate,
against expectations. Global economic growth
in 2012 is predicted to recede to the range of
3.25%, mainly due to the uncertainties arising
from the settlement of the Euro zone debt crisis.
(source: IMF)
95
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Industri
Industrial Review
96
Tinjauan Industri
Selain didukung kondisi makro ekonomi yang kondusif,
secara demografis Indonesia merupakan pasar yang
sangat potensial dengan jumlah penduduk sekitar
240 juta jiwa. Pertumbuhan ekonomi Indonesia yang
berkelanjutan sejak beberapa tahun terakhir telah
menciptakan kelas menengah yang terus berkembang
yang merupakan motor penggerak konsumsi dan
pertumbuhan ekonomi. Dengan Produk Domestik
Bruto (PDB) per kapita yang telah mencapai US$ 3.000
dan terus bertumbuh, dengan komposisi penduduk
usia muda yang besar dan tingkat urbanisasi yang
tinggi, Indonesia menawarkan potensi pasar yang
sangat menarik, khususnya di segmen produk
konsumen termasuk produk kesehatan.
Industry Review
In addition to its conducive macro-economic
condition, Indonesia is a highly potential market
demographically, with a population of over 240 million.
Indonesias continuous economic growth over the
last few years has generated a new middle class that
steadily widens, and is the driver for consumption and
economic progress. With a growing Gross Domestic
Product (GDP) of over US$ 3,000 per capita, a huge
young population and high urbanization, Indonesia
offers a very attractive market potential, especially in
the consumer segment including consumer health
products.
97
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Industri
Industrial Review
98
Dengan
adanya
rencana
pemerintah
untuk
menerapkan jaminan kesehatan secara nasional mulai
tahun 2014, industri farmasi Indonesia memiliki potensi
yang besar untuk tumbuh lebih lanjut, khususnya
pada segmen obat resep generik. Sementara itu,
produk obat bebas juga diperkirakan akan tetap
menjadi bagian yang besar dari keseluruhan pasar
karena harga terjangkau. Ketersediaan produk obat
bebas yang dapat dengan mudah diperoleh dengan
harga terjangkau akan tetap menjadi komponen yang
signifikan dalam industri farmasi Indonesia. Perseroan
juga melihat potensi pengembangan yang besar pada
segmen obat bebas ke arah penggunaan bahan dasar
alami dan herbal. Hal ini sejalan dengan pergeseran
permintaan konsumen terhadap produk-produk alami.
Pada segmen produk konsumen, juga terjadi tren
peningkatan permintaan konsumen terhadap produkproduk yang menawarkan kemudahan yang diprediksi
menjadi area pertumbuhan yang potensial.
Prospek Usaha
Perekonomian Indonesia diprediksi akan tetap
bertumbuh pada tahun 2012. Namun demikian,
prospek perekonomian global yang melambat pada
2011 diperkirakan akan mulai berdampak bagi
prospek pertumbuhan ekonomi domestik pada tahun
2012. Hal ini terutama terjadi akibat nilai ekspor
yang menurun karena menurunnya aktivitas ekonomi
global. Sementara itu, impor diperkirakan masih
mengalami peningkatan yang cukup tinggi.
Business Prospects
The Indonesian economy is predicted to continue
growing in 2012. However, the slowdown of global
economic prospects is expected to begin affecting
domestic economic growth from 2012. This mostly
comes from lower export volumes, due to weaker
global economic activities. Meanwhile, imports are
expected to continue to increase.
99
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Tinjauan Usaha
Business Review
Divisi Obat Resep
Prescription Pharmaceuticals Division
Produk yang
tersebar ke
seluruh pelosok
dengan harga
terjangkau
Product availability
across Indonesia at
affordable prices
Rp
2.78
Triliun Trillion
7.7
Pertumbuhan Growth
100
Corporate
Governance
Consolidated
Financial
Statements
2,580
2010
2,778
2011
Tinjauan Umum
Indonesia memiliki pasar obat resep yang
sangat berpotensi untuk berkembang lebih jauh
terutama di tahun-tahun mendatang. Selaras
dengan tingginya tingkat pertumbuhan penduduk
dengan tingkat konsumsi obat per kapita yang
masih tergolong rendah dibandingkan dengan
negara-negara berkembang lainnya, pasar obat
resep Indonesia diyakini akan terus berkembang.
Selain itu, rencana diberlakukannya UndangUndang Badan Penyelenggara Jaminan Sosial
dan didukung oleh komitmen Pemerintah untuk
meningkatkan besarnya anggaran kesehatan
Pemerintah, industri farmasi memiliki potensi
untuk tumbuh lebih jauh. Pada tahun 2011,
pertumbuhan pasar obat resep Indonesia
tercatat sebesar 10% dibandingkan dengan
tahun 2010 (sumber: IMS Health 2011).
Overview
The Indonesian prescription pharmaceuticals
market possesses great potential, riding on
high population growth; with lower spending on
pharmaceuticals compared to other developing
countries, the Indonesian prescription drug
market is expected to continue to expand.
In addition, the plan to roll out the bill on the
Social Security Provider Body, supported by
the Governments commitment to an increased
healthcare budget, the pharmaceuticals industry
has strong growth potential. In 2011, the
Indonesian pharmaceuticals market grew by
10%, compared to the 2010 figure (source: IMS
Health 2011).
101
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Usaha
: Divisi Obat Resep
Business Review : Prescription Pharmaceuticals Division
102
Kinerja Operasional
Pada tahun 2011, Divisi Obat Resep Kalbe menguasai
pangsa pasar sebesar 12-13% (sumber : IMS Health
2011), dengan nilai penjualan bersih tercatat senilai
Rp2.778 miliar, dengan tingkat pertumbuhan sebesar
7,7%. Nilai penjualan Divisi Obat Resep memberikan
kontribusi sebesar 25% terhadap total pendapatan
Perseroan di tahun 2011. Marjin laba kotor tercatat
sebesar 65,9%, menurun dibandingkan 67,1%
pada tahun 2010. Selama tahun 2011 Divisi Obat
Resep meluncurkan 24 produk baru, yang terdiri
dari 4 produk obat generik, 12 produk obat generik
bermerek, dan 8 produk obat lisensi. Hingga akhir
tahun 2011, Kalbe memproduksi 383 produk obat di
16 kelas terapi. Melalui peluncuran produk-produk
baru untuk segmen yang berbeda-beda tersebut,
Kalbe semakin memperkuat kelengkapan rangkaian
produk obat resep yang didedikasikan untuk seluruh
segmen ekonomi masyarakat.
Operational Performance
In 2011, Kalbes Prescription Pharmaceuticals Division
commanded a 12-13% market share (source: IMS
Health 2011), with net sales of Rp 2,778 billion and
a growth rate of 7.7%. Net sales of the Prescription
Pharmaceuticals Division contributed 25% to
total Company net sales in 2011. The gross profit
margin amounted to 65.9%, lower compared to
the 67.1% figure in 2010. In 2011 the Prescription
Pharmaceuticals Division launched 24 new products,
consisting of 4 generic products, 12 branded generic
drugs and 8 licensed products. As of end-2011, Kalbe
manufactures 383 products in 16 therapeutical classes.
Through product launching across all segments, Kalbe
further strengthens its complete prescription product
range targeted at all consumer economic segments.
StarMuno
Suplemen untuk meningkatkan daya tahan tubuh
bagi orang dewasa dan anak-anak
Supplement to boost immune system
for adults and children
103
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
104
105
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Tinjauan Usaha
Business Review
Divisi Produk Kesehatan
Consumer Health Division
Terus berinovasi
untuk memberikan
kemudahan bagi
konsumen
Keep inovating
to provide
convenience
for consumers
Rp
1.84
Triliun Trillion
8.3
Pertumbuhan Growth
106
Corporate
Governance
Consolidated
Financial
Statements
1.701
2010
1.842
2011
Tinjauan Umum
Divisi Produk Kesehatan Kalbe meliputi kategori
produk obat bebas bersifat kuratif serta produkproduk konsumsi yang memiliki manfaat
kesehatan seperti suplemen dan produk bersifat
preventif lainnya, minuman energi serta produk
minuman kesehatan. Pada kategori produk
obat bebas, portofolio Kalbe mencakup lebih
dari 6 kelas terapi obat bebas dengan merekmerek yang dominan menguasai pangsa pasar
dalam beberapa dekade terakhir. Beberapa
diantaranya adalah produk Promag dan Waisan
yang menguasai pasar kelas terapi obat maag;
produk Neo Entrostop di kelas terapi obat diare;
produk Komix, Woods, Mextril dan Mixadin di
kelas terapi obat batuk; serta produk Mixagrip,
Mixagrip Flu dan Batuk dan Procold di kelas
terapi obat flu. Di samping itu, Kalbe juga
memiliki produk unggulan Kalpanax dan Mikorex
pada kelas terapi anti-jamur.
Overview
Kalbes Consumer Health Division offers overthe-counter drugs with therapeutic benefits,
consumer products with health benefits,
including supplements and other preventive
products, along with energy drinks and healthy
ready-to-drink products. Kalbes over-thecounter portfolio category covers more than
6 therapeutical classes with strong brands,
commanding a dominant market share, over
recent decades. To name a few, there are
Promag and Waisan, which are dominant in the
antacid therapeutic class, Neo Entrostop in the
antidiarrheal therapeutic class, the product lines
of Komix, Woods, Mextril and Mixadin in the class
of cough remedies, as well as Mixagrip, Mixagrip
Flu and Cough medicine, and Procold in the cold
remedy class. Further, Kalbe has Kalpanax and
Mikorex, leading brands in anti-fungal treatment.
107
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
108
Kinerja Operasional
Pada tahun 2011, Kalbe mempertahankan penguasaan
pangsa pasar terbesar di kategori obat bebas sebesar
13% (sumber : IMS Health 2011) sedangkan pada
minuman energi Kalbe menguasai pangsa pasar
sebesar 24% berdasarkan jumlah volume penjualan
di tahun 2011 (sumber : AC Nielsen).
Operational Performance
In 2011 Kalbe maintained its foothold with the dominant
market share in the over-the-counter category with
13% (source: IMS Health 2011) while in the energy
drink class Kalbe commanded a market share of 24%
in 2011, based on volume (source: AC Nielsen).
Fatigon Hydro
Minuman isotonik alami
dari air kelapa asli
Natural Isotonic drink made
of real coconut water
In 2011 the Company did not increase production capacity for over-the-counter, energy drink and readyto-drink products.
109
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Usaha
: Divisi Produk Kesehatan
Business Review : Consumer Health Division
110
Perseroan
juga
terus
memfokuskan
pada
pengembangan produk minuman siap saji dengan
mengandalkan produk Fatigon Hydro dan Tipco.
Untuk meningkatkan kelancaran produksi agar
dapat memenuhi permintaan pasar, Perusahaan
akan melakukan investasi untuk menambah fasilitas
produksi untuk Fatigon Hydro pada tahun 2012.
111
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Tinjauan Usaha
Business Review
Divisi Nutrisi
Nutritionals Division
Terus bersinergi
untuk menjadi
pilihan utama
konsumen
Continue to
create synergy to
be consumers'
main choice
Rp
2.42
Triliun Trillion
5.5
Pertumbuhan Growth
112
Corporate
Governance
Consolidated
Financial
Statements
2,293
2010
2,420
2011
Tinjauan Umum
Pertumbuhan ekonomi Indonesia disertai dengan
semakin meningkatnya pengetahuan masyarakat
akan pentingnya nutrisi untuk menunjang kesehatan
telah mendorong pertumbuhan industri susu di
Indonesia. Jumlah konsumsi susu bubuk nasional
pada tahun 2011 mencatat pertumbuhan nilai
sebesar 6% sedangkan pertumbuhan berdasarkan
volume sebesar 4% (sumber: AC Nielsen).
Overview
Indonesias economic growth, accompanied
by increasing awareness of the importance of
nutrition in maintaining health, has fueled the
growth of the Indonesian milk industry. National
milk consumption in 2011 recorded 6% growth in
value and 4% in volume (source: AC Nielsen).
Divisi Nutrisi Kalbe mempunyai rangkaian produkproduk nutrisi yang lengkap untuk seluruh lapisan
usia konsumen, mulai dari bayi, balita, anak-anak,
pra-remaja, dewasa, ibu hamil dan menyusui,
hingga usia senja; serta produk-produk nutrisi
untuk konsumen dengan kebutuhan khusus.
113
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Usaha
: Divisi Nutrisi
Business Review : Nutritionals Division
114
Kinerja Operasional
Walaupun industri susu bubuk di Indonesia didominasi
oleh perusahaan-perusahaan multinasional, Kalbe
Nutritionals mampu memperkuat posisi penguasaan
pangsa pasarnya menjadi sebesar 9% (sumber : AC
Nielsen).
Operational Performance
Despite a strong multinational company presence in the
powdered milk market, Kalbe Nutritionals managed to
strengthen its market share, rising to 9% (source: AC
Nielsen).
Nutrive Benecol
Minuman kesehatan dengan
kandungan khusus untuk
menurunkan kolesterol
Smoothie with special
ingredient to lower cholesterol
Kalbe Nutritionals also continues to conduct directto-customer marketing activities, involving the entire
family, aiming to educate and motivate Indonesian
families to lead healthy lives. In 2011, the Nutritionals
Division intensified direct-to-customer marketing
activities, such as through mall-to-mall roadshows and
the launching of a Kalbe e-store, an online shopping
site targeted to provide convenience for consumers to
purchase Kalbe nutritionals products, using the NHD
service free of charge. Currently, Kalbe e-store deliver
around Jakarta and its surrounding areas.
115
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Tinjauan Usaha
Business Review
Divisi Distribusi dan Logistik
Distribution and Logistics Division
Melebarkan
sayap distribusi ke
seluruh pelosok
Indonesia
Spreading
distribution reach
across Indonesia
Rp
3.87
Triliun Trillion
6.0
Pertumbuhan Growth
116
Corporate
Governance
Consolidated
Financial
Statements
3,654
3,873
2010
2011
Tinjauan Umum
Dengan kondisi geografis Indonesia yang berupa
kepulauan, kelancaran distribusi produk adalah
tantangan tersendiri. Minimnya infrastruktur
transportasi dan kondisi yang buruk menimbulkan
kendala tambahan dalam mendistribusikan
produk di Indonesia.
Kemampuan distribusi
yang tangguh ke lebih dari 1 juta outlet di seluruh
Indonesia menjadi faktor yang sangat penting
untuk menjamin ketersediaan produk.
Overview
As a result of Indonesian geography as an
archipelago, ensuring a smooth flow of product
distribution presents a special challenge.
Marginal transportation infrastructure and poor
conditions have added to challenges faced in
distributing products in Indonesia. However, an
excellent distribution capability to more than 1
million outlets throughout Indonesia is a crucial
point to ensure product availability.
117
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Usaha
: Divisi Distribusi dan Logistik
Business Review : Distribution and Logistics
118
Kinerja Operasional
Pada tahun 2011, Divisi Distribusi dan Logistik
Perseroan mencatat pertumbuhan penjualan yang positif
dibandingkan tahun 2010. Pada tahun 2011, penjualan
Divisi Distribusi dan Logistik tercatat senilai Rp 3.873
miliar , dengan tingkat pertumbuhan sebesar 6,0%.
Nilai penjualan Divisi Distribusi dan Logistik memberikan
kontribusi sebesar 36% terhadap total pendapatan
Perseroan di tahun 2011. Pada tahun 2010 Perseroan
masih mencatat adanya kontribusi penjualan dari PT
Kageo Igar Jaya Tbk, yang merupakan anak perusahaan
Kalbe yang bergerak di bidang pengemasan. Pada bulan
Agustus 2010, Perseroan melakukan divestasi saham
PT Kageo Igar Jaya Tbk. Jika kontribusi penjualan dari
usaha kemasan tersebut tidak diperhitungkan, Divisi
Distribusi dan Logistik mencatat pertumbuhan sebesar
12,8%. Secara konsolidasi akuntansi di Kalbe Grup
Marjin laba kotor tercatat sebesar 30,7%, meningkat
dibandingkan 29,0% pada tahun 2010.
Operational Performance
In 2011, the Distribution and Logistics Division recorded
positive sales growth compared to that of 2010. The
net sales of the Distribution and Logistics Division in
2011 amounted to Rp 3,873 billion, with growth of
6.0%. In terms of sales, Distribution and Logistics
provided a 36% contribution to total Company net
sales in 2011. In year 2010, the Company still recorded
the contribution of sales of PT Kageo Igar Jaya Tbk, a
Kalbe subsidiary engaged in the packaging business.
However, in August 2010, the Company divested PT
Kageo Igar Jaya Tbk. If the sales of the packaging
business were to be removed, the Distribution and
Logistics Division would have recorded growth of
12.8%. Based on acounting consolidation in Kalbe
Group gross profit margin amounted to 30.7%,
increased compared to the 29.0% booked in 2010.
Secara keseluruhan, kontribusi penjualan produkproduk prinsipal pihak ketiga terhadap total pendapatan
Divisi Distribusi dan Logistik tercatat sebesar 33%
di tahun 2011, meningkat 2% jika dibandingkan
dengan tahun 2010. Sedangkan kontribusi penjualan
produk-produk Grup Kalbe tercatat sebesar 67% dari
pendapatan di tahun 2011.
119
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Usaha
: Divisi Distribusi dan Logistik
Business Review : Distribution and Logistics
120
121
122
Meningkatkan
efektivitas
pemasaran
dan
penjualan, melalui branding management,
program marketing dan penjualan & distribusi
yang terfokus dan terintegrasi sehingga dapat
memperluas ketersediaan dan visibility produk.
Improving marketing and sales effectiveness, through
branding management, focused and integrated
marketing and selling & distribution to spread product
availability and visibilty
2
3
123
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Tinjauan Operasional
Operational Review
Riset dan Pengembangan
Research and Development
Semangat inovasi
untuk mendorong
pertumbuhan
berkelanjutan
Innovation spirit to
drive sustainable
growth
Rp
91.2
Miliar
Billion
124
Consolidated
Financial
Statements
95
91
5,005
2010
2011
125
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
126
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Produk Baru
Dalam segmen obat resep, Kalbe secara aktif
melakukan kegiatan riset dan pengembangan untuk
menciptakan teknologi baru dalam meningkatkan
kualitas produk yang dikembangkan. Perseroan
terus mengakuisisi berbagai teknologi terkini dalam
pembuatan sediaan obat. Salah satu inisiatif yang
berhasil dicapai adalah penerapan teknologi liofilisasi
untuk sediaan injeksi, yang bermanfaat meningkatkan
kualitas, mempercepat kelarutan dan meningkatkan
stabilitas obat.
New Products
In the prescription pharmaceuticals segment, Kalbe
has actively implemented research and development
to create new technologies, to advance the quality
of product development. The Company has acquired
several of the latest technologies in pharmaceutical
materials manufacturing. One of the initiatives
achieved has been the implementation of liophilisation
technology for injection formats, aimed to improve
accuracy, speed up the dissolving process and
increase drug stability.
Inovasi Baru
Sebagai produsen produk obat dan produk kesehatan,
Kalbe meyakini pentingnya meningkatkan nilai tambah
bagi konsumen. Kegiatan riset dan pengembangan
selain ditujukan untuk formulasi produk, juga dilakukan
untuk terus menciptakan terobosan baru untuk
memberikan kenyamanan dan kemudahan konsumsi,
maupun meningkatkan efektivitas manfaat klinis produk.
New Innovations
As a pharmaceuticals and consumer health products
manufacturer, Kalbe believes in the importance of
enhancing values for consumers. Aside from product
formulation, research and development are activities
also aimed at creating new breakthroughs in providing
convenience in consumption, or to increase the
effectiveness of a products clinical benefits.
127
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
128
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
129
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Tinjauan Operasional
Operational Review
Pengelolaan Rantai Pasokan
Supply Chain Management
Menciptakan
rantai pasokan
yang semakin
efisien dan efektif
Creating a more
efficient and effective
supply chain
Rp
1.47
Triliun Trillion
17.5
Pertumbuhan Growth
130
Consolidated
Financial
Statements
1,473
1,254
5,005
2010
2011
Dalam
rangka
meningkatkan
efisiensi
dan efektifitas rantai pasokan dan untuk
meningkatkan arus kas Perseroan, Kalbe terus
melakukan perbaikan secara terstruktur dan
berkesinambungan dalam pengelolaan rantai
131
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Program in 2011
The main focus of improvements in 2011 was to
continue various efforts in supply chain improvements
started in 2010, aimed at improving the net operating
Vendor
Vendor
132
Planning Cycle
Siklus Perencanaan
Lead Time
Logistics Cycle
Siklus Logistik
Cabang
Branch
133
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
134
2008
2009
2010
2011
Perputaran Piutang
43
48
44
50
Perputaran Persediaan
142
123
110
115
Days of Inventory
Perputaran Utang
27
38
35
57
158
133
120
108
Results
Continuous efforts to improve supply chain
management have been implemented since 2008,
with the inception of the Supply Chain Task Force.
Achievements have been evident in the improvement
of the average inventory turnover, diving from 142
days in 2008 to 115 days in 2011. This progress has
contributed positively to the improvement in the net
operating cycle, from 158 days in 2008 to 108 days
in 2011.
135
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Tinjauan Operasional
Operational Review
Portofolio Bisnis yang Disempurnakan
Enhanced Business Portfolio
Transformasi
bisnis yang
berkelanjutan untuk
memperkokoh
posisi kepemimpinan
pasar
Continuous
business
tranformation to
strengthen market
leadership
136
Consolidated
Financial
Statements
137
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
138
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
139
Performance
Highlights
Management
Report
Tinjauan Operasional
Operational Review
140
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
141
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Tinjauan Keuangan
Financial Review
Memperkokoh
posisi keuangan
untuk menopang
pengembangan
usaha
Strengthening
financial position to
support business
growth
Rp
1.48
Triliun Trillion
15.2
Pertumbuhan Growth
142
Consolidated
Financial
Statements
143
Management
Report
Performance
Highlights
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
2011
Naik (Turun)
Increase
(Decrease)
2010
Nilai Amount
Penjualan Neto
10,912
10,227
685
6.7%
Net Sales
5,361
5,060
301
5.9%
Laba Bruto
5,551
5,166
385
7.4%
Gross Profit
1,987
1,770
217
12.2%
(464)
(427)
(37)
8.8%
1,523
1,344
179
13.3%
17
15
629.3%
1,540
1,346
194
14.4%
1,482
1,286
196
15.2%
158
137
21
15.2%
144
Rp
Descriptions
Penjualan Neto
Tahun 2011 merupakan periode yang cukup menantang
bagi Perseroan, terutama dalam pencapaian target
pertumbuhan penjualan. Pada tahun 2011, Perseroan
mencatat penjualan neto sebesar Rp 10.912 miliar,
meningkat sebesar 6,7% dibandingkan Rp 10.227
miliar pada tahun 2010. Pada tahun 2010 Perseroan
masih mencatat adanya kontribusi penjualan dari PT
Kageo Igar Jaya Tbk, yang merupakan entitas anak
Kalbe yang bergerak di bidang kemasan. Pada bulan
Agustus 2010, Perseroan melakukan divestasi saham
PT Kageo Igar Jaya Tbk. Jika kontribusi penjualan
dari usaha kemasan tersebut tidak diperhitungkan,
Perseroan mencatat pertumbuhan penjualan sebesar
9,0%.
Net Sales
2011 was quite a challenging period for the Company,
particularly in achieving the target of sales growth. In
2011, the Companys net sales were recorded at Rp
10,912 billion, a rise by 6.7% compared to the 2010
figure of Rp 10,227 billion. In year 2010, the Company
still recorded the sales contribution of PT Kageo Igar
Jaya Tbk, a Kalbe subsidiary engaged in the packaging
business. However, in August 2010, the Company
divested PT Kageo Igar Jaya Tbk. If the sales of the
packaging business were to be removed, the Company
would have recorded a sales growth of 9.0%.
2011
Rp
Naik (Turun)
2010
Rp
Increase (Decrease)
%
Rp
Descriptions
Obat Resep
2,777
25.4%
2,580
25.2%
197
7.7%
Prescription Pharmaceuticals
Produk Kesehatan
1,842
16.9%
1,701
16.6%
141
8.3%
Consumer Health
Nutrisi
2,420
22.2%
2,293
22.4%
127
5.5%
Nutritionals
Distribution and Logistics
3,873
35.5%
3,654
35.8%
219
6.0%
10,912
100.0%
10,227
100.0%
685
6.7%
145
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
146
147
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
148
Laba Bruto
Pada tahun 2011 Perseroan berhasil membukukan
laba bruto sebesar Rp 5.551 miliar, meningkat sebesar
7,4% dibanding tahun 2010 yang memiliki laba bruto
sebesar Rp 5.166 miliar. Margin laba bruto meningkat
dari tahun 2010 sebesar 50,5% menjadi 50,9% pada
tahun 2011. Peningkatan margin laba bruto tersebut
merupakan dampak dari penguatan nilai tukar
Rupiah, pengaturan kombinasi produk serta upaya
peningkatan produktivitas dan efisiensi produksi.
Gross Profit
In 2011 the Company succeeded in earning a gross
profit amounting to Rp 5,551 billion. This was an
increase of 7.4%, compared to the 2010 figure, with
gross profit amounting to Rp 5,166 billion. The margin
of gross profit increased from 50.5% in 2010 to 50.9%
in 2011. The improvement of gross profit margin as
an impact of the strengthening of the Indonesian
Rupiah, product-mix management, and the efforts at
improving productivity and production efficiency.
Naik (Turun)
2011
Rp
2010
%
Descriptions
Increase (Decrease)
Rp
Rp
Obat Resep
1,830
33.0%
1,731
33.5%
99
5.7%
Prescription Pharmaceuticals
Produk Kesehatan
1,039
18.7%
979
19.0%
60
6.1%
Consumer Health
Nutrisi
1,494
26.9%
1,397
27.0%
97
6.9%
Nutritionals
1,188
21.4%
1,059
20.5%
129
12.2%
5,551
100.0%
5,166
100.0%
385
7.4%
2011
Naik (Turun)
2010
Nilai Amount
Beban penjualan
Beban umum dan administrasi
Beban penelitian dan pengembangan
Increase
(Decrease)
Rp
Descriptions
(2,905)
(2,699)
(206)
7.6%
Selling expense
(587)
(581)
(6)
1.0%
(91)
(95)
-3.9%
(13)
(21)
-36.4%
(12)
(23)
11
-47.2%
97
55
42
76.3%
Interest income
Penghasilan bunga
Laba atas penjualan aset tetap
13
(7)
-56.2%
(16)
16
-100.0%
(58)
(28)
(30)
107.0%
Miscellaneous, net
(3,564)
(3,395)
(209)
4.9%
Rupa-rupa, neto
Total
Total
149
Management
Report
Performance
Highlights
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
Laba Sebelum Manfaat (Beban) Pajak Penghasilan dan Laba Tahun Berjalan (Miliar Rupiah)
Income Before Income Tax Benefit (Expense) and Income for the Year (Billion Rupiah)
Tahun Years
Keterangan
2011
2010
Nilai Amount
Laba Sebelum Manfaat (Beban)
Pajak Pengasilan
Manfaat (Beban) Pajak Penghasilan
Laba Tahun Berjalan
150
Naik (Turun)
Increase
(Decrease)
Rp
Descriptions
1,987
1,770
217
12.2%
(464)
(426)
(38)
8.8%
1,523
1,344
179
13.3%
Laba
tahun
berjalan
Perseroan
mengalami
pertumbuhan sebesar 13,3% dari Rp 1,344 miliar
pada tahun 2010 menjadi Rp 1,523 miliar pada tahun
2011. Dengan memperhitungkan bagian laba tahun
berjalan yang diatribusikan kepada kepentingan
non-pengendali sebesar Rp 41 miliar, Perseroan
mencatat laba tahun berjalan yang dapat diatribusikan
kepada pemilik entitas induk sebesar Rp 1.482 miliar,
meningkat sebesar 15,2% dibandingkan Rp 1.286
miliar pada tahun 2010. Selain karena pengaruh kinerja
operasional, peningkatan tersebut juga disebabkan
oleh peningkatan kepemilikan pada PT Enseval Putera
Megatrading Tbk.
151
Management
Report
Performance
Highlights
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
2011
Naik (Turun)
Increase
(Decrease)
2010
Nilai Amount
Aset lancar
5,956
Rp
5,031
Descriptions
925
18.4%
Current assets
2,318
2,001
317
15.9%
Non-current assets
Total aset
8,274
7,032
1,242
17.7%
Total assets
1,630
1,146
484
42.2%
Current liabilities
128
114
14
12.4%
Non-current liabilities
1,758
1,260
498
39.5%
Total liabilities
0.2
(0.2)
-100.0%
Goodwill negatif
Ekuitas, neto
Total liabilitas dan ekuitas
6,516
5,772
744
12.9%
8,274
7,032
1,242
17.7%
Negative goodwill
Equity, net
Total llabilities and equity
Assets
The Company recorded an increase in total assets as
per December 31, 2011, reaching Rp 8,274 billion,
compared to total assets as per December 31, 2010
of Rp 7,032 billion, which marked a rise of 17.7%.
Aset
Perseroan mencatat kenaikan total aset per tanggal
31 Desember 2011 menjadi sebesar Rp 8.274 miliar,
dibandingkan total aset per 31 Desember 2010 sebesar
Rp 7.032 miliar, atau meningkat sebesar 17,7%.
Aset Lancar (Miliar Rupiah)
Current Assets (Billion Rupiah)
Tahun Years
Keterangan
2011
Rp
152
Naik (Turun)
2010
Rp
Increase/Decrease
%
Rp
Descriptions
2,291
38.5%
1,902
37.8%
389
20.5%
114
1.9%
0.1%
109
2,042.1%
1,530
25.7%
1,263
25.1%
267
21.2%
105
1.8%
101
2.0%
4.0%
Others receivables
1,705
28.6%
1,551
30.8%
154
10.0%
Inventories, net
21
0.3%
11
0.2%
10
88.5%
190
3.2%
198
4.0%
(8)
-4.5%
5,956
100.0%
5,031
100.0%
925
18.4%
Aset Lancar
Aset lancar Perseroan meningkat menjadi Rp 5.956
miliar pada tahun 2011, dibandingkan Rp 5.031
miliar pada tahun sebelumnya, atau menunjukkan
peningkatan sebesar 18,4%.
Current Assets
The Companys current assets grew to Rp 5,956 billion
in 2011, compared to the previous years figure of Rp
5,031 billion, which showed a rise of 18.4%.
Short-term Investments
Short-term investments rose to Rp 114 billion from Rp
5 billion in 2010, a significant hike of 2,042.1%. This
improvement was mainly caused by the investments in
marketable securities in the form of mutual funds and
through the posting of unrealized gains on appreciation
in market value of short-term investments, of both the
Company and its subsidiaries.
Descriptions
2011
Lancar
2010
1,107
942
1-30 hari
334
260
1-30 days
31-60 hari
61
42
31-60 days
61-90 hari
28
25
61-90 days
18
Over 90 days
1,548
1,271
Total
(18)
(8)
1,530
1,263
Total
Dikurangi cadangan penurunan nilai
Piutang usaha neto
Current
Overdue
153
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
154
Piutang Usaha
Sebagai imbas langsung dari kenaikan penjualan
perusahaan, piutang usaha yang dimiliki Perseroan
mengalami peningkatan sebesar 21,2% dari Rp
1.263 miliar pada tahun 2010 menjadi Rp 1.530 miliar
pada tahun 2011, masing-masing setelah dikurangi
cadangan penurunan nilai sebesar Rp 8 miliar dan Rp
18 miliar pada tahun 2010 dan 2011.
Trade Receivables
As a direct outcome of the increase in Company sales,
Kalbes trade receivables increased by 21.2%, from Rp
1,263 billion in 2010 to Rp 1,530 billion in 2011, each
after deducting allowance for impairment amounting
to Rp 8 billion and Rp 18 billion consecutively in 2010
and 2011.
Kolektibilitas Piutang
Pada tahun 2011, rata-rata perputaran piutang
mengalami peningkatan sebanyak 6 hari, dari 44
hari pada tahun 2010 menjadi 50 hari. Manajemen
Perseroan berkeyakinan bahwa piutang Perseroan
dapat ditagihkan sesuai jadwal dan jumlah penyisihan
piutang ragu-ragu senilai Rp 18 miliar cukup untuk
menutup kemungkinan kerugian atas tidak tertagihnya
piutang usaha.
Collectability of Receivables
In 2011, the average turnover of receivables increased
by 6 days, from 44 days in 2010 to 50 days. Company
management remain convinced that Company
receivables could be collected as scheduled, and the
allowance for impairment amounting to Rp 18 billion
was adequate to cover possible losses that may arise
from the non-collection of the accounts.
Piutang Lain-lain
Piutang lain-lain Perseroan mengalami peningkatan
sebesar 4,0% dari Rp 101 miliar pada tahun 2010
menjadi Rp 105 miliar pada tahun 2011.
Other Receivables
The Companys other receivables increased by 4.0%,
from Rp 101 billion in 2010 to Rp 105 billion in 2011.
Persediaan, Neto
Peningkatan penjualan diimbangi dengan peningkatan
nilai persediaan Perseroan yang mengalami
peningkatan sebesar 10,0% dari Rp 1.551 miliar pada
tahun 2010 menjadi Rp 1.705 miliar pada tahun 2011.
Pada tahun 2011, rata-rata perputaran persediaan
mengalami peningkatan sebanyak 5 hari, dari 110 hari
pada tahun 2010 menjadi 115 hari pada tahun 2011.
Inventories, Net
Sales increases were accompanied by a 10.0% rise in
Company inventory value, which was Rp 1,551 billion
in 2010 against Rp 1,705 billion in 2011. In 2011, the
average turnover of inventory increased by 5 days,
from 110 days in 2010 to 115 days.
Naik (Turun)
2011
Rp
2010
%
Rp
Increase (Decrease)
%
Rp
Descriptions
Penyertaan saham
54
2.3%
49
2.4%
10.9%
38
1.6%
35
1.7%
7.9%
28
1.2%
29
1.5%
(1)
-3.5%
1,860
80.2%
1,605
80.2%
255
15.9%
233
10.1%
238
11.9%
(5)
-1.9%
0.4%
0.4%
0.1
-1.2%
97
4.2%
37
1.9%
60
161.0%
2,318
100.0%
2,001
100.0%
317
15.9%
Non-current Assets
The Companys non-current assets increased from Rp
2,001 billion in 2010 to Rp 2,318 billion in 2011. The
improvement of non-current assets was significantly
influenced by the increase of property, plant and
equipment from Rp 1,605 billion in 2010 to Rp 1,860
billion in 2011, which was mainly comprised of direct
ownership and construction in progress. In addition to
property, plant and equipment, improvement of noncurrent assets was also influenced by the increase of
other non-current assets, as well as the investment of
shares in stocks.
Liabilitas
Pada tahun 2011 total liabilitas Perseroan meningkat
menjadi Rp 1.758 miliar dibandingkan tahun 2010
sebesar Rp 1.260 miliar. Sebagian besar liabilitas yang
dimiliki Perseroan berasal dari 92,7% liabilitas jangka
pendek, dan sisanya 7,3% berasal dari liabilitas
jangka panjang. Peningkatan liabilitas ini disebabkan
peningkatan utang usaha sebesar 74,2% atau sekitar
Rp 362 miliar.
Liabilities
In 2011 the Companys total liabilities increased to Rp
1,758 billion, compared to 2010 total liabilities, which
reached Rp 1,260 billion. Most of the Companys
liabilities were derived from current liabilities of 92.7%
with the remainder coming from non-current liabilities
of 7.3%. The increase of liabilities was caused by the
hike of trade payables, up 74.2% or about Rp 362
billion.
155
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
2011
Rp
2010
%
Rp
Increase/Decrease
%
Rp
Descriptions
140
8.6%
24
2.1%
116
476.6%
Short-term loans
Utang usaha
850
52.1%
488
42.6%
362
74.2%
Trade payables
Utang lain-lain
203
12.4%
139
12.1%
64
45.6%
Other payables
283
17.4%
302
26.4%
(19)
-6.2%
Accrued expenses
Utang pajak
154
9.5%
193
16.8%
(39)
-19.9%
Taxes payables
0.3
0.0%
0.3
0.0%
(0.0)
-7.4%
1,630
100.0%
1,146
100.0%
484
42.2%
156
Naik (Turun)
Current Liabilities
Current liabilities increased by 42.2% to Rp 1,630
billion in 2011, compared to Rp 1,146 for the previous
year.
Short-term Loans
Short-term loans underwent a rise in 2011, up 476.6%
for an increase of Rp 116 billion from the 2010 figure
of Rp 24 billion to Rp 140 billion by 2011. The rise
in short-term loans was derived from fixed loans
received in Rupiah from Bank CIMB Niaga, revolving
credit received from The Hong Kong and Shanghai
Banking Corporation Ltd in US Dollars, and fixed loans
received from DBS Bank in Singapore Dollars.
Utang Usaha
Kenaikan utang usaha memberikan kontribusi terbesar
terhadap total kenaikan kewajiban lancar Perseroan.
Utang usaha mengalami kenaikan yang cukup besar
pada tahun 2011 yaitu sebesar 74,2%, meningkat dari
semula Rp 488 miliar pada tahun 2010 menjadi Rp
850 miliar pada tahun 2011. Utang usaha meningkat
terutama karena adanya peningkatan pembelian
kepada pihak ketiga sebagai pemasok barang jadi
pada Divisi Distribusi dan Logistik. Pada tahun
2011, rata-rata perputaran utang usaha mengalami
peningkatan sebanyak 22 hari, dari 35 hari pada tahun
2010 menjadi 57 hari pada tahun 2011.
Trade Payables
The increase of trade payables shared greatest
contribution towards the hike of the Companys
current liabilities. The trade payables saw a significant
increase in 2011, up by 74.2%, a rise from the 2010
figure of Rp 488 billion to Rp 850 billion in 2011. This
increase in trade payables was mainly resulting from
increased purchases of finished goods from third party
suppliers in the Distribution and Logistics Division.
For 2011, the average turnover of trade payables
increased by 22 days, from 35 days in 2010 to 57 days
in 2011.
Utang Lain-lain
Utang lain-lain terutama terdiri dari utang kepada
agen periklanan dan perusahaan ekspedisi. Utang
lain-lain Perseroan pada tahun 2011 juga mengalami
peningkatan sebesar 45,6% dari Rp 139 miliar pada
tahun 2010 menjadi Rp 203 miliar pada tahun 2011.
Other Payables
Other payables consist of payables to advertising
agencies and expedition companies. Other payables
in 2011 also underwent a rise by 45.6% from Rp 139
billion in 2010 to Rp 203 billion in 2011.
Accrued Expenses
Accrued expenses cover accruals for selling, royalties
and other expenses. The Company recorded a decline
in accrued expenses, down by 6.2% to Rp 283 billion
in 2011 compared to the Rp 302 billion in 2010. This
decline was triggered by a decrease in accrual for
other expenses.
Utang Pajak
Utang pajak Perseroan mengalami penurunan sebesar
19,9 % dari Rp 193 miliar pada tahun 2010 menjadi Rp
154 miliar pada tahun 2011, yang terutama disebabkan
oleh penurunan taksiran utang pajak penghasilan
pasal 29.
Taxes Payables
The Companys taxes payables decreased by 19.9%,
going from Rp 193 billion in 2010 to Rp 154 billion
in 2011, which was mainly caused by a decrease in
estimated income tax payable Article 29.
2011
Rp
Naik (Turun)
2010
%
10
7.7%
Rp
Increase (Decrease)
%
6.7%
Rp
%
2
28.8%
0.4
0.3%
0.7
0.7%
(0.4)
(51.0%)
Estimasi liabilitas
imbalan kerja karyawan
Total liabilitas jangka panjang
Descriptions
118
92.0%
105
92.6%
13
11.7%
128
100.0%
114
100.0%
14
12.4%
Non-Current Liabilities
Non-current liabilities increased by 12.4% to Rp 128
billion in 2011, compared to Rp 114 billion for the
previous year.
157
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
2011
Rp
Modal saham
Naik (Turun)
2010
Rp
Increase (Decrease)
%
Rp
508
7.8%
508
8.8%
0.0%
Capital stock
0.1%
0.1%
0.0%
(3)
-0.1%
(1)
0.0%
(2)
140.1%
(37)
-0.6%
(37)
-0.6%
0.0%
Saldo laba
Telah ditentukan
penggunaannya
Belum ditentukan
penggunaannya
Modal treasuri
Retained earnings
62
1.0%
49
0.8%
13
26.0%
Appropriated
6,345
97.4%
5,532
95.8%
813
14.7%
Unappropriated
(687)
-10.5%
(687)
-11.9%
0.0%
Pendapatan (beban)
komprehensif lainnya:
Treasury stock
Other comprehensive
income (expenses):
0.0%
0.1%
(3)
-61.3%
20
0.3%
(0.0)
0.0%
20
-51,938.4%
6,215
95.4%
5,374
93.1%
841
15.7%
Sub total
Sub total
Kepentingan Non-pengendali
Ekuitas, Neto
158
Descriptions
301
4.6%
398
6.9%
(97)
-24.4%
Non-controlling Interest
6,516
100.0%
5,772
100.0%
744
12.9%
Equity, Net
Ekuitas, Neto
Pada tahun 2011, ekuitas Perseroan meningkat sebesar
12,9% menjadi Rp 6.516 miliar dibandingkan Rp 5.772
miliar pada tahun 2010. Peningkatan tersebut terutama
disebabkan oleh peningkatan saldo laba ditahan
Perseroan meningkat sebesar 14,8% dari Rp 5.581
miliar pada tahun 2010 menjadi Rp 6.407 miliar pada
tahun 2011. Sehubungan dengan Program Pembelian
Kembali Saham yang sudah berakhir pada tahun 2009,
sampai dengan tanggal 31 Desember 2011, saham yang
dibeli kembali oleh Perseroan mencapai Rp 687 miliar
atau sejumlah 780.990.000 saham.
Equities, Net
In 2011 the Companys equities improved by 12.9%,
rising to Rp 6,516 billion compared to Rp 5,772
billion in 2010. This improvement was mainly due to
an increase of Company retained earnings, which
reached 14.8% from Rp 5,581 billion in 2010 against
Rp 6,407 billion in 2011. In relations with the Share
Repurchase Program ended in 2009, up to December
31, 2011, the Company had already repurchased
780,990,000 shares at a total cost of Rp 687 billion.
159
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
2011
2010
Nilai Amount
Arus kas dari aktivitas operasi, neto
Increase
(Decrease)
Rp
Descriptions
1,254
219
17.5%
(631)
(232)
(399)
171.8%
(407)
(575)
168
-29.2%
435
447
(12)
-2.6%
160
1,473
Naik (Turun)
161
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
162
Pemasaran
Aspek pemasaran merupakan salah satu kegiatan
utama dalam menunjang tercapainya pertumbuhan
penjualan yang berkelanjutan. Pada tahun 2011,
Perseroan
melanjutkan
pelaksanaan
strategi
pemasaran yang langsung melibatkan konsumen
dengan tujuan meningkatan efektivitas pemasaran
dan mempererat hubungan dengan konsumen.
Berbagai kegiatan yang diadakan antara lain meliputi
berbagai aktivitas yang memperoleh tanggapan yang
positif dan partisipasi yang tinggi dari konsumen
seperti Prenagen Peduli Sesama Ibu oleh Prenagen,
Cerebrovit X-cellent Generation Roadshow oleh
Cerebrovit yang merupakan ajang kompetisi remaja di
berbagai kota besar di Indonesia untuk menunjukkan
bakat dan kemampuan mereka, serta kampanye
Gerakan Lambung Sehat Indonesia oleh Promag
untuk mengajak masyarakat menjadi lebih peduli
pada kesehatan lambung.
Marketing
Marketing is one of the main aspects in supporting the
achievement of sustainable sales growth. In 2011, the
Company continued implementing a marketing strategy
which directly involves consumers, in order to improve
marketing effectiveness as well as to strengthen the
Companys relationship with consumers. Various
activities were hosted by Kalbe and received positive
responses and participation of consumers. These
included Prenagen Cares for Mothers by Prenagen,
Cerebrovit X-cellent Generation Roadshow by
Cerebrovit, as a competition event for youth in several
major cities, to showcase their talent and capabilities,
and the Indonesian Movement for Gastric Health
campaign by Promag, the objective being to
encourage people to be more concerned about their
gastric health.
Produksi
Sebagai perusahaan farmasi terbesar di Asia
Tenggara, Perseroan memiliki fasilitas produksi yang
sangat memadai dan telah memenuhi persyaratan
sertifikasi yang diwajibkan. Pada akhir tahun 2011
Perseroan telah menyelesaikan pembangunan
pabrik obat generik dengan kapasitas 87 juta tablet
per bulan untuk mendukung strategi Perseroan
untuk memperkuat posisi pada pasar obat generik.
Dengan tambahan fasilitas tersebut, Perseroan saat
ini memiliki 10 fasilitas produksi yang terdiri dari 9
pabrik di Indonesia dan 1 pabrik di Nigeria. Perseroan
juga tengah membangun fasilitas produksi untuk obat
kanker yang diperkirakan akan selesai pada akhir
tahun 2012.
Manufacturing
As the largest pharmaceutical company in Southeast
Asia, the Company possesses sophisticated
manufacturing facilities, compliant with required
certification. As of the end of 2011, the Company has
completed construction of a generic pharmaceutical
manufacturer with a capacity of 87 million tablets per
month, to support Company strategy in strengthening
its position in the generic pharmaceutical market.
With the addition of this new facility, the Company
currently has 10 manufacturing facilities, consisting of
nine factories in Indonesia and one factory in Nigeria.
The Company is also in the process of constructing
a manufacturing facility for cancer drugs, which is
expected to be completed by the end of 2012.
Capital Expenditure
To sustain business growth, the Company focuses on
planned and continuous capital expenditures. In 2011
the Company invested Rp 469 billion to finance fixed
assets, funds which were, among others, used to
finance the construction of a generic pharmaceutical
facility, upgrading of distribution branches, increase
of warehouse capacity in branches, maintenance and
renewal of manufacturing machinery, the purchase
of both new machinery and laboratory equipment for
the research and development unit, the expansion of
distribution fleets, the renovation of IT hardware, the
expansion of business applications and integrated IT
infrastructures and other purchases for items such as
office supplies.
163
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
Kebijakan Dividen
Sebagai perusahaan terbuka, Kalbe memiliki
kebijakan untuk membayar dividen tunai setiap tahun,
dengan mempertimbangkan laba yang diperoleh,
kewajiban pembentukan dana cadangan sesuai
dengan peraturan yang berlaku, rencana Perseroan
dan kondisi keuangan Perseroan.
Dividend Policies
As a listed company, Kalbe abides by a policy to
declare a cash dividend payment each year, after
considering the income for the year and obligations to
allocate reserves in accordance with applicable laws
and regulations, the Companys plan, as well as the
Companys financial condition.
2009
2008
2007
2006
2005
70.0
25.0
12.5
10.0
10.0
51.0
26.0
17.0
14.0
14.0
164
Subsequent Events
On March 8, 2012, the Company received a Notification
of the verdict from the Supreme Court of the Republic
of Indonesia concerning JP Morgan case against the
Company, and the official copy of Supreme Court
Decision No. 2681K/Pdt/2010 Jo.No. 89/Pdt.G/2009
/PN.Jkt.Pst. In its verdict, the Supreme Court of the
Republic of Indonesia accepted the Companys
exception and denied the claim of JP Morgan.
165
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
166
4. P
eraturan Kepala Badan Pengawas Obat
dan
Makanan
No.HK.03.1.23.10.11.08481
Tahun 2011 tentang Kriteria dan Tata Laksana
Registrasi Obat Menggantikan Peraturan
Kepala Badan Pengawas Obat dan Makanan
No.HK.00.05.3.1950 Tahun 2003 tentang Kriteria
dan Tata Laksana Registrasi Obat.
Mengatur mulai dari kriteria obat, kategori registrasi
obat hingga tata laksana registrasi obat
untuk
melindungi masyarakat dari peredaran obat yang
tidak memenuhi khasiat, keamanan dan mutu.
4.
The National Food and Drug Supervisory
Agency Regulation No.HK.03.1.23.10.11.08481
of 2011, regarding Criteria and Procedures
for Drug Registration, Replacing the National
Food and Drug Supervisory Agency Decree No.
HK.00.05.3.1950 of 2003 regarding Criteria and
Procedures for Drug Registration.
Regulating drug criteria, categories of drug
registration, and procedures for drug registration
to protect the public from the distribution of drugs
which do not meet standards of efficacy, safety and
quality.
167
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
168
S
esuai dengan PSAK No. 1 (Revisi 2009), Kalbe
telah mereklasifikasi kepentingan non-pengendali
pada tanggal 31 Desember 2010 dan 1 Januari
2010/31 Desember 2009 masing-masing sebesar
Rp 398 miliar dan Rp 480 miliar sebagai bagian dari
ekuitas. Oleh karena itu, laporan posisi keuangan
konsolidasian Kalbe pada tanggal 31 Desember
2010 dan 1 Januari 2010/31 Desember 2009 telah
disajikan kembali.
2. Prinsip-prinsip konsolidasian
Efektif tanggal 1 Januari 2011, Grup Kalbe
menerapkan secara retrospektif PSAK No. 4 (Revisi
2009), Laporan Keuangan Konsolidasian dan
Laporan Keuangan Tersendiri, kecuali beberapa
hal berikut yang diterapkan secara prospektif: (i)
rugi entitas anak yang menyebabkan saldo defisit
bagi kepentingan non-pengendali (KNP); (ii)
kehilangan pengendalian pada entitas anak; (iii)
perubahan kepemilikan pada entitas anak yang
tidak mengakibatkan hilangnya pengendalian; (iv)
hak suara potensial dalam menilai keberadaan
pengendalian; dan (v) konsolidasian atas entitas
anak yang memiliki pembatasan jangka panjang.
2. Principles of consolidation
Effective January 1, 2011, the Kalbe Group
retrospectively adopted PSAK No. 4 (Revised
2009), Consolidated and Separate Financial
Statements, except for certain items which
were applied prospectively: (i) losses within a
subsidiary that result in a deficit balance to noncontrolling interest (NCI); (ii) loss of control over a
subsidiary; (iii) changes in the ownership interest in
a subsidiary that do not result in the loss of control;
(iv) potential voting power in ascertaining control;
(v) consolidation over subsidiaries with long term
restriction
3. Kombinasi bisnis
Efektif tanggal 1 Januari 2011, Grup Kalbe
mengadopsi secara prospektif PSAK No. 22 (Revisi
2010), Kombinasi Bisnis bagi kombinasi bisnis
yang tanggal akuisisinya pada atau setelah awal
tahun/periode buku yang dimulai pada atau setelah
tanggal 1 Januari 2011. Sesuai dengan ketentuan
transisi dari PSAK No. 22 (Revisi 2010), pada
tanggal 1 Januari 2011, Grup Kalbe:
3. Business Combinations
Effective January 1, 2011, Kalbe Group prospectively
adopted PSAK No. 22 (Revised 2010), Business
Combinations for business combinations whose
acquisition date is on or after the beginning of a
reporting year/period commencing on or after
January 1, 2011. In accordance with the transitional
provisions of PSAK No. 22 (Revised 2010), on
January 1, 2011, Kalbe Group:
m
elakukan uji penurunan nilai atas goodwill sesuai
dengan PSAK No. 48 (Revisi 2009), Penurunan
Nilai Aset, sejak awal tahun/periode buku yang
dimulai pada atau setelah tanggal 1 Januari 2011
PSAK No. 48 (Revisi 2009) menetapkan prosedurprosedur yang diterapkan entitas agar aset dicatat
tidak melebihi jumlah terpulihkannya. Suatu aset
dicatat melebihi jumlah terpulihkannya jika total
tersebut melebihi jumlah yang akan dipulihkan
melalui penggunaan atau penjualan aset. Pada
kasus demikian, aset mengalami penurunan nilai
dan pernyataan ini mensyaratkan entitas mengakui
rugi penurunan nilai. PSAK yang direvisi ini juga
menentukan kapan entitas membalik suatu rugi
penurunan nilai dan pengungkapan yang diperlukan.
169
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Tinjauan Keuangan
Financial Review
170
171
172
Implementasi
Tata Kelola
Perusahaan
yang Efektif dan
Transparan
Effective and Transparent Corporate
Governance Implementation
173
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Implementasi tata
kelola perusahaan
yang efektif dan
transparan
Effective and
transparent corporate
governance
implementation
174
Consolidated
Financial
Statements
175
Performance
Highlights
Management
Report
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
176
Management
Discussion &
Analysis
and
Mekanisme GCG
Kalbe telah memiliki kelengkapan kebijakan-kebijakan
(soft-structure) yang mengatur berbagai aspek
pelaksanaan GCG di Kalbe. Soft-structure GCG
disusun sedemikian rupa sesuai dengan kebutuhan
dan mengacu pada berbagai ketentuan yang berlaku
di Indonesia. Soft-structure GCG yang berlaku di
Kalbe adalah sebagai berikut:
a. Visi, Misi, Motto, serta nilai-nilai Perseroan yang
telah tertanam dalam sejarah perjalanan Kalbe dan
diperbaharui sesuai dengan perkembangan bisnis
Perseroan
b. Pedoman Good Corporate Governance PT Kalbe
Farma Tbk, yang telah diberlakukan sejak tahun
2001.
c. B
uku Saku Panduan Pelaksanaan Tata Kelola
Perusahaan yang telah didistribusikan kepada
seluruh karyawan Kalbe sejak tahun 2005.
d. Piagam Audit Internal
e. Kebijakan hukum Kalbe Good Legal Practice sejak
tahun 2006
f. K
ebijakan Teknologi Informasi
g. K
ebijakan mengenai hak dan kewajiban karyawan
h. Kebijakan mengenai tanggung jawab sosial
Perseroan
i. Berbagai Standard Operating Procedures
Mechanism of GCG
Kalbe has soft-structure devices which manage
various aspects of GCG implementation in Kalbe. Soft
structure of GCG is well arranged based on the needs
and refers to several regulations in Indonesia. Soft
structure of GCG applied in Kalbe are as follows:
a. V
ision, Mission, Motto and Company values which
have been inherent through the history of Kalbe
and rejuvenated, along with the development of
Company businesses
b. Good Corporate Governance Guidelines of PT
Kalbe Farma Tbk, which have been enacted since
2001.
c. G
CG Implementation Guideline Pocket Book which
has been distributed to all Kalbe staff since 2005.
d. Internal Audit Charter
e. K
albe Legal policy - Good Legal Practice since
2006
f. Policy of Information Technology
g. Policy on employee rights and obligations
h. Policy employees' corporate social responsibilities
i. Various Standard Operating Procedures
177
Management
Report
Performance
Highlights
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Direksi
Board of Directors
Komite Audit
Audit Committee
178
Komite Nominasi
Nomination
Committee
Dewan Komisaris
Board of Commissioners
Komite Remunerasi
Remuneration
Committee
Komite GCG
GCG Committee
179
Performance
Highlights
180
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
RUPS Tahunan
Selama tahun 2011, Kalbe telah melaksanakan 1
(satu) kali RUPS Tahunan. RUPS Tahunan tersebut
diaksanakan pada tanggal 25 Mei 2011 di Gedung
Bintang Toedjoe, Jl. Jend. A. Yani No. 2, Pulomas,
Jakarta.
Annual GMS
During 2011, Kalbe has conducted 1 (one) Annual
GMS. The Annual GMS was carried out on May 25,
2011 in Bintang Toedjoe Building, Jl. Jend A. Yani No.
2, Pulomas, Jakarta.
Pemberitahuan
Notification
Pengumuman
Announcement
Panggilan
Invitation
Hasil RUPS
GMS Result
M
elalui surat Perseroan kepada
Bapepam-LK No. 021/CSECKF/IV-11 Perihal Pemberitahuan
Pelaksanaan RUPS Tahunan
Perseroan.
B
y Letter of the company
to Bapepam-LK No. 021/
CSEC-KF/IV-11 Concerning
Announcement of the Annual
GMS of the Company
M
elalui iklan di surat kabar
Harian Bisnis Indonesia dan
Investor Daily.
B
y advertisement in daily
newspaper Bisnis Indonesia
and Investor Daily.
2. a
. Menyetujui
dan
mengesahkan
Laporan
Keuangan Perseroan yang memuat Neraca dan
Perhitungan Laba Rugi Perseroan untuk tahun
buku yang berakhir pada tanggal 31 Desember
2010 yang telah diaudit oleh Kantor Akuntan
Publik Purwantono, Suherman & Surja.
b. Memberikan pelunasan dan pembebasan
tanggung jawab sepenuhnya kepada Dewan
Komisaris dan Direksi Perseroan yang akan
berakhir masa jabatannya segera setelah
ditutupnya Rapat atas tindakan pengawasan
dan pengurusan yang mereka lakukan dalam
tahun buku yang berakhir pada tanggal 31
Desember 2010 (acquit et decharge), sepanjang
tindakan-tindakan mereka tersebut tercermin
dalam Laporan Keuangan dan Laporan Tahunan
Perseroan untuk tahun buku yang berakhir pada
tanggal 31 Desember 2010.
b. G
ave full discharge to the Board of commissioners
and the Board of Directors whose termsof
appoinment will expire after the closing of
the meeting from all their responsibilities
for performance of supervisory and their
management duties for the fiscal year ending
December 31, 2010 (acquit et decharge), for
as long as their actions are reflected in the
Companys Financial Statements and Annual
Report for the fiscal year ending December 31,
2010.
181
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
b. D
elegated authority to the Board of Directors of the
Company to perform all and any necessary actions
in connection with the distribution of said cash
dividend, including but not limited to determining
the time, date and method of payment of the cash
dividend.
Dewan Komisaris
Board of Commissioners
Presiden Komisaris President Commissioner
Komisaris Commissioner
Komisaris Commissioner
Komisaris Commissioner
Direksi
Board of Directors
Presiden Direktur President Director
Wakil Presiden Direktur Vice President Director
Direktur Director
Direktur Director
Direktur Director
Bapak Vidjongtius
Direktur Director
182
5.M
enyetujui pelimpahan wewenang kepada Dewan
Komisaris Perseroan untuk menetapkan jumlah gaji
dan/atau honorarium anggota Dewan Komisaris dan
anggota Direksi Perseroan serta untuk menetapkan
jumlah gaji dan/atau honorarium anggota Dewan
Komisaris dan anggota Direksi Perseroan.
Dewan Komisaris
Dewan Komisaris merupakan organ perusahaan yang
bertugas dan bertanggung jawab secara kolektif
untuk melakukan pengawasan dan memberikan
nasehat kepada Direksi serta memastikan bahwa
Kalbe melaksanakan GCG pada seluruh tingkatan
atau jenjang organisasi.
Board of Commissioners
Board of Commissioners is the organ of the Company
which has the duty and collective responsibility to
supervise and advise the Board of Directors and
to ensure that Kalbe has implemented GCG at all
organizational levels or hierarchy.
183
Performance
Highlights
184
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
a. C
onduct supervision over the management of
the Company by the Board of Directors and give
approval and ratification of the work plan and
annual budget of the Company.
the
Board
of
Nama
Name
Jabatan
Title
Masa Jabatan
Period
Presiden Komisaris
President Commissioner
2011 - 2014
Santoso Oen
Komisaris
Commissioner
2011 - 2014
Komisaris
Commissioner
2011 - 2014
Ferdinand Aryanto
Komisaris
Commissioner
2011 - 2014
Wahjudi Prakarsa
Komisaris Independen
Independent Commissioner
Independen
Independent
2011 - 2014
Komisaris Independen
Independent Commissioner
Independen
Independent
2011 - 2014
Johannes Setijono
185
Performance
Highlights
Management
Report
Company
Profile
186
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Dalam
rangka
mendukung
pertumbuhan
yang
berkelanjutan,
serta
mempertahankan
kondisi kesehatan Kalbe, Dewan Komisaris
merekomendasikan perlunya dilakukan upaya
perbaikan sekaligus pemeliharaan kinerja Kalbe yang
mencakup faktor-faktor sebagai berikut:
1. Kebutuhan akan penyempurnaan kebijakankebijakan Peseroan dalam mendukung penerapan
praktik GCG di Perseroan.
2. Pemantauan aspek eksekusi rencana strategis
Perseroan termasuk pengembangan penerapan
manajemen risiko.
3. Upaya-upaya peningkatan kinerja Perseroan
dalam meningkatkan nilai bagi seluruh pemangku
kepentingan.
Nama
Name
Santoso Oen
Ferdinand Aryanto
Wahjudi Prakarsa
Catatan :
Ketidakhadiran dalam rapat terutama disebabkan oleh perjalanan dinas.
Absence was mainly due to business trip
23 Februari 2011
February 23, 2011
25 Mei 2011
May 25, 2011
187
Performance
Highlights
188
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
22 Agustus 2011
August 22, 2011
23 November 2011
November 23, 2011
Direksi
Direksi
adalah
organ
perusahaan
yang
bertanggungjawab
penuh
atas
pengurusan
perusahaan untuk kepentingan dan tujuan perusahaan
sesuai dengan ketentuan anggaran dasar.
Board of Directors
The Board of Directors is the companys organ that
holds full responsibility of corporate management for
its interests and objectives, in accordance with its
Articles of Association.
189
Management
Report
Performance
Highlights
Corporate
Governance
Consolidated
Financial
Statements
Susunan Direksi
Susunan Direksi berdasarkan RUPS tanggal 25 Mei
2011 sebagai berikut:
Nama Name
190
Management
Discussion &
Analysis
Company
Profile
Jabatan Title
Presiden Direktur
President Director
2011 - 2014
2011 - 2014
Direktur
Director
2011 - 2014
Herman Widjaja
Direktur
Director
2011 - 2014
Vidjongtius
Direktur
Director
2011 - 2014
Ongkie Tedjasurja
Direktur
Director
2011 - 2014
Presiden Direktur
President Director
Bertanggung jawab untuk mengkoordinasikan seluruh kegiatan operasional Perseroan
Responsible for coordinating all Company's operational activities
Direktur
Director
Bertanggung jawab untuk segmen usaha Distribusi dan Logistik
Responsible for Distribution and Logistics Division
Herman Widjaja
Direktur
Director
Bertanggung jawab untuk segmen usaha Obat Resep
Responsible for Prescription Pharmaceuticals Division
Vidjongtius
Direktur
Director
Bertanggung jawab untuk bidang Keuangan dan Teknologi Informasi
Responsible for Finance and Information Technology
Ongkie Tedjasurja
Direktur
Director
Bertanggung jawab untuk bidang Pemasaran Korporasi dan segmen usaha Nutrisi
Responsible for Corporate Marketing and Nutritionals Division
191
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Consolidated
Financial
Statements
Corporate
Governance
Rapat Direksi
Board of Directors Meetings
41
39
40
35
Herman Widjaja
35
Vidjongtius
36
Ongkie Tedjasurja
13
* Ketidakhadiran dalam rapat terutama disebabkan oleh perjalanan dinas. Ongkie Tedjasurja diangkat menjadi Direktur berdasarkan keputusan
RUPS Tahunan tanggal 25 Mei 2011.
Absence from meetings was mainly due to business trip. Ongkie Tedjasurja was appointed as a Director based on the Annual GMS decision on
May 25, 2011.
192
Nama Name
Bernadette Ruth
Irawati Setiady
Jabatan Title
Presiden
Komisaris
President
Commissioner
Komisaris
Commissioner
PT Kalbe
Morinaga
Indonesia*
PT Enseval Putera
Megatrading Tbk*
Komisaris
Independen
Independent
Commissioner
Presiden Direktur
President Director
Wakil Presiden
Direktur
Vice President
Director
PT Kalbe Farma
Tbk
Direktur
Director
Asiawide Kalbe
Philippines, Inc.*
PT Sanghiang
Perkasa*
Johanes
Berchman Apik
Ibrahim
PT Saka Farma
Laboratories*
PT Sanghiang
Perkasa*
PT Bintang
Toedjoe*
PT Kalbe Farma
Tbk
Kalbe
International Pte.
Ltd*
Asiawide Kalbe
Philippines, Inc.*
Budi Dharma
Wreksoatmodjo
PT Sanghiang
Perkasa*
PT Enseval
Medika Prima*
PT Milenia
Dharma Insani*
PT Enseval Putera
Megatrading Tbk*
PT Kalbe Farma
Tbk
PT Global
Chemindo
Megatrading*
Herman Widjaja
PT Enseval Putera
Megatrading Tbk*
PT Renalmed
Tiara Utama*
PT Kalbe Farma
Tbk
Vidjongtius
PT Bifarma
Adiluhung*
PT Kalbe Farma
Tbk
Ongkie Tedjasurja
PT Kalbe
Morinaga
Indonesia*
PT Kalbe Farma
Tbk
PT Finusolprima
Farma
International*
PT Hexpharm
Jaya
Laboratories*
PT Dankos
Farma*
PT Sanghiang
Perkasa*
Kalbe Vision Pte.
Ltd.*
* Entitas anak
* Subsidiaries
193
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Pelatihan Direksi
Dalam rangka peningkatan dan pengembangan
kompetensi untuk menunjang tugas pengelolaan
perusahaan, Direksi telah mengikuti berbagai seminar,
workshop, conference dan talk show baik di dalam
maupun luar negeri. Pada tahun 2011, pelatihan yang
telah dijalankan oleh Direksi adalah sebagai berikut:
194
Corporate
Governance
Consolidated
Financial
Statements
Tanggal
Date
Perihal
Topic
Penyelenggara
Institution
Lokasi
Location
Nama Direksi
Director's Names
February 23 - 25
New Me Program
Qarakter Tuai
Qarakter
Bandung
November 29
Markplus
Jakarta
Herman Widjaja
October 11 12
Jakarta
Remuneration
Policy
for
the
Board
of
Commissioners and Board of Directors
Remuneration for the Board of Directors and
Commissioners refers to the resolution made by the
Shareholders as stipulated in the GMS, with respect
to the results of a review conducted by the Company.
The review of remuneration considers the following
aspects:
1. F
inancial performance and achievement of the
Company's Key Performance Indicators (KPIs).
2. Individual performance.
3. Fairness with other peer companies.
4. C
onsideration of long-term goals and strategies of
the Company.
195
Management
Report
Performance
Highlights
Management
Discussion &
Analysis
Company
Profile
Pengungkapan
Kepemilikan
Saham
Serta
Hubungan Keuangan
Per posisi 31 Desember 2011, anggota Dewan
Komisaris tidak memiliki saham di Kalbe, sedangkan
anggota Direksi yang memiliki saham di Kalbe adalah
sebagai berikut:
Nama Name
Consolidated
Financial
Statements
Jabatan Title
2.124.500
-
Direktur Director
Herman Widjaja
Direktur Director
Vidjongtius
Direktur Director
Ongkie Tedjasurja
Direktur Director
Komite Audit
Dalam menunjang pelaksanaan GCG, Kalbe telah
membentuk Komite Audit yang bertugas membantu
Dewan Komisaris berdasarkan Surat Keputusan
Dewan Komisaris No.01/SK/VIII/DeKom/KF/LC/2011
tanggal 22 Agustus 2011 tentang Pengangkatan
Komite Audit.
Audit Committee
In supporting the implementation of GCG, Kalbe has
established an Audit Committee to assist the Board
of Commissioners, based on the Decree of the Board
of Commissioners No.01/SK/VIII/DeKom/KF/LC/2011
dated August 22, 2011 regarding the Appointment of
an Audit Committee.
196
Corporate
Governance
1
2
Nama Name
Jabatan Title
1.
Ketua Chairman
2.
Ichsan Gunawan
Anggota Member
3.
Dianawati Sugiarto
Anggota Member
Farid Anfasa
Moeloek
Ichsan Gunawan
Dianawati
Sugiarto
Keterangan:
= independen - = tidak independen
197
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Consolidated
Financial
Statements
5. M
emberikan penjabaran tugas dan tanggung jawab
Komite Audit untuk tahun buku yang bersangkutan
sesuai dengan kebutuhan auditor eksternal.
Frekuensi Pertemuan
Komite Audit mengadakan rapat secara berkala.
Selama tahun 2011 Komite Audit mengadakan rapat
sebanyak 3 kali dengan tingkat kehadiran masingmasing anggota Komite Audit seperti tercantum pada
tabel di bawah.
Frequency of Meetings
The Audit Committee convenes meetings periodically.
Throughout 2011 the Audit Committee convened
meetings 3 times with the level of attendance of each
member of the Audit Committee as listed in the table
below.
No.
Ichsan Gunawan
Dianawati Sugiarto
1.
February 2, 2011
2.
3.
198
Corporate
Governance
Komite Nominasi
Dalam menunjang pelaksanaan GCG, Kalbe telah
membentuk Komite Nominasi yang bertugas
membantu Dewan Komisaris berdasarkan Surat
Keputusan Dewan Komisaris No. 34/III/08/Komite
Nominasi/KF-LD tanggal 1 Maret 2008 tentang
Penunjukan dan Pengangkatan Pejabat Komite
Nominasi.
Nomination Committee
In support of the implementation of GCG, Kalbe
has established a Nomination Committee to assist
the Board of Commissioners, based on Board
of Commissioners Decree No. 34/III/08/Komati
Nominasi / KF-LD, dated March 1, 2008, regarding
the Appointment and Designation of Nomination
Committee Officers.
Nama Name
Jabatan Title
1.
Johannes Setijono
Ketua Chairman
2.
Anggota Member
3.
Anggota Member
Frekuensi Pertemuan
Komite Nominasi mengadakan rapat secara berkala.
Selama tahun 2011 Komite Nominasi mengadakan
rapat sebanyak 2 kali dengan tingkat kehadiran
masing-masing anggota Komite Nominasi tercantum
pada tabel di bawah.
No.
Frequency of Meetings
The Nomination Committee meets on a regular basis.
During 2011 the Nomination Committee met 2 times
with the level of attendance of each member of the
Nomination Committee as listed in the table below.
1.
2.
November 3, 2011
199
Performance
Highlights
Management
Report
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
Komite Remunerasi
Dalam menunjang Dewan Komisaris dalam
pelaksanaan tugasnya, Kalbe telah membentuk
Komite Remunerasi berdasarkan Surat Keputusan
Dewan Komisaris No. 33/III/08/Komite Remunerasi/
KF-LD tanggal 1 Maret 2008 tentang Penunjukan dan
Pengangkatan Pejabat Komite Remunerasi.
Remuneration Committee
In supporting the execution of its duties by the
Board of Commissioners, Kalbe has established
a Remuneration Committee, based on the Board
of Commissioners Decree No. 33/III/08/Komite
Remunerasi/KF-LD, dated March 1, 2008, concerning
the Appointment and Designation of Remuneration
Committee Officers.
Remuneration
Committee
Membership
Composition
As of
31 December 2011, the Remuneration
Committee members were as follows:
200
Management
Discussion &
Analysis
Nama Name
Jabatan Title
1.
Johannes Setijono
Ketua Chairman
2.
Anggota Member
3.
Anggota Member
Frekuensi Pertemuan
Komite Remunerasi mengadakan rapat secara berkala.
Selama tahun 2011 Komite Remunerasi mengadakan
rapat sebanyak 2 kali dengan tingkat kehadiran
masing-masing
anggota
Komite
Remunerasi
tercantum pada tabel di bawah.
No.
Frequency of Meetings
The Remuneration Committee meets on a regular
basis. During 2011 the Remuneration Committee met
2 times with the level of attendance of each member
of the Remuneration Committee as listed in the table
below.
Jumlah Kehadiran Number of Attendance
Johannes Setijono
1.
2.
November 3, 2011
201
Performance
Highlights
Management
Report
Company
Profile
Corporate
Governance
Jabatan Title
1.
Johannes Setijono
Ketua Chairman
2.
Anggota Member
3.
Anggota Member
4.
Vidjongtius
Anggota Member
No.
Consolidated
Financial
Statements
Business
Risk
Committee
Membership
Composition
As of 31 December 2011, the Business Risk Committee
members are as follows:
Nama Name
Frekuensi Pertemuan
Komite Risiko Usaha mengadakan rapat secara
berkala. Selama tahun 2011 Komite Risiko Usaha
mengadakan rapat sebanyak 2 (dua) kali dengan
tingkat kehadiran masing-masing anggota Komite
Risiko Usaha tercantum pada tabel di bawah.
202
Management
Discussion &
Analysis
Frequency of Meetings
The Business Risk Committee meets on a regular
basis. During 2011 the Business Risk Committee met
2 times, with the level of attendance of each member
of the Business Risk Committee as listed in the table
below.
Jozef Darmawan
Angkasa
Budi Dharma
Wreksoatmodjo
Vidjongtius
1.
2.
October 5, 2011
Komite GCG
Dalam menunjang pelaksanaan GCG, Kalbe telah
membentuk Komite GCG yang bertugas membantu
Dewan Komisaris berdasarkan Surat Keputusan
Dewan Komisaris No. 35/III/08/GCG/KF-LD tanggal
1 Maret 2008 tentang Penunjukan dan Pengangkatan
Pejabat Komite Good Corporate Governance (GCG).
GCG Committee
In supporting the implementation of GCG, Kalbe
established the GCG Committee, which assists the
Board of Commissioners, based on the Board of
Commissioners Decree No. 35/III/08/GCG/KF-LD
dated March 1, 2008, concerning the Appointment
and Designation of Good Corporate Governance
(GCG) Committee Officers.
No
4. T
o carry out other tasks given by the Board of
Commissioners related to the development and
implementation of GCG.
Nama Name
Jabatan Title
1.
Vidjongtius
Ketua Chairman
2.
Agustinus Haryono
3.
Anggota Member
4.
Joyce V. Handajani
Anggota Member
5.
Febiana Rinasari
Anggota Member
Frekuensi Pertemuan
Komite GCG mengadakan rapat secara berkala.
Selama tahun 2011 Komite GCG mengadakan rapat
sebanyak 4 kali dengan tingkat kehadiran masingmasing anggota Komite GCG tercantum pada tabel di
bawah.
No.
Frequency of Meetings
GCG Committee meets on a regular basis. During
2011 the GCG Committee met 4 times with the level
of attendance of each member of the GCG Committee
as listed in the table below.
Agustinus Haryono
Bernadus Karmin
Winata
Joyce V. Handajani
Febiana Rinasari
1.
2.
3.
August 8, 2011
4.
203
Performance
Highlights
204
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
2. M
enyusun dan melaksanakan rencana kerja Audit
Internal tahunan berdasarkan hasil analisis risiko
(risk-based audit)
3. M
enguji
dan
mengevaluasi
pelaksanaan
pengendalian internal dan sistem manajemen risiko
sesuai dengan kebijakan perusahaan
4. M
emberikan saran perbaikan dan informasi yang
objektif tentang kegiatan yang diperiksa pada
semua tingkat manajemen
5. M
embuat laporan hasil audit dan menyampaikan
laporan tersebut kepada Presiden Direktur dan
Dewan Komisaris dan/atau Komite Audit
6. M
emantau,
menganalisis
dan
melaporkan
pelaksanaan tindak lanjut (corrective action)
perbaikan yang telah disarankan
7. B
ekerja sama dengan Komite Audit dalam
pelaksanaan tugas dan tanggung jawab Komite
Audit
8. K
oordinasi dengan Unit Audit Internal yang berada
di dalam grup Perseroan
205
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Consolidated
Financial
Statements
Target
Deputy Director
General Manager
Manager
Supervisor
Officer
10
12
Administrator
Pelatihan Training
QIA Certification
Peserta Participant
24,0
Keterangan Description
PIA Certification
19,3
6,3
26,1
23,5
Risk Management
24,8
CRMD dan
Center for Risk Management Studies Indonesia
24,9
PRMF
25
68,8
WIM Consult
Internal Training
13
31,7
Total
206
Corporate
Governance
249,4
Internal deviation
The Company is committed to implement an
effective Internal Control System, so as to prevent
the occurrence of irregularities / non-compliance
procedures by officers / officials, permanent or
temporary staff (salaried or outsourced) related to
work processes and operational activities.
207
Performance
Highlights
Management
Report
Management
Discussion &
Analysis
Company
Profile
Risiko Teknikal
Technical Risk
Manajemen Kas
Cash Management
Consolidated
Financial
Statements
Risiko Operasional
Operational Risk
Risiko Komersial
Commercial Risk
Risiko Keuangan
Financial Risk
Total
16
31
47
11
24
30
10
26
54
11
42
114
Lain-Lain
Others
Total
208
Corporate
Governance
Audit Eksternal
Fungsi pengawasan independen terhadap aspek
keuangan Perseroan dilakukan dengan melaksanakan
pemeriksaan Audit Eksternal yang dilakukan oleh
Kantor Akuntan Publik. Sesuai dengan hasil dari
Rapat Umum Pemegang Saham Tahunan PT Kalbe
Farma Tbk tanggal 25 Mei 2011, wewenang dan kuasa
penunjukan Akuntan Publik Independen yang akan
melakukan audit atas Laporan Keuangan Perseroan
untuk tahun buku yang berakhir pada tanggal 31
Desember 2011 diberikan kepada Direksi Perseroan
dengan persetujuan Dewan Komisaris Perseroan.
External Audit
The independent monitoring of the Companys
financial aspects was carried out by conducting an
External Audit, performed by a Public Accounting Firm.
In accordance with the results of the Annual General
Meeting of Shareholders of PT Kalbe Farma Tbk
dated 25 May 2011, the authorization to appoint the
Independent Public Accountant who would conduct
the audit of the Company's Financial Statements at
the fiscal year ended 31 December 2011 was granted
to the Companys Board of Directors with the approval
of the Board of Commissioners.
2011
2010
2009
2008
2007
2011
2,531
2010
2,566
2009
2,490
2008
2,550
2007
2,483
Manajemen Risiko
Situasi lingkungan eksternal dan internal perusahaan
mengalami perkembangan pesat yang diikuti
dengan semakin kompleksnya risiko kegiatan bidang
usaha yang dijalani oleh Perseroan. Hal tersebut
mendorong Kalbe untuk meningkatkan praktek GCG
dan penerapan manajemen risiko yang memadai.
Penerapan manajemen risiko diharapkan memberikan
manfaat berupa:
1. Penyediaan informasi kepada pihak manajemen
mengenai eksposur risiko yang dihadapi;
2. Peningkatan metode dan proses pengambilan
keputusan yang sistematis;
3. Penilaian risiko yang melekat pada setiap produk
atau kegiatan usaha Kalbe.
Risk Management
The external environment and the internal situation
of companies are both undergoing rapid change,
resulting in increasingly complex business risk in the
Companys lines of business. This spurred Kalbe to
improve its practice of good corporate governance
while ensuring adequate risk management.
Implementation of risk management is expected to
provide benefits such as:
1. S
upplying information to management about
exposure to risks;
2. Improvement of methods and a systematic
decision-making process;
3. Assessment of risks inherent in each product or
business activity of Kalbe.
209
Performance
Highlights
210
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Profil Risiko
Beberapa risiko utama yang memiliki pengaruh
penting terhadap kegiatan usaha Kalbe antara lain:
1. Risiko Kompetisi Bisnis
D
alam era pasar terbuka sekarang ini, persaingan
dalam sektor farmasi dan produk kesehatan lainnya
akan semakin ketat dengan banyaknya produsen
lokal maupun internasional yang beroperasi.
Persaingan tersebut timbul dalam berbagai aspek,
antara lain sumber daya keuangan dan kemampuan
operasional pesaing internasional yang lebih
kuat, serta inovasi produk, metode promosi dan
pemasaran, perubahan permintaan pasar, daya
beli masyarakat yang terbatas serta kesiapan
menghadapi persaingan bisnis yang tidak sehat.
Risk Profile
Among the major risks which could exert an important
influence on Kalbe's business activities:
1. B
usiness Competition Risk
In today's era of open markets, competition in the
pharmaceutical sector and other health products
will be more stringent, with larger numbers of both
international and local producers crowding the field.
Competition arises in various aspects, including
financial resources and the stronger operational
capabilities of international competitors, as well
as product innovation, marketing and promotion,
changes in market demand, limited purchasing
power and readiness to face unhealthy business
competition.
2. Risiko Keuangan
Dalam menjalankan kegiatan bisnis, Grup Kalbe
juga menghadapi risiko keuangan yang timbul
sebagai akibat fluktuasi mata uang asing, anggaran,
pembiayaan, serta likuiditas. Karena sebagian besar
bahan baku Kalbe diimpor, hal ini menimbulkan
dampak dalam bentuk kerentanan terhadap
fluktuasi valuta asing. Fluktuasi mata uang asing,
terutama dalam Dollar Amerika, sangat berdampak
pada biaya produksi.
2. Financial Risk
In the course of business, Kalbe Group also faces
financial risks arising from fluctuations in foreign
currency, budgeting, financing, and liquidity.
Because most of Kalbe's raw materials are imported,
this creates an impact in the form of vulnerability
to fluctuations in foreign currency. Fluctuations
in foreign currency, mainly in U.S. dollars, exert a
significant impact on production costs.
211
Performance
Highlights
212
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
4. Risiko Reputasi
Risiko reputasi ini meliputi komplain konsumen,
penarikan kembali produk dan juga kemungkinan
adanya sabotase terhadap produk, serta
pencemaran nama baik. Di saat seperti sekarang
ini, dimana citra perusahaan sangatlah penting,
maka pencemaran reputasi merupakan risiko yang
harus diperhatikan.
4. Reputation Risk
Reputation risk includes consumer complaints,
product recalls and also the possibility of sabotage
of a product, as well as defamation. In contemporary
times, where corporate image is important, the
pollution of reputation is also a risk that must be
considered.
213
Performance
Highlights
214
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Kepatuhan
Kepatuhan merupakan suatu aspek penting di dalam
menjalankan usaha, baik untuk menjamin kelancaran
kegiatan operasional maupun menjaga reputasi
suatu perusahaan sebagai warga korporasi yang
baik. Sebagai perwujudan tanggung jawab sebagai
warga korporasi, dan terlebih sebagai perusahaan
terbuka, Perseroan senantiasa memperhatikan
kepatuhan terhadap peraturan perundang-undangan
yang berlaku, termasuk di dalamnya peraturan
pasar modal. Ketidakpatuhan terhadap peraturan
perundangan dapat berakibat teguran dari pihak
regulator dan mencemarkan reputasi baik Perseroan.
Dalam menjalankan kegiatan operasionalnya, Kalbe
menghadapi berbagai jenis peraturan hukum dan
perubahan regulasi yang terkait, serta aturan yang
dibuat dalam perjanjian dengan pihak ketiga. Kalbe
menerapkan kepatuhan terhadap hukum yang berlaku,
sehingga Perseroan dapat memenuhi berbagai
perjanjian dan peraturan yang berlaku, dengan
memperhatikan kesiapan dari segi legalitas Perseroan
maupun kompetensi dan ketersediaan sumber daya.
Compliance
Compliance is an important aspect of running a
business, both for ensuring smooth operations and
for maintaining a company's reputation as a good
corporate citizen. As part of its responsibility as
a public company, Kalbe adheres to compliance
with prevailing regulations, including capital market
regulations. Failure to comply with regulations may
result in sanctions from regulators and may negatively
impact the Companys reputation. In running its
operations, Kalbe is required to conform to various
types of legal requirements and related regulatory
changes, as well as to rules made through contractual
agreements concluded with third parties. Kalbe
maintains compliance with applicable laws, so that
the Company can fulfill contractual agreements and
applicable regulations as anticipatory measures,
building capabilities in terms of corporate legality and
necessary resources.
Aksi Korporasi
Selama tahun 2011, Kalbe telah melakukan sejumlah
aksi korporasi sebagai berikut:
1. Peningkatan kepemilikan saham Kalbe atas EPMT
yang merupakan anak perusahaan Kalbe.
Peningkatan kepemilikan Kalbe atas EPMT
dilakukan melalui Penawaran Umum Terbatas
I EPMT sebanyak 359.568.375 lembar saham,
yang terdiri dari 358.980.890 lembar saham
berdasarkan Hak Memesan Efek Terlebih Dahulu
yang dimiliki Kalbe dan 587.485 lembar saham atas
Penjatahan Pemesanan Tambahan; serta melalui
pembelian melalui pasar modal reguler yaitu Bursa
Efek Indonesia. Hingga tanggal 31 Desember
2011, jumlah kepemilikan Kalbe atas EPMT
tercatat sebesar 91,75% dari seluruh saham yang
ditempatkan dan disetor oleh EPMT.
Corporate Actions
During 2011, Kalbe conducted a number of corporate
actions as follows:
1. Increasing the shareholding of Kalbe in EPMT, a
subsidiary of Kalbe.
Increased ownership of Kalbe in EPMT through an
EPMT Right Issue 1, recording a total of 359,568,375
shares, consisting of 358,980,890 shares under
Pre-emptive Rights owned by Kalbe and 587,485
shares in Additional Booking Allotment, as well
as a regular capital market purchase, through the
Indonesian Stock Exchange (BEI). As of December
31, 2011, the number of EPMT shares held by Kalbe
was recorded at 91.75% of total shares issued and
fully paid by EPMT.
Sekretaris Perusahaan
Sekretaris Perusahaan merupakan pihak penghubung
yang menjembatani kepentingan antara Perseroan
dengan pihak eksternal, terutama dalam menjaga
persepsi publik atas citra Perseroan dan pemenuhan
tanggung jawab oleh Perseroan. Sekretaris
Perusahaan bertanggung jawab kepada Direksi.
Corporate Secretary
The Corporate Secretary is the liaison who bridges
interests between the Company and external parties,
principally in an effort to maintain a positive public
perception of the Companys image and as the
Companys fulfillment of its responsibilities. The
Corporate Secretary reports to the Board of Directors.
215
Performance
Highlights
216
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
217
Performance
Highlights
218
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
K
albe Family Portal provides information for the
benefit of employees and also provides access to
information to support their daily work. This portal is
prepared as a facility to support work activities, as
well as acting as a medium of effective information.
2. E-mail Blast
E-mail Blast merupakan fasilitas sirkulasi informasi
massal yang diatur pengirimannya, baik kepada
seluruh karyawan, maupun kelompok karyawan
tertentu. Fasilitas tersebut merupakan sarana
yang efektif bagi Perseroan untuk menyampaikan
informasi secara cepat dan menyeluruh kepada
seluruh karyawan Kalbe dan anak perusahaan di
berbagai lokasi yang tersebar di seluruh Indonesia.
Selama tahun 2011 tak kurang dari 104 judul e-mail
blast telah dikirimkan kepada karyawan.
2. E-mail Blast
E-mail Blast is a facility through which mass-circulation
of information delivery can be arranged, either to
all employees, or to certain employee groups. The
facility is an effective means for the Company to
deliver information quickly and thoroughly to all
Kalbe employees and to its subsidiaries in various
locations spread throughout Indonesia. During the
year 2011, no fewer than 104 email blast titles were
sent out to employees.
Hubungan Investor
Sekretaris Perusahaan juga menangani Hubungan
Investor dalam rangka menjaga dan meningkatkan
komunikasi antara Perseroan dengan para investor
baik di tingkat lokal maupun internasional. Fungsi
Hubungan Investor antara lain menyediakan informasi
terkini terkait kinerja usaha Perseroan dan pandangan
masa depan yang membantu investor dalam
keputusan investasi pada saham Perseroan.
Investor Relations
The Corporate Secretary also handles Investor
Relations, in order to maintain and improve
communication between the Company and investors,
both locally and internationally. The Investor Relations
function, including provision of the latest information
related to the Company's business performance and
future outlook, helps investors in making investments
in shares of the Company.
Frekuensi Frequency
13
Kunjungan ke Pabrik
Site Visit
125
Paparan Publik
Public Expose
Keterbukaan Informasi
Sesuai dengan prinsip transparansi dan pemenuhan
tanggung jawab atas kepatuhan terhadap peraturan
perundangan yang berlaku di bursa efek dan pasar
modal terkait keterbukaan informasi, Kalbe senantiasa
menyampaikan informasi yang terkini terkait dengan
setiap perkembangan yang terjadi di Perseroan
kepada pemegang saham dan pihak otoritas pasar
modal melalui berbagai jalur komunikasi demi
memastikan komunikasi yang efektif. Selain pelaporan
langsung kepada pasar modal dan bursa, informasi
disampaikan kepada pemegang saham secara umum
melalui pengumuman BEI dan di media massa.
Information Disclosure
In accordance with the principles of transparency and
the fulfillment of the responsibility for compliance with
the laws and regulations on the stock exchanges and
capital markets related to the disclosure of information,
Kalbe always delivers the latest information related
to any developments in the Company to the
shareholders and capital market authorities through
various communication channels, to ensure effective
communication. In addition to reporting directly
to capital market and stock exchange authorities,
information is submitted to the shareholders in general
through IDX announcements and the media.
Frekuensi Frequency
46
Laporan Tahunan
Annual Report
Siaran Pers
Press Release
20
219
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
No
220
Tanggal Date
Topik Topic
February 27
Kalbe Farma Memperingati Hari Kanker Sedunia Merajut Asa dengan Kanker
Kalbe Farma Commemorated World Cancer Day Sustaining Hope with Cancer
March 10
Kalbe Farma Memperingati Hari Ginjal Sedunia 2011 Lindungi Ginjal, Selamatkan Jantung
Kalbe Farma Commemorated World Kidney Day 2011 Protect Your Kidney, Save Your Heart
March 29
March 31
April 8
Kalbe Farma Berbagi Untuk Sehat Pengobatan Gratis dan Paket Sembako
Kalbe Farma Cares for Health Free Medical Check and Food Package
April 18
April 27
May 10
May 18
10
May 25
11
June 5
12
July 14
13
July 24
Kalbe Berbagi Untuk Sehat - Lanjutkan Pengobatan Gratis dan Perbaikan Fasilitas Kesehatan Bagi Korban Merapi
Kalbe Cares for Health Continuing Free Medical Treatment and Health Facilities Renovation for Merapi Victims
14
July 28
Finalis Kalbe Junior Scientist Award Memperingati Hari Anak Nasional Bersama Wapres Boediono dan Mendiknas M.
Nuh Kalbe Junior Scientist
Kalbe Junior Scientist Award Finalists Commemorated National Children Day with Vice President Boediono and
Minister of National Education M. Nuh
15
July 29
16
September 10
Kalbe Junior Science Fair Inovasi untuk Kehidupan yang Lebih Baik
Kalbe Junior Science Fair Innovation for a Better Life
17
September 12
Pemenang Favorit Junior Scientist Award Win on Zero: Permainan Matematika Melatih Mencari Selisih
Favourite Winner in Junior Scientist Award Win on Zero: Mathematics Game to Find the Difference
18
October 5
19
October 27
20
December 15
Kalbe Farma dukung Hari Kesehatan Nasional Indonesia Salurkan Pengobatan Gratis kepada
1.000 warga Jawa Timur
Kalbe Farma Supported Indonesia National Health Daya Providing Free Medical Treatment
for 1,000 East Javanese People
Vidjongtius
Sekretaris Perusahaan
Tel. (021) 4287-3888
Fax. (021) 4287-3680
E-mail: vidjongtius@kalbe.co.id atau
Hubungan Investor
Tel. (021) 4287-3888
Fax. (021) 4287-3680
Email: investor.relations@kalbe.co.id
Vidjongtius
Corporate Secretary
Tel. (021) 4287-3888
Fax. (021) 4287-3680
Email: vidjongtius@kalbe.co.id or
Investor Relations
Tel. (021) 4287-3888
Fax. (021) 4287-3680
Email: investor.relations@kalbe.co.id
221
Performance
Highlights
222
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Opsi Saham
Sampai dengan periode pelaporan yang berakhir pada
31 Desember 2011, Kalbe tidak melakukan penerbitan
hak opsi atas saham Perseroan.
Stock Options
Up to the reporting period which ended on December
31, 2011, Kalbe did not issue option rights on shares
of the Company.
223
Performance
Highlights
224
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Perkara Litigasi
Permasalahan hukum adalah permasalahan hukum
perdata dan pidana yang dihadapi Kalbe selama
periode tahun laporan dan telah diajukan melalui
proses hukum.
Litigation
Legal issues are civil and criminal legal issues faced
during the period of Kalbe and reports have been filed
through the legal process.
Legal Suits/Claims
In January 2009, pursuant to Letter No.004/CSECKF/I- 09 dated January 16, 2009 on Disclosure of
Information by the Company to the Indonesia Stock
Exchange, the Company reported that JP Morgan
Chase Bank, N.A., London (JP Morgan) had filed
a claim amounting to US$ 19,194,206 related to, in
the opinion of JP Morgan, a breach of conditions of
the 2002 ISDA Master Agreement for a derivative
transaction. The Company rejected such a claim on
the grounds that the Company neither approved nor
signed the document concerned.
Perkembangan Perkara
Kemudian, pada bulan Februari 2009, Perseroan
melalui kuasa hukumnya yaitu advokat dan konsultan
hukum dari Law Firm Hotman Paris & Partners
telah mengajukan gugatan perdata di Pengadilan
Negeri Jakarta Selatan dengan nomor perkara 256/
Pdt.G/2009/PN.Jkt.Sel. Gugatan perdata ini ditujukan
kepada JP Morgan Chase Bank, National Association,
Cabang Jakarta dan pihak-pihak terkait sehubungan
dengan klaim di atas. Dasar gugatan adalah adanya
perbuatan melawan hukum dan pelanggaran terhadap
Peraturan Bank Indonesia tertentu, atas hal tersebut
Perseroan menuntut kompensasi ganti rugi sejumlah
US$ 120 juta.
Case Developments
Later, in February 2009, the Company, through its
legal attorney, Hotman Paris & Partners Law Firm,
filed a lawsuit in the South Jakarta District Court, with
the case number 256/Pdt.G/2009/PN.Jkt.Sel. This
lawsuit was filed against JP Morgan Chase Bank,
National Association, Jakarta Branch and its related
parties, regarding the above-mentioned claim. The
underlying basis of the lawsuit is a violation of the
law and a breach of certain articles of Bank Indonesia
regulations, for which the Company demanded
compensation of US$ 120 million.
225
Performance
Highlights
226
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Benturan Kepentingan
Benturan kepentingan adalah keadaan dimana
terdapat konflik antara kepentingan ekonomis Kalbe
dan kepentingan ekonomis pribadi Anggota Direksi,
Anggota Dewan Komisaris, pemegang saham utama
atau pihak terafiliasi dari Anggota Direksi, Anggota
Dewan Komisaris atau pemegang saham utama.
Selama tahun 2011, tidak terdapat transaksi yang
mengandung benturan kepentingan.
Conflict of Interest
Conflict of interest is a circumstance where there is
a conflict between economic interests of Kalbe and
personal economic interests of members of Kalbe's
Board of Directors, Board of Commissioners, main
shareholders or their affiliated parties. During 2011,
there was no transactions with conflict of interest.
Commitment to Consumers
To maintain business continuity and growth of the
Company, Kalbe maintains a commitment to deliver
customers the best of services.
F
or energy drink products and over-the-counter
products manufactured by PT Bintang Toedjoe, a
Kalbe subsidiary, consumers can contact customer
service at 0-800-123-7007.
Etika
Kalbe menyadari pentingnya suatu Pedoman Etika
dalam pelaksanaan kegiatan operasional Perseroan.
Oleh sebab itu, saat ini Perseroan tengah menyusun
suatu Pedoman Etika yang akan menjadi pedoman
berperilaku bagi seluruh jajaran Kalbe dalam
melakukan interaksi dan hubungan dengan segenap
pemangku kepentingan. Selain itu, adanya Pedoman
Etika diharapkan dapat menghindari terjadinya
penyimpangan terhadap standar perilaku yang
ditetapkan dan menjadi pedoman dalam mendeteksi
Ethics
Kalbe realizes the importance of a Code of Conduct
in the implementation of the operational activities of
the Company. Therefore, the Company is currently
preparing a Code of Conduct which will serve as
guidelines for all Kalbe Institutions in conducting
interaction and relationships with all stakeholders. In
addition, the Code of Conduct is expected to avoid
any deviation from established standards of behavior
and to serve as guidelines in detecting violations.
Compliance with the Code of Conduct will avoid any
1. Organizing
outing events with several health
communities
2. Organizing seminars and symposiums on health
routines attended by patients and consumers.
227
Performance
Highlights
228
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Sosialisasi Etika
Kalbe akan melakukan sosialisasi dalam penerapan
Pedoman Etika kepada seluruh karyawan, mulai dari
level operasional sampai kepada top management.
Sosialisasi ini dimaksudkan agar seluruh insan Kalbe
memiliki pemahaman yang sama dan senantiasa
patuh terhadap Pedoman Etika. Kalbe melakukan
penegakan terhadap Pedoman Etika yang dilakukan
dengan melakukan pemantauan secara berkala
terhadap penegakan Pedoman Etika dan menyediakan
fasilitas bagi pengaduan terhadap pelanggaran
Pedoman Etika.
Socialization of Ethics
Kalbe will conduct socialization of the implementation
of its Code of Conduct for all employees, starting from
the operational level through to top management.
Socialization is intended for all individuals to possess
the same understanding and always to abide by the
Code of Conduct. Kalbe is enforcing the Code of
Conduct by periodically monitoring its enforcement
and provides facilities for complaints concerning
violations of the Code of Conduct.
Whistleblowing System
Perseroan menyadari bahwa terjadinya fraud dapat
menyebabkan kerugian bagi Kalbe dan mempengaruhi
citra Kalbe, sehingga dapat berdampak terhadap
produktivitas kerja jajaran Kalbe maupun kelangsungan
usaha Kalbe secara keseluruhan. Kalbe bertekad
untuk menciptakan kegiatan operasional Perseroan
yang terbebas dari praktik-praktik korupsi, kolusi dan
nepotisme serta menjunjung tinggi Pedoman Etika,
Whistleblowing System
The Company realizes that the existence of fraud may
cause harm to Kalbe and affect the image of Kalbe,
so it can have an impact on labor productivity and
business continuity as a whole. Kalbe is determined
to create Company operational activities that are
free from corrupt practices and to uphold the Code
of Conduct, which the Company seeks to actively
promote to increase the participation of all elements
229
Performance
Highlights
230
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
231
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Kepada Yth.
Dewan Komisaris
PT Kalbe Farma Tbk
Jakarta
To:
Board of Commissioners
PT Kalbe Farma Tbk
Jakarta
1.
Ketua
Anggota
Anggota
232
Basis
of Audit Committee Establishment
The Audit Committee was formed based on
Law No.40 Year 2007 on Limited Liability
Companies, rules and regulations on Good
Corporate Governance issued by Bapepam-LK,
the Indonesia Stock Exchange (IDX) and the
National Committee on Governance (KNKG),
and the Decree of the Chairman of Bapepam
No.Kep-29/PM/2004 dated September 24, 2004,
on the Establishment and Working Guidelines for
the Audit Committee.
Chairman
Member
Member
a. Mendukung
implementasi
sistem
pengendalian internal yang baik.
b. Melakukan evaluasi terhadap laporan
keuangan teraudit berdasarkan peraturan
yang berlaku.
c. Melakukan kajian atas lingkup dan kesesuaian
audit eksternal, honorarium audit eksternal serta
kemandirian dan obyektivitas auditor eksternal.
d. Memberikan penjabaran tugas dan tanggung
jawab Komite Audit untuk tahun buku yang
bersangkutan sesuai dengan kebutuhan
auditor eksternal.
a. T
o support the implementation of an effective
internal control system.
b. To carry out an evaluation of audited financial
statements based on applicable regulations.
c. T
o evaluate the scope and consistency of the
external audit, honoraria for the external audit
as well as the independency and objectivity of
the external auditor.
d. To prepare a description of the duties and
responsibilities of the Audit Committee for the
current fiscal year, as required by the external
auditor.
a. Laporan keuangan;
b. Sistem pengendalian internal;
c. Pelaksanaan dan hasil dari proses
pengendalian internal;
d. Manajemen risiko;
e. Kepatuhan terhadap hukum dan peraturan;
f. Sistem dan implementasi Tata Kelola
Perusahaan yang Baik (Good Corporate
Governance).
a. Financial statements;
b. Internal control system;
c. Implementation and result of the internal
control system;
d. Risk management;
e. Compliance to laws and regulations;
f. System and implementation of Good Corporate
Governance.
Ichsan Gunawan
Anggota
Member
Dianawati Sugiarto
Anggota
Member
233
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Kepada Yth.
Dewan Komisaris
PT Kalbe Farma Tbk
Jakarta
To:
Board of Commissioners
PT Kalbe Farma Tbk
Jakarta
Ketua
Anggota
Chairman
Members
: Johannes Setijono
: Bernadette Ruth Irawati Setiady
Johanes Berchman Apik Ibrahim
Johannes Setijono
Ketua
Chairman
234
: Johannes Setijono
: Bernadette Ruth Irawati Setiady
Johanes Berchman Apik Ibrahim
Kepada Yth.
Dewan Komisaris
PT Kalbe Farma Tbk
Jakarta
To:
Board of Commissioners
PT Kalbe Farma Tbk
Jakarta
Ketua
Anggota
Chairman
Members
: Johannes Setijono
: Bernadette Ruth Irawati Setiady
Johanes Berchman Apik Ibrahim
: Johannes Setijono
: Bernadette Ruth Irawati Setiady
Johanes Berchman Apik Ibrahim
Johannes Setijono
Ketua
Chairman
235
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Kepada Yth.
Dewan Komisaris
PT Kalbe Farma Tbk
Jakarta
To:
Board of Commissioners
PT Kalbe Farma Tbk
Jakarta
Ketua
Anggota
Chairman
Members
: Johannes Setijono
: Jozef Darmawan Angkasa
Budi Dharma Wreksoatmodjo
Vidjongtius
Johannes Setijono
Ketua
Chairman
236
: Johanes Setijono
: Jozef Darmawan Angkasa
Budi Dharma Wreksoatmodjo
Vidjongtius
Vidjongtius
Anggota
Member
Kepada Yth.
Dewan Komisaris
PT Kalbe Farma Tbk
Jakarta
To:
Board of Commissioners
PT Kalbe Farma Tbk
Jakarta
Berdasarkan
Surat
Keputusan
No.35/III/08/
Komite GCG/KF-LD pada tanggal 1 Maret 2008,
Dewan Komisaris Perseroan membentuk Komite
Good Corporate Governance (GCG) dalam rangka
membantu pelaksanaan tugas kepengawasan
Dewan Komisaris dan pemberian nasehat kepada
Direksi dalam pengelolaan Perusahaan. Komite
GCG mempunyai peran dan tanggung jawab untuk
membantu Dewan Komisaris sehubungan dengan
penerapan prinsip GCG di lingkungan Perseroan.
Ketua
Wakil Ketua
Anggota
Chairman
Vice Chairman
Members
: Vidjongtius
: Agustinus Haryono
: Bernadus Karmin Winata
Joyce V. Handajani
Febiana Rinasari
: Vidjongtius
: Agustinus Haryono
: Bernadus Karmin Winata
Joyce V. Handajani
Febiana Rinasari
Selama
tahun
2011,
Komite
GCG
telah
menyelenggarakan rapat sebanyak 4 (empat) kali
yang dihadiri lengkap oleh Ketua dan seluruh anggota
Komite GCG. Beberapa hal utama yang dibahas
antara lain adalah upaya peningkatan implementasi
GCG yang juga didasari oleh Panca Sradha Kalbe
sebagai Nilai Perusahaan di seluruh aspek dalam
Perseroan dan melakukan kajian serta memberikan
rekomendasi atas penyempurnaan Pedoman Good
Corporate Governance Perseroan serta Piagam
Komite. Komite GCG juga melakukan pengkajian
upaya pengembangan praktek Good Corporate
Governance dalam Perseroan.
Vidjongtius
Ketua
Chairman
237
238
Pengembangan
Komunitas
Tumbuh Menjadi
Bagian dari
Perjalanan yang
Berkelanjutan
The Journey to Sustainability
Becomes Part of Community
Development
239
Performance
Highlights
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
240
241
Performance
Highlights
242
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Sejalan
dengan misi Kalbe yaitu meningkatkan
kesehatan untuk kehidupan yang lebih baik, Kalbe
terus berinovasi dalam melaksanakan tanggung
jawab sosial kepada seluruh pemangku kepentingan
dan masyarakat. Kalbe menyadari bahwa Kalbe
berasal dari masyarakat, dan hadir untuk masyarakat,
oleh karena itu sebagian keuntungan Perseroan akan
dikembalikan kepada masyarakat sebagai bentuk
tanggung jawab sosial Perseroan. Bentuk tanggung
jawab sosial Perusahaan diarahkan untuk membantu
mengurangi permasalahan sosial, memberdayakan
masyarakat,
membina
dan
mengupayakan
perubahan perilaku serta mengupayakan pencapaian
kesejahteraan masyarakat sehingga pada akhirnnya
tercipta keharmonisan yang berkelanjutan diantara
Kalbe dan masyarakat.
Landasan Hukum
Dasar hukum pelaksanaan CSR di Kalbe adalah
terutama mengacu kepada UU Perusahaan Terbatas
No 40 tahun 2007 yang di antaranya mengatur
kewajiban perusahaan untuk melaksanakan kegiatan
tanggung jawab sosial dan lingkungan yang bertujuan
mewujudkan pembangunan ekonomi berkelanjutan
guna meningkatkan kualitas kehidupan dan lingkungan
yang bermanfaat bagi perusahaan sendiri, komunitas
setempat, dan masyarakat pada umumnya.
Legal Basis
CSR implementation in Kalbe mainly refers to the
Law of Limited Liability Companies, No 40, year 2007
which, among others, regulates companies roles
in the implementation of social responsibility and
environmental activities aimed at creating sustainable
development, to increase quality of life and the
environment, to provide benefits for companies, for
the surrounding community and toward society in
general.
CSR Organization
Kalbes CSR acitivities are managed by its Corporate
Social Responsibility Unit, located at the Companys
head office. Structurally, the CSR unit is a part of
the Corporate Communication Division, under direct
supervision of Vidjongtius as Director and Corporate
Secretary.
243
Performance
Highlights
244
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
K
albe Cares Education: Education is the foundation
in building a nation. Kalbe believes that education
is a key to the advancement of a nation. The main
focus of the Education pillar of Kalbe Cares lies in
innovation for a better life.
Program Lingkungan
Dalam rangka mendukung program pemerintah
untuk mencerdaskan anak bangsa, meningkatkan
kualitas dan kuantitas pelayanan kesehatan, serta
membangun dan memperbaiki infrastruktur
di
Indonesia, Kalbe senantiasa meningkatkan Program
Kegiatan Pelayanan Sosial Kemasyarakatan
Environmental Program
In order to support the governments program to
educate the nations children, enhancing both the
quality and quantity of healthcare, as well as developing
and improving the infrastructure in Indonesia, Kalbe
continuously works to improve through its Social
Services Works Program.
245
Performance
Highlights
Management
Report
Company
Profile
Corporate
Governance
Consolidated
Financial
Statements
1. K
albe bekerjasama dengan Pemerintah serta
puskesmas di Lebak, Serang untuk memberikan
akses kesehatan baik berupa pengobatan gratis
maupun pembagian paket sembako untuk ratusan
warga prasejahtera di Lebak, Serang.
2. K
albe kembali menunjukkan kepeduliannya kepada
para korban bencana Merapi, melalui pemberian
akses kesehatan baik berupa pengobatan gratis
maupun perbaikan sarana lingkungan Puskesmas
di Cangkringan, Yogyakarta
3. K
albe membangun kepedulian untuk kelangsungan
hidup sesama, dengan menggalang keterlibatan
karyawan dalam gerakan donor darah di
berbagai kantor Kalbe di Indonesia, yang berhasil
menyumbangkan lebih dari 500 kantong darah
untuk Palang Merah Indonesia.
246
Management
Discussion &
Analysis
4. K
albe bekerjasama dengan Rumah Sakit Mitra
Keluarga dan Perdami melanjutkan partisipasinya
dalam mengurangi angka katarak di Indonesia
melalui program bakti sosial operasi katarak kepada
28 warga di Tegal, Jawa Tengah.
5. K
albe sebagai perusahaan yang menyediakan
solusi kesehatan, memiliki kepedulian yang tinggi
terhadap kesehatan ibu dan anak. Melalui program
Prenagen Peduli Sesama Ibu kepada ibu-ibu
hamil di daerah Cirendeu, Jakarta Utara, Kalbe
mendukung pentingnya kesehatan Ibu dalam
menentukan kualitas hidup generasi masa depan
bangsa Indonesia.
6. K
albe telah melebarkan sayap kepedulian melalui
program Bantuan Obat-obatan ke berbagai wilayah
di Indonesia melalui sumbangan obat-obatan
serta vitamin. Kegiatan mencangkup 8 wilayah di
Indonesia.
6. K
albe has expanded its coverage of social activities
through the Medicine Supply Program to various
regions in Indonesia, through the donation of
medicines and vitamin supplements. Activities
covered eight regions across Indonesia.
247
Performance
Highlights
248
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Perlindungan Karyawan
Karyawan merupakan aset strategis Perseroan. Kalbe
berkomitmen untuk memberikan hak-hak karyawan
Employee Protection
Employees are strategic assets of the Company. Kalbe
is committed to fulfill employees rights in the form
Perlindungan Konsumen
Komitmen Kalbe dalam memberikan pelayanan
terbaik (service excellence) tidak berhenti hanya
pada pemenuhan tanggung jawab yang dibebankan
oleh peraturan perundang-undangan, namun juga
memberikan pelayanan lebih dengan memberikan
manfaat tambahan bagi konsumen.
Consumer Protection
Kalbes commitment to providing service excellence
does not stop at the fulfillment of responsibilities
imposed by legislation, but also extends to provision
of extra services with additional value for consumers.
249
Performance
Highlights
250
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
AMDAL
AMDAL
100%
Pengendalian
Pencemaran Air
Water Pollution Control
100%
Pengendalian
Pencemaran Udara
Air Pollution Control
100%
Pengelolaan
Limbah B3
Hazardous Waste
Management
Air
Bentuk komitmen perusahaan dalam mencegah
terjadinya pencemaran air adalah dengan penyiapan
sistem pengendalian pencemaran air yang handal.
Proses sistem pengendalian tersebut dilakukan dengan
mengolah air limbah dari operasional pabrik terlebih
dahulu (pretreatment) melalui instalasi pengolahan limbah
Waste Water Treatment Plant (WWTP) agar memenuhi
Baku Mutu Lingkungan (BML) baik dari Pemerintah
maupun dari Pengelola Kawasan sebelum dibuang ke
badan air atau pun dikirim ke instansi pengolahan air
limbah kawasan industri. Kalbe mempunyai fasilitas
instalasi pengelolaan limbah yang sangat baik yaitu PT
Kalbe Morinaga Indonesia, anak perusahaan Kalbe,
yang memberikan hasil pengelolaan limbah dengan
kualitas jauh diatas standar yang telah ditentukan oleh
Pemerintah.
Water
The Company's commitment to prevent water pollution
is through preparing a reliable water pollution control
system. The process control system is implemented
by treating waste water from plant operations first
(pre-treatment) through processing at the Waste
Water Treatment Plant (WWTP) to meet Environmental
Quality Standards (BML), either from the government
or from Area Management, before being discharged
into bodies of water or sent to the waste water
treatment agency in the industrial area. Kalbe has
superior standard waste management facilities at PT
Kalbe Morinaga Indonesia, Kalbe's subsidiary, which
apply waste management practices and results well
above the standards stipulated by the Government.
Udara
Perusahaan melakukan pengendalian pencemaran
udara melalui pemantauan dan pengukuran secara
periodik terhadap emisi gas buang baik dari sumber
emisi tidak bergerak seperti cerobong pabrik maupun
Air
The Company has conducted air pollution control
through monitoring and periodic measurement
of emissions from fixed/permanent sources of
emissions, such as factory chimneys, as well as from
251
Performance
Highlights
252
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Penerapan Teknologi
Powerboss pada utilitas
sistem tata udara pabrik dan Flowlogic pada mesin
compressed air telah berhasil mengurangi penggunaan
energi sebesar 10% dari masing-masing instalasi
tersebut.
253
Performance
Highlights
254
Management
Report
Company
Profile
Management
Discussion &
Analysis
Corporate
Governance
Consolidated
Financial
Statements
Composting
Perseroan
senantiasa
mendukung
program
pemerintah dalam penanganan sampah, salah satunya
melalui program composting limbah organik yaitu
sampah rumput/daun. Program tersebut dilaksanakan
untuk mengurangi pembuangan sampah organik
sekaligus mengurangi penggunaan pupuk kimia
dalam perawatan tanaman di area pabrik. Sampai
dengan kuartal IV 2011, proyek ini masih dalam
pengembangan untuk menghasilkan kualitas kompos
yang baik dengan beberapa perbaikan proses.
Composting
The Company always supports government programs
in waste management, one of them through its organic
waste composting program using grass/leaves waste.
The program was implemented to reduce the disposal
of organic waste while reducing the use of chemical
fertilizers in the care of plants in the plant area. Up
until the fourth quarter of 2011, the project is still in
development to yield good-quality compost with some
improvement processes.
Target
Pengembangan
Program
Ramah
Lingkungan yang akan Diterapkan di Tahun 2012
Target of Environmentally
Development for 2012
The Company
strives to conduct continuous
improvements
in the environmental field. This
commitment is realized through the Company's efforts
to improve performance in protecting the environment,
and to prevent pollution at every stage of the business.
Sound
Program
255
256
Daftar Isi
Table of Contents
Halaman/
Page
4-5
7-8
Catatan atas Laporan Keuangan Konsolidasian . 9-116 .......Notes to the Consolidated Financial Statements
***************************
Catatan/
Notes
2011
2010
1 Januari 2010/
31 Desember 2009/
January 1, 2010/
December 31, 2009
ASET
ASSETS
ASET LANCAR
Kas dan setara kas
2d,2t,4,31
Investasi jangka pendek
2t,5,31
Piutang usaha, setelah dikurangi
cadangan penurunan nilai sejumlah
Rp18.158.649.905 pada
31 Desember 2011,
Rp8.332.605.382 pada
31 Desember 2010
dan Rp7.379.112.880
pada 1 Januari 2010/
2t,
31 Desember 2009
6,13,31
Piutang lain-lain
2t,31
2e,2f,7,
Persediaan, neto
8,13,22
Pajak pertambahan nilai
dibayar dimuka
Aset lancar lainnya
2g,9
Total Aset Lancar
2.291.335.810.101
113.871.418.384
1.901.871.765.050
5.315.920.203
1.562.664.177.408
62.596.260.106
1.529.991.628.590
105.319.628.145
1.262.710.670.671
101.246.432.140
1.203.940.830.063
114.138.739.079
CURRENT ASSETS
Cash and cash equivalents
Short-term investments
Trade receivables, net of
allowance for impairment
accounts of Rp18,158,649,905
as of December 31, 2011,
Rp8,332,605,382 as of
December 31, 2010 and
Rp7,379,112,880 as of
January 1, 2010/
December 31, 2009
Other receivables
1.705.189.186.310
1.550.828.819.836
1.561.382.418.796
Inventories, net
20.950.213.638
189.465.355.139
11.115.707.317
198.455.549.532
5.210.236.155
186.234.901.247
5.956.123.240.307
5.031.544.864.749
4.696.167.562.854
NON-CURRENT ASSETS
2b,
2t,10,31
2s,17
2s,17
Penyertaan saham
Aset pajak tangguhan, neto
Tagihan restitusi pajak penghasilan
Aset tetap, setelah dikurangi
akumulasi penyusutan sejumlah
Rp1.324.424.087.758 pada
31 Desember 2011,
Rp1.159.500.666.443 pada
31 Desember 2010 dan
Rp1.151.519.613.206 pada
1 Januari 2010/
2e,2h,2i,7,11,
31 Desember 2009
22,23
2b,2l,
Aset tidak berwujud, neto
2m,12,23
Uang muka pembelian aset
tetap
Aset tidak lancar lainnya
2j,2n
53.707.821.069
37.532.392.018
28.382.911.213
48.428.818.826
34.774.005.806
29.421.377.747
1.860.288.483.732
1.605.266.031.098
233.007.450.563
237.557.876.110
261.359.311.220
8.078.386.066
97.433.427.872
8.179.111.571
37.324.577.381
4.648.423.080
20.252.412.300
2.318.430.872.533
2.000.951.798.539
1.786.279.107.318
TOTAL ASET
8.274.554.112.840
7.032.496.663.288
6.482.446.670.172
TOTAL ASSETS
37.403.818.826
29.354.137.617
35.133.127.194
Catatan/
Notes
2011
2010
1 Januari 2010/
31 Desember 2009/
January 1, 2010/
December 31, 2009
2s,17
2i,2t,11,31
2r,28
285.388.096
308.292.399
500.414.074
CURRENT LIABILITIES
Short-term loans
Trade payables
Other payables
Third parties
Related party
Accrued expenses
Taxes payable
Current maturities of obligations
under finance leases
1.630.588.528.518
1.146.489.093.666
1.574.137.415.862
9.838.821.193
7.638.833.280
8.326.437.947
364.977.932
745.147.107
1.045.834.600
117.826.726.771
105.488.358.666
108.002.706.839
NON-CURRENT LIABILITIES
Deferred tax liabilities, net
Obligations under finance leases
net of current maturities
Estimated liabilities for employees
service entitlement benefits
128.030.525.896
113.872.339.053
117.374.979.386
1.758.619.054.414
1.260.361.432.719
1.691.512.395.248
TOTAL LIABILITIES
218.201.733
262.431.783
NEGATIVE GOODWILL
140.056.547.003
850.398.382.129
24.290.351.153
488.240.634.231
339.131.952.804
481.511.454.167
198.842.540.750
3.581.179.155
283.137.947.283
154.286.544.102
135.477.154.358
3.575.227.613
301.962.490.132
192.634.943.780
119.572.353.198
262.996.654
359.976.797.639
273.181.447.326
2c
Catatan/
Notes
2011
2010
1 Januari 2010/
31 Desember 2009/
January 1, 2010/
December 31, 2009
EKUITAS
Ekuitas yang Dapat
Diatribusikan kepada
Pemilik Entitas Induk
Modal saham - nilai nominal
Rp50 per saham
Modal dasar 17.000.000.000 saham
Modal ditempatkan dan disetor
penuh - 10.156.014.422 saham
Tambahan setoran modal
Selisih transaksi dengan pihak
non-pengendali
Selisih transaksi restrukturisasi
entitas sepengendali
Saldo laba
Telah ditentukan penggunaannya
Belum ditentukan penggunaannya
Modal treasuri 780.990.000 saham pada
31 Desember 2011 dan 2010
dan 782.490.000 saham
pada 1 Januari 2010/
31 Desember 2009
Pendapatan (beban)
komprehensif lainnya:
Selisih kurs atas penjabaran
laporan keuangan
EQUITY
Equity Attributable to the Equity
Holders of the Parent Company
19
2k,19
2b
507.800.721.100
4.441.133.136
507.800.721.100
4.441.133.136
(3.069.982.400)
(1.278.400.605)
(36.758.673.814)
(36.758.673.814)
19
62.310.754.355
6.345.128.516.533
2k,19
2b
(687.283.369.009)
49.447.454.095
5.531.806.356.465
(687.283.369.009)
2.184.702.988
5.647.785.396
20.064.328.029
(38.705.564)
6.214.818.130.918
5.373.784.301.200
4.310.437.877.062
Sub-total
301.116.927.508
398.132.727.636
480.233.966.079
Non-controlling Interest
Ekuitas, Neto
6.515.935.058.426
5.771.917.028.836
4.790.671.843.141
Equity, Net
8.274.554.112.840
7.032.496.663.288
6.482.446.670.172
Kepentingan Non-pengendali
2b,18
2011
PENJUALAN NETO
10.911.860.141.523
5.360.686.806.582
LABA BRUTO
5.551.173.334.941
Beban penjualan
Beban umum dan administrasi
Beban penelitian
dan pengembangan
Beban bunga dan keuangan
Rugi selisih kurs, neto
Penghasilan bunga
Laba atas penjualan aset
tetap
Rugi penjualan saham
Entitas Anak, neto
Rupa-rupa, neto
LABA SEBELUM MANFAAT
(BEBAN) PAJAK PENGHASILAN
(2.905.465.910.128)
(586.524.605.026)
(91.211.579.687)
Catatan/
Notes
2p,2u,20,21
2p,2u,2t,
8,11,20,22,28
11,23,32a,
32e,32f,32g
11,24,28
2o,11,25
(13.172.498.498)
(12.362.082.622)
96.933.578.727
13,26
2q,2t,34
4,5,27
5.730.134.350
2h,11
(57.841.010.389)
10
10,12,17
1.987.259.361.668
2010
10.226.789.206.223
NET SALES
5.060.403.621.307
5.166.385.584.916
GROSS PROFIT
(2.699.582.557.897)
Selling expense
(580.973.135.334) General and administrative expense
Research and
(94.926.170.307)
development expense
Interest expense and
(20.716.334.764)
financial charges
(23.397.515.198)
Loss on foreign exchange, net
54.977.618.234
Interest income
Gain on sale of property and
13.083.065.728
equipment
Loss on sale of
(16.477.053.110)
shares in Subsidiaries, net
(27.938.892.833)
Miscellaneous, net
1.770.434.609.435
(464.883.708.409)
581.167.033
(429.049.461.282)
2.413.820.269
(464.302.541.376)
(426.635.641.013)
2s,17
1.522.956.820.292
1.343.798.968.422
(3.463.082.408)
2.622.516.394
OTHER COMPREHENSIVE
INCOME (EXPENSES):
Unrealized gains (losses) on
available-for-sale
financial assets
Differences arising from foreign
currency translation
1.539.721.311.065
1.346.097.557.038
COMPREHENSIVE INCOME
FOR THE YEAR
20.227.573.181
5,10
(323.927.778)
Catatan/
Notes
2011
2010
1.482.236.969.778
40.719.850.514
1.286.330.026.012
57.468.942.410
1.522.956.820.292
1.343.798.968.422
Total
1.498.876.920.963
40.844.390.102
1.288.628.614.628
57.468.942.410
1.539.721.311.065
1.346.097.557.038
Total
137
158
2v,19,33
The original consolidated financial statements included herein are in Indonesian language.
Ekuitas yang Dapat Diatribusikan kepada Pemilik Entitas Induk/Equity Attributable to the Equity Holders of the Parent Company
Pendapatan (Beban) Komprehensif Lainnya/
Other Comprehensive Income (Expenses)
Catatan/
Notes
19
2k,19
19
2t,5,10
2b,10
19
19
2t,5,10
Modal
Ditempatkan dan
Disetor Penuh/
Issued and
Fully Paid
Capital
Selisih
Transaksi
Restrukturisasi
Entitas
Sepengendali/
Difference in
Values of
Restructuring
Transactions
among Entities
Under Common
Control
Selisih
Transaksi
Dengan Pihak
Non-pengendali/
Differences
Arising from
Transaction with
Non-controlling
Interest
Tambahan
Setoran Modal/
Additional
Paid-in Capital
Saldo Laba/
Retained Earnings
Telah Ditentukan
Penggunaannya/
Appropriated
Belum Ditentukan
Penggunaannya/
Unappropriated
Modal treasuri/
Treasury Stock
507.800.721.100
2.640.000.000
(7.250.663.530)
(36.758.673.814)
40.157.416.692
9.290.037.403
(9.290.037.403 )
1.801.133.136
-
(253.900.360.551 )
19.524.750.000
1.286.330.026.012
-
1.320.024.000
-
2.622.516.394
-
507.800.721.100
4.441.133.136
507.800.721.100
4.441.133.136
5.972.262.925
(1.278.400.605 )
(1.278.400.605 )
-
(1.791.581.795 )
-
507.800.721.100
4.441.133.136
(3.069.982.400 )
(36.758.673.814 )
(36.758.673.814 )
-
49.447.454.095
5.531.806.356.465
200.200.090
49.447.454.095
5.532.006.556.555
12.863.300.260
(36.758.673.814 )
4.489.141.978.407
Selisih Kurs
atas
Penjabaran
Laporan
Keuangan/
Differences
Arising from
Foreign
Currency
Translations
62.310.754.355
(12.863.300.260 )
(710.921.009.540 )
54.669.300.000
1.482.236.969.778
6.345.128.516.533
Catatan atas laporan keuangan konsolidasian terlampir merupakan bagian yang tidak terpisahkan
dari laporan keuangan konsolidasian secara keseluruhan.
(688.603.393.009 )
(687.283.369.009 )
(687.283.369.009 )
(687.283.369.009 )
3.025.269.002
5.647.785.396
5.647.785.396
-
285.222.214
(323.927.778 )
(38.705.564 )
(38.705.564 )
-
Kepentingan
Non-pengendali/
Non-controlling
Interest
Sub-total/
Sub-total
4.310.437.877.062
3.121.157.136
(253.900.360.551 )
19.524.750.000
1.288.628.614.628
5.972.262.925
5.373.784.301.200
Ekuitas, Neto/
Equity, Net
480.233.966.079
(171.824.991 )
(10.189.497.450 )
57.468.942.410
11.984.202.801
(141.193.061.213 )
398.132.727.636
(171.824.991)
3.121.157.136
(264.089.858.001)
19.524.750.000
1.346.097.557.038
11.984.202.801
(135.220.798.288)
5.771.917.028.836
200.200.090
18.001.643
218.201.733
5.373.984.501.290
398.150.729.279
5.772.135.230.569
(30.942.726 )
(30.942.726)
(3.463.082.408 )
-
20.103.033.593
-
(1.791.581.795 )
(710.921.009.540 )
54.669.300.000
1.498.876.920.963
-
(8.631.701.491 )
40.844.390.102
49.807.422.742
(179.022.970.398 )
(1.791.581.795)
(719.552.711.031)
54.669.300.000
1.539.721.311.065
49.807.422.742
(179.022.970.398)
2.184.702.988
20.064.328.029
6.214.818.130.918
301.116.927.508
6.515.935.058.426
The accompanying notes form an integral part of these consolidated financial statements.
4.790.671.843.141
Catatan/
Notes
2011
ARUS KAS DARI AKTIVITAS
OPERASI
Penerimaan kas dari pelanggan
Pembayaran kas untuk pemasok
dan karyawan
Kas yang dihasilkan dari operasi
Penerimaan tagihan restitusi pajak
penghasilan
Pembayaran pajak penghasilan
Pembayaran untuk beban operasi
lainnya, neto
Kas Neto Diperoleh dari
Aktivitas Operasi
ARUS KAS DARI AKTIVITAS
INVESTASI
Hasil penjualan investasi
jangka pendek
Penerimaan penghasilan bunga
Hasil penjualan aset tetap
Hasil penjualan investasi
jangka panjang
Perolehan aset tetap
Penempatan pada investasi jangka
pendek dan deposito berjangka
Perolehan saham Entitas Anak
dari pihak ketiga
Penerimaan (perolehan) dari aktivitas
investasi lainnya, neto
Kas Neto Digunakan untuk
Aktivitas Investasi
ARUS KAS DARI AKTIVITAS
PENDANAAN
Penerimaan utang bank
Penerimaan setoran modal
saham dari kepentingan nonpengendali Entitas Anak
Pembayaran dividen kas:
Perusahaan
Entitas Anak
Pembayaran utang bank
Pembayaran beban bunga
Pembayaran utang sewa
pembiayaan
Penerimaan dari penjualan
modal treasuri
Penarikan kembali saham
Entitas Anak
Kas Neto Digunakan untuk
Aktivitas Pendanaan
11.692.691.590.575
2010
11.039.919.268.228
(6.666.419.098.277)
(6.637.307.422.355)
5.026.272.492.298
4.402.611.845.873
5.468.734.764
(424.641.078.879)
17
20.723.925.034
(435.230.559.227)
(3.133.604.924.877)
(2.734.197.347.984)
1.473.495.223.306
1.253.907.863.696
125.000.000.000
99.743.128.114
4,5
26
22.069.554.517
11
(469.105.400.047)
(233.555.498.181)
(172.978.048.157)
(2.127.329.364)
(630.953.593.118)
3.121.157.136
(1.215.290.983)
(574.668.046.895)
579.500.805.283
676.112.994.004
49.721.581.911
11.984.202.801
(549.527.564.394)
(7.934.007.020)
(463.734.609.433)
(14.586.783.377)
(234.375.610.551)
(18.729.940.573)
(990.657.002.290)
(20.716.334.764)
(414.715.912)
(192.221.675)
(406.975.292.942)
Catatan/
Notes
2011
KENAIKAN NETO
KAS DAN SETARA KAS
Pengaruh Neto Perubahan
Kurs pada Kas dan Setara Kas
yang Didenominasi dalam
Mata Uang Asing
KAS DAN SETARA KAS
AWAL TAHUN
435.566.337.246
(13.156.493.737)
1.893.315.663.897
1.559.682.224.604
2b
2.289.700.859.692
2.291.335.810.101
(1.634.950.409)
Neto
2.289.700.859.692
2010
447.106.008.855
(39.181.141.451)
(100.316.075.825)
1.893.315.663.897
4
13
1.901.871.765.050
(8.556.101.153)
1.893.315.663.897
Net
1.
UMUM
a.
1.
Pendirian Perusahaan
GENERAL
a.
1.
UMUM (lanjutan)
b.
1.
b.
Kegiatan Perusahaan
Penawaran umum perdana dan
pencatatan sebagian saham
Perusahaan
Pencatatan saham Perusahaan
Bursa Efek Jakarta
(sekarang Bursa Efek Indonesia)
Bursa Efek Surabaya
(sekarang Bursa Efek Indonesia)
Pembagian saham bonus
Bursa Efek Surabaya
(sekarang Bursa Efek Indonesia)
Bursa Efek Jakarta
(sekarang Bursa Efek Indonesia)
Penawaran umum terbatas
Pembagian saham bonus
Bursa Efek Surabaya
(sekarang Bursa Efek Indonesia)
Bursa Efek Jakarta
(sekarang Bursa Efek Indonesia)
Pembagian dividen saham
Bursa Efek Surabaya
(sekarang Bursa Efek Indonesia)
Bursa Efek Jakarta
(sekarang Bursa Efek Indonesia)
Perubahan nilai nominal saham dari
Rp1.000 menjadi Rp500 per
saham (stock split)
Jumlah Saham/
Number of
Shares
20.000.000
Tanggal/
Date
30 Juli 1991/
July 30, 1991
30.000.000
23 April 1992/
April 23, 1992
22 Mei 1992/
May 22, 1992
50.000.000
10 November 1992/
November 10, 1992
17 November 1992/
November 17, 1992
8.000.000
4 Mei 1993/
May 4, 1993
75.600.000
15 Juli 1994/
July 15, 1994
18 Juli 1994/
July 18, 1994
32.400.000
15 Juli 1994/
July 15, 1994
18 Juli 1994/
July 18, 1994
216.000.000
1.728.000.000
1.900.800.000
GENERAL (continued)
4.060.800.000
10
7 Oktober 1996/
October 7, 1996
24 Agustus 1999/
August 24, 1999
6 Desember 2000/
December 6, 2000
19 Desember 2003/
December 19, 2003
1.
UMUM (lanjutan)
b.
Kegiatan Perusahaan
Tambahan penempatan saham
sehubungan dengan
penggabungan usaha
Total
(*)
c.
1.
GENERAL (continued)
b.
Jumlah Saham/
Number of
Shares
Tanggal/
Date
Total
(*)
c.
Board of Commissioners
Johannes Setijono
Santoso Oen
Jozef Darmawan Angkasa
Ferdinand Aryanto
Wahjudi Prakarsa
Farid Anfasa Moeloek
Direksi
Presiden Direktur
Wakil Presiden Direktur
Direktur
Direktur
Direktur
Direktur
President Commissioner
Commissioner
Commissioner
Commissioner
Independent Commissioner
Independent Commissioner
Board of Directors
President Director
Vice President Director
Director
Director
Director
Director
Board of Commissioners
Johannes Setijono
Santoso Oen
Jozef Darmawan Angkasa
Ferdinand Aryanto
Wahjudi Prakarsa
Farid Anfasa Moeloek
Direksi
Presiden Direktur
Wakil Presiden Direktur
Direktur
Direktur
Direktur
President Commissioner
Commissioner
Commissioner
Commissioner
Independent Commissioner
Independent Commissioner
Board of Directors
11
President Director
Vice President Director
Director
Director
Director
1.
UMUM (lanjutan)
c.
1.
GENERAL (continued)
c.
Audit Committee
Ketua
Anggota
Anggota
Chairman
Member
Member
Sekretaris Perusahaan
Corporate Secretary
Sekretaris Perusahaan
d.
Vidjongtius
Corporate Secretary
d.
Nama
Entitas Anak/
Names of
Subsidiaries
Farmasi:/
Pharmaceutical:
PT Bintang Toedjoe
- Bintang
Toedjoe (1)
Kegiatan
Usaha/
Produk/
Nature of
Business
Activities/
Products
Farmasi/
Pharmaceutical
Mulai
Beroperasi
Komersial/
Commencement
Tempat
of
Kedudukan/ Commercial
Domicile
Operations
Jakarta
1949
12
Persentase Pemilikan
Efektif/
Effective Percentage
of Ownership
2011
%
100,00
2010
%
100,00
Total Aset
Sebelum Eliminasi
(Dalam Jutaan)/
Total Assets
Before Elimination
(In Millions)
2011
440.977
2010
356.169
1.
UMUM (lanjutan)
d.
1.
Nama
Entitas Anak/
Names of
Subsidiaries
Kegiatan
Usaha/
Produk/
Nature of
Business
Activities/
Products
GENERAL (continued)
d.
Mulai
Beroperasi
Komersial/
Commencement
Tempat
of
Kedudukan/ Commercial
Domicile
Operations
Corporate Structure
(continued)
Persentase Pemilikan
Efektif/
Effective Percentage
of Ownership
2011
%
2010
%
and
Subsidiaries
Total Aset
Sebelum Eliminasi
(Dalam Jutaan)/
Total Assets
Before Elimination
(In Millions)
2011
2010
PT Hexpharm Jaya
Laboratories
- Hexpharm (1)
Farmasi/
Pharmaceutical
Jakarta
1995
100,00
100,00
248.004
204.374
PT Saka Farma
Laboratories
- Saka (1) (a)
Farmasi/
Pharmaceutical
Jakarta
1997
100,00
100,00
53.833
48.320
PT Finusolprima Farma
Farmasi/
Internasional
Pharmaceutical
- Finusolprima (1)
Jakarta
1981
100,00
100,00
113.733
117.174
PT Bifarma Adiluhung
- Bifarma (1)
Farmasi/
Pharmaceutical
Jakarta
1997
100,00
100,00
5.198
2.813
Innogene Kalbiotech
Pte. Ltd.
- Innogene (1) (b)
Farmasi/
Pharmaceutical
Singapura/
Singapore
2004
93,34
93,17
51.475
33.716
PT Dankos Farma
- Danfar (1)
Farmasi/
Pharmaceutical
Jakarta
2006
100,00
100,00
129.864
153.457
Jakarta
2006
81,64
81,64
6.941
7.156
Makanan
Kesehatan/
Health Foods
Jakarta
1982
100,00
100,00
1.315.342
1.202.284
Makanan
Kesehatan/
Health Foods
Jakarta
2007
70,00
70,00
317.642
318.185
Jakarta
1993
91,75
83,75
4.370.747
3.254.770
Jakarta
1980
91,75
83,75
121.436
109.382
Makanan Kesehatan:/
Health Food:
PT Sanghiang Perkasa
- Sanghiang (1)
PT Kalbe Morinaga (1)
Indonesia
- KMI
Distributor
Obat-obatan/
Pharmaceutical
Distributor
13
1.
UMUM (lanjutan)
d.
1.
Nama
Entitas Anak/
Names of
Subsidiaries
Kegiatan
Usaha/
Produk/
Nature of
Business
Activities/
Products
GENERAL (continued)
d.
Mulai
Beroperasi
Komersial/
Commencement
Tempat
of
Kedudukan/ Commercial
Domicile
Operations
Corporate Structure
(continued)
Persentase Pemilikan
Efektif/
Effective Percentage
of Ownership
2011
%
2010
%
and
Subsidiaries
Total Aset
Sebelum Eliminasi
(Dalam Jutaan)/
Total Assets
Before Elimination
(In Millions)
2011
2010
PT Millenia Dharma
Insani (MDI) (2)
Penjualan
Obat-obatan
dan Peralatan
Kedokteran/
Sales of
Pharmaceuticals
and Medical
Equipment
Jakarta
2003
91,75
83,75
27.222
22.889
PT Enseval Medika
Prima (EMP) (2)
Distributor
Peralatan
Kesehatan/
Distribution of
Medical
Instruments
Jakarta
2008
91,75
83,75
343.286
268.039
PT Global Chemindo
Megatrading
(GCM) (2)
Penjualan
Bahan Baku
Obat-obatan/
Trading of Raw
Materials for
Pharmaceutical
Products
Jakarta
2008
91,75
83,75
235.438
218.146
PT Renalmed Tiara
Utama
(RTU) (2)
Perdagangan
Peralatan
Kesehatan dan
Barang Habis
Pakai/
Trading of Medical
Instruments and
Consumable
Products
Jakarta
2008
91,60
81,66
40.829
42.970
Pengembangan, Singapura/
Produksi,
Singapore
Pemasaran dan
Distribusi produk
Kesehatan mata/
Development,
Production,
Marketing and
Distribution of
Eye health
Products
2008
100,00
100,00
7.817
7.873
2007
100,00
100,00
211.240
197.637
Kalbe International
Pte. Ltd.
(KI) (1)
Pemasaran
Produk
Kesehatan dan
Farmasi/
Wholesale of
Medical and
Pharmaceutical
Products
Singapura/
Singapore
14
1.
UMUM (lanjutan)
d.
1.
Nama
Entitas Anak/
Names of
Subsidiaries
Asiawide Kalbe
Philippines,Inc.
(AKPI) (3) (e)
Kegiatan
Usaha/
Produk/
Nature of
Business
Activities/
Products
d.
Mulai
Beroperasi
Komersial/
Commencement
Tempat
of
Kedudukan/ Commercial
Domicile
Operations
Pemasaran
Filipina/
dan Distribusi
Philippines
Minuman Energi
ready-to-drink/
Marketing and
Distribution of
Energy Drinks in a
Ready-to-Drink Format
GENERAL (continued)
2010
Corporate Structure
(continued)
Persentase Pemilikan
Efektif/
Effective Percentage
of Ownership
2011
%
50,00
2010
%
50,00
and
Subsidiaries
Total Aset
Sebelum Eliminasi
(Dalam Jutaan)/
Total Assets
Before Elimination
(In Millions)
2011
18.815
2010
28.667
(a)
(a)
(b)
(b)
(c)
(c)
(d)
(d)
15
1.
UMUM (lanjutan)
d.
1.
(e)
2.
GENERAL (continued)
d.
Corporate Structure
(continued)
and
Subsidiaries
(e)
2.
a.
a.
Dasar
penyajian
konsolidasian
laporan
keuangan
16
2.
2.
keuangan
17
2.
2.
Prinsip-prinsip konsolidasian
b.
Principles of consolidation
18
2.
2.
19
2.
2.
mengakui
setiap
perbedaan
yang
dihasilkan sebagai laba rugi; dan
mereklasifikasi
bagian
induk
atas
komponen yang sebelumnya diakui
sebagai pendapatan komprehensif lain ke
komponen laba rugi komprehensif dalam
laporan
laba
rugi
komprehensif
konsolidasian, atau mengalihkan secara
langsung ke saldo laba.
20
2.
2.
Foreign Subsidiaries
Akun-akun
laporan
posisi
keuangan
konsolidasian menggunakan kurs tengah pada
tanggal laporan posisi keuangan (Rp9.068 per
US$1 pada tanggal 31 Desember 2011 dan
Rp8.991 per US$1 pada tanggal 31 Desember
2010).
The
consolidated
statements
of
comprehensive income
accounts
used
average exchange rates during the year
(Rp8,773 to US$1 in 2011 and Rp9,078 to
US$1 in 2010).
21
2.
c.
2.
Kombinasi bisnis
c.
Business combinations
22
2.
2.
Kombinasi
bisnis
dicatat
dengan
menggunakan
metode
akuisisi.
Biaya
perolehan dari sebuah akuisisi diukur pada
nilai agregat imbalan yang dialihkan, diukur
pada nilai wajar pada tanggal akuisisi dan
jumlah setiap KNP pada pihak yang diakuisisi.
Untuk setiap kombinasi bisnis, pihak
pengakuisisi mengukur KNP pada pihak yang
diakuisisi baik pada nilai wajar ataupun pada
proporsi kepemilikan KNP atas aset neto yang
teridentifikasi dari pihak yang diakuisisi. Biayabiaya akuisisi yang timbul dibebankan
langsung dan dimasukkan dalam beban
administrasi.
23
2.
2.
24
2.
2.
Where goodwill forms part of a cashgenerating unit and part of the operation
within that unit is disposed of, the goodwill
associated with the operation disposed of is
included in the carrying amount of the
operation when determining the gain or loss
on disposal of the operation. Goodwill
disposed of in this circumstance is measured
based on the relative values of the operation
disposed of and the portion of the CGU
retained.
kombinasi
bisnis
dicatat
dengan
menggunakan metode pembelian. Biayabiaya transaksi yang secara langsung
dapat
diatribusikan
pada
akuisisi
merupakan bagian dari harga perolehan
akuisisi. KNP (sebelumnya dikenal
sebagai
hak
minoritas)
diukur
berdasarkan proporsi atas nilai tercatat
aset neto teridentifikasi;
25
2.
d.
2.
Penyertaan
saham
dengan
persentase
pemilikan Grup di bawah 20% dinyatakan
sebesar nilai pasar wajar (Catatan 2t).
Setara kas
d.
Cash equivalents
Cash and cash equivalents comprise cash on
hand and in banks, call and time deposits
with maturities of three (3) months or less
at the time of placement and not pledged as
collateral.
26
2.
f.
2.
Transaksi
ini
dilakukan
berdasarkan
persyaratan yang disetujui oleh kedua belah
pihak, dimana persyaratan tersebut mungkin
tidak sama dengan transaksi lain yang
dilakukan dengan pihak-pihak yang tidak
berelasi.
Persediaan
f.
Inventories
27
2.
2.
Prepaid expenses
Aset tetap
h.
10 - 20
3-8
2 - 20
2-8
2-8
5
28
2.
2.
29
2.
2.
Sewa
Leases
i)
ii)
30
2.
2.
31
2.
Penurunan
(lanjutan)
Nilai
Aset
2.
Non-keuangan
Impairment
(continued)
of
Non-financial
Assets
32
2.
k.
Penurunan
(lanjutan)
Nilai
Aset
2.
Non-keuangan
of
Non-financial
Assets
Modal Treasuri
k.
Treasury stock
Treasury stock, which is intended to be
reissued and/or re-sold in the future, is stated
at acquisition cost and presented as a
deduction from Capital Stock under the
Shareholders Equity section of the
consolidated statements of financial position.
The excess of proceeds from future re-sale of
treasury stock over the related acquisition
cost or vice-versa shall be accounted for as
an addition or deduction from additional paidin capital.
Impairment
(continued)
l.
m. Software cost
Cost incurred in connection with the
acquisitions of computer software, including
all costs which are directly associated in
preparing such assets until they are ready for
use, is amortized using the straight-line
method over five (5) years.
33
2.
2.
Biaya ditangguhkan
Deferred cost
o.
34
2.
p.
Biaya penelitian
(lanjutan)
dan
2.
pengembangan
Research
and
(continued)
development
costs
p.
35
2.
q.
Pengakuan
(lanjutan)
pendapatan
dan
2.
beban
Revenue
and
(continued)
expense
recognition
q.
Foreign
currency
balances
transactions
and
36
2.
2.
q.
2011
1 Euro/Rupiah
1 Dolar Amerika Serikat/Rupiah
100 JP/Rupiah
1 SGD Dolar/Rupiah
1 MYR/Rupiah
and
2010
11.739
9.068
11.680
6.974
2.852
11.956
8.991
11.029
6.981
2.916
EUR1/Rupiah
U.S. Dollar 1/Rupiah
JP100/Rupiah
SGD Dollar 1/Rupiah
MYR1/Rupiah
Foreign
currency
balances (continued)
r.
37
2.
2.
s.
Pajak
tangguhan
dihitung
dengan
menggunakan tarif pajak yang berlaku atau
secara substansial telah berlaku pada tanggal
laporan posisi keuangan. Perubahan nilai
tercatat aset dan liabilitas pajak tangguhan
yang disebabkan oleh perubahan tarif pajak
dibebankan pada tahun berjalan, kecuali untuk
transaksi-transaksi yang sebelumnya telah
langsung dibebankan atau dikreditkan ke
ekuitas.
38
2.
2.
Instrumen keuangan
Financial Instruments
PSAK No. 55 (Revisi 2006) mengatur prinsipprinsip dasar pengakuan dan pengukuran aset
keuangan, liabilitas keuangan, dan kontrak
pembelian dan penjualan item non keuangan.
Pernyataan ini, antara lain, memberikan
definisi dan karakteristik terhadap derivatif,
kategori instrumen keuangan, pengakuan dan
pengukuran, akuntansi lindung nilai dan
penetapan hubungan lindung nilai.
i.
i.
Aset Keuangan
Financial Assets
39
2.
2.
t.
Subsequent measurement
40
2.
2.
t.
setelah
pengakuan
awal
41
2.
2.
t.
setelah
pengakuan
awal
42
2.
2.
Penghentian pengakuan
Derecognition
43
2.
2.
Pengakuan awal
Initial recognition
44
2.
2.
Subsequent measurement
45
2.
2.
Penghentian pengakuan
Derecognition
Liabilitas
keuangan
dihentikan
pengakuannya ketika liabilitas yang
ditetapkan dalam kontrak dihentikan atau
dibatalkan atau kadaluwarsa.
iii.
iv.
46
2.
v.
2.
Informasi segmen
Segment information
v.
47
2.
3.
2.
(i)
3.
Pertimbangan
Judgments
48
3.
SUMBER
(lanjutan)
ESTIMASI
KETIDAKPASTIAN
3.
SOURCE OF
(continued)
ESTIMATION
UNCERTAINTY
Pertimbangan (lanjutan)
Judgements (continued)
Sewa
Leases
Purchase Price
Impairment
49
Allocation
and
Goodwill
3.
SUMBER
(lanjutan)
ESTIMASI
KETIDAKPASTIAN
3.
SOURCE OF
(continued)
ESTIMATION
UNCERTAINTY
50
3.
SUMBER
(lanjutan)
ESTIMASI
KETIDAKPASTIAN
3.
SOURCE OF
(continued)
ESTIMATION
UNCERTAINTY
Pajak penghasilan
Income Tax
Pertimbangan
signifikan
dilakukan
dalam
menentukan provisi atas pajak penghasilan badan.
Terdapat transaksi dan perhitungan tertentu yang
penentuan pajak akhirnya tidak pasti dalam
kegiatan usaha normal. Grup mengakui liabilitas
atas pajak penghasilan badan berdasarkan
estimasi apakah akan terdapat tambahan pajak
penghasilan badan.
51
3.
4.
SUMBER
(lanjutan)
ESTIMASI
KETIDAKPASTIAN
3.
SOURCE OF
(continued)
ESTIMATION
UNCERTAINTY
4.
2011
Kas
Rupiah
Dolar A.S.
Mata uang lainnya
Sub-total
Bank - pihak ketiga
Rupiah
PT Bank Danamon Indonesia Tbk.
PT Bank CIMB Niaga Tbk.
PT Bank Pembangunan Daerah
Jawa Timur
PT Bank Permata Tbk.
PT Bank Central Asia Tbk.
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank Mandiri (Persero) Tbk.
Citibank N.A., Jakarta
PT Bank OCBC NISP Tbk.
Lain-lain (masing-masing di bawah
Rp5 miliar)
Dolar A.S.
Citibank, Singapura
Citibank N.A., Jakarta
PT Bank Central Asia Tbk.
The Hong Kong and Shanghai
Banking Corporation Ltd., Jakarta
PT Bank Permata Tbk.
Lain-lain (masing-masing di bawah
Rp5 miliar)
Mata uang lainnya
PT Bank Central Asia Tbk.
Lain-lain (masing-masing
di bawah Rp5 miliar)
Sub-total
2010
8.623.639.212
1.683.905.458
822.727.366
10.494.764.843
1.186.786.097
424.948.430
11.130.272.036
12.106.499.370
54.931.226.007
31.803.763.842
40.778.496.357
6.732.584.352
26.606.633.287
25.889.001.684
24.675.137.670
11.288.648.170
36.341.707.860
27.273.174.367
13.695.264.046
13.638.909.060
13.425.374.157
1.652.017.200
1.457.833.409
24.061.546.694
9.162.231.006
5.058.905.287
3.972.704.932
3.751.988.013
34.702.001.655
12.641.101.075
8.974.124.231
1.962.200.965
24.494.764.340
16.040.780.611
4.220.901.198
3.198.008.485
8.352.708.949
12.865.540.102
10.837.608.906
9.975.992.993
1.599.547.852
6.763.849.552
9.074.208.451
8.688.674.031
295.537.533.738
255.051.627.058
52
Cash on hand
Rupiah
U.S. Dollar
Other currencies
Sub-total
Cash in banks - third parties
Rupiah
PT Bank Danamon Indonesia Tbk.
PT Bank CIMB Niaga Tbk.
PT Bank Pembangunan Daerah
Jawa Timur
PT Bank Permata Tbk.
PT Bank Central Asia Tbk.
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank Mandiri (Persero) Tbk.
Citibank N.A., Jakarta
PT Bank OCBC NISP Tbk.
Others (each below Rp5 billion)
U.S. Dollar
Citibank, Singapore
Citibank N.A., Jakarta
PT Bank Central Asia Tbk.
The Hong Kong and Shanghai
Banking Corporation Ltd., Jakarta
PT Bank Permata Tbk.
Others (each below Rp5 billion)
Other currency
PT Bank Central Asia Tbk.
Others (each below Rp5 billion)
Sub-total
4.
4.
2011
341.978.471.230
112.509.235.173
237.900.000.000
147.957.053.899
220.056.666.666
111.634.051.457
175.925.335.503
125.780.121.844
93.320.702.137
127.364.830.684
9.767.750.359
141.728.116.078
38.722.883.920
36.000.000.000
78.526.165.083
93.524.452.055
34.921.471.962
28.341.113.925
19.000.000.000
15.000.000.000
12.000.000.000
5.000.000.000
4.525.819.104
2.500.000.000
1.800.000.000
1.000.000.000
-
99.006.032.292
7.000.000.000
84.200.000.000
66.612.236.039
50.094.127.328
17.000.000.000
9.500.000.000
79.000.000.000
13.500.000.000
6.700.000.000
195.101.918.155
117.950.642.489
90.837.277.024
58.977.774.348
45.514.726.668
4.495.500.000
117.046.673.062
8.991.000.000
-
27.254.054.848
23.078.060.000
9.098.334.726
4.534.000.000
88.920.990.003
6.023.970.000
51.203.023.387
53.963.735.648
22.640.517.084
4.495.500.000
4.495.500.000
U.S. Dollar
PT Bank CIMB Niaga Tbk.
PT Bank Permata Tbk.
PT Bank UOB Indonesia
PT Bank Internasional Indonesia Tbk.
PT ANZ Panin Bank
PT Bank Rakyat Indonesia
(Persero) Tbk.
PT Bank Central Asia Tbk.
PT Bank OCBC NISP Tbk.
PT Bank Bukopin Tbk.
PT Bank Negara Indonesia
(Persero) Tbk.
PT Bank ICBC Indonesia
PT Bank Pan Indonesia Tbk.
PT Bank Mega Tbk.
10.825.405.604
8.821.501.668
6.984.699.050
Euro
PT Bank Central Asia Tbk.
738.525.124
7.991.677.323
Philippines Peso
Philippine Business Bank
1.984.668.004.327 1.634.713.638.622
Sub-total
2.291.335.810.101 1.901.871.765.050
53
4.
4.
2011
Call deposit dan deposito berjangka
Rupiah
Dolar A.S.
Euro
Rand Afrika Selatan
Peso Filipina
5.
2010
4,95% - 9,25%
0,25% - 4,90%
0,10% - 0,25%
4,90%
4,25%
SHORT-TERM INVESTMENTS
2010
102.500.000.000
4.760.700.000
300.000.000
4.720.275.000
40.395.000
40.395.000
5.256.267.270
1.314.056.114
83.831.474
171.418.729
113.871.418.384
5.315.920.203
Marketable securities
Available-for-sale
Mutual fund units
Bonds
Other marketable securities
(each below Rp1 billion)
Unrealized gains on appreciation
in market values of short-term
investments, net
Company
Subsidiaries
Short-term Investments
2011
5,00% - 9,50%
0,25% - 4,90%
4,90%
4,25%
5.
Surat-surat berharga
Tersedia untuk dijual
Unit reksadana
Obligasi
Surat berharga lainnya
(masing-masing di
bawah Rp1 miliar)
Laba belum direalisasi atas kenaikan
nilai pasar investasi jangka
pendek, neto
Perusahaan
Entitas Anak
2010
7,75%
7,75%
U.S. Dollar
As of December 31, 2011 and 2010, the shortterm investments in bonds avalaible-for-sale
denominated in U.S. Dollar is as follows:
54
5.
5.
Rating
PLN 2020 (Majapahit Holding B.V)
BB-
525.000
2010
102.200.000.000
300.000.000
300.000.000
Total
102.500.000.000
300.000.000
Total
6.
2010
1.398.812.133.706
149.338.144.789
1.117.375.218.771
153.668.057.282
Domestic customers
Foreign customers
Total
Dikurangi cadangan penurunan nilai
1.548.150.278.495 1.271.043.276.053
(18.158.649.905)
(8.332.605.382)
Total
Less allowance for impairment
1.529.991.628.590
55
1.262.710.670.671
6.
6.
Rupiah
Lancar
Lewat jatuh tempo
1 - 30 hari
31 - 60 hari
61 - 90 hari
Lebih dari 90 hari
Total/
Total
983.840.987.763
122.827.954.618
1.106.668.942.381
307.128.208.214
36.659.519.372
26.702.049.753
1.550.804.731
26.529.052.618
24.571.132.044
1.819.105.835
16.521.463.547
333.657.260.832
61.230.651.416
28.521.155.588
18.072.268.278
Current
Overdue
1 - 30 days
31 - 60 days
61 - 90 days
Over 90 days
Total
Dikurangi cadangan
penurunan nilai
1.355.881.569.833
192.268.708.662
1.548.150.278.495
Total
1.348.621.785.400
(7.259.784.433)
(10.898.865.472)
(18.158.649.905)
181.369.843.190
1.529.991.628.590
2010
Mata Uang Asing
(Setara dalam
Rupiah)/
Foreign
Currencies
(Equivalent
Rupiah)
Rupiah
Lancar
Lewat jatuh tempo
1 - 30 hari
31 - 60 hari
61 - 90 hari
Lebih dari 90 hari
Total/
Total
811.719.537.175
130.042.920.908
941.762.458.083
234.765.223.812
32.894.854.007
24.101.566.493
1.010.322.290
25.785.491.561
9.269.613.108
727.566.825
726.179.874
260.550.715.373
42.164.467.115
24.829.133.318
1.736.502.164
Current
Overdue
1 - 30 days
31 - 60 days
61 - 90 days
Over 90 days
Total
Dikurangi cadangan
penurunan nilai
1.104.491.503.777
166.551.772.276
1.271.043.276.053
Total
1.098.171.010.119
(6.320.493.658)
(2.012.111.724)
(8.332.605.382)
164.539.660.552
1.262.710.670.671
2010
8.332.605.382
12.671.634.074
(2.845.589.551)
7.379.112.880
3.290.083.788
(2.336.591.286)
18.158.649.905
8.332.605.382
56
6.
6.
7.
8.
7.
SIGNIFICANT
BALANCES
AND
TRANSACTIONS WITH RELATED PARTIES
Group
obtained insurance
policies from
PT Asuransi Mitra Maparya (AMM), with
combined insurance coverage amounting to
Rp3,278 billion,
US$42.2 million,
SGD108
thousand and JPY750 thousand as of
December 31, 2011, and Rp3,052 billion,
US$43 million, EUR592 thousand, SGD39
thousand and JPY750 thousand
as of
December 31, 2010. The said insurance policies
covered portions of inventories and property, plant
and equipment against risks of losses by fire,
flood and other risks, on a blanket basis (Notes 8
and 11).
PERSEDIAAN, NETO
8.
INVENTORIES, NET
2010
682.151.830.956
589.953.138.410
23.312.532.888
390.604.855.353
12.367.588.484
15.403.710.769
736.099.849.614
455.630.181.029
16.908.445.873
328.749.077.525
8.821.107.678
13.795.524.553
Total
Dikurangi penyisihan
persediaan usang
1.713.793.656.860
1.560.004.186.272
(8.604.470.550)
(9.175.366.436)
Total
Less allowance for inventory
obsolence
Neto
1.705.189.186.310
1.550.828.819.836
Net
57
8.
8.
9.
2010
9.175.366.436
5.962.901.096
12.074.141.863
17.072.505.703
(12.645.037.749)
(13.011.232.205)
(848.808.158)
8.604.470.550
9.175.366.436
9.
2010
1 Januari 2010/
31 Desember 2009
74.012.570.814
58.415.148.339
41.076.574.683
66.831.724.178
38.029.765.200
10.591.294.947
67.123.766.907
69.797.095.708
3.119.538.578
83.943.171.969
58.078.227.377
3.136.927.218
Prepaid expenses
Advances for purchase of raw material
and finished goods
Other advances
Others
189.465.355.139
198.455.549.532
186.234.901.247
Total
Nilai Perolehan/
Cost
Investasi pada entitas asosiasi
Orange Kalbe Limited (OKL)
37.403.818.826
Akumulasi Bagian
atas Rugi Neto/
Accumulated Share
in Net Losses
(8.633.497.757)
58
Nilai
Tercatat/
Carrying Value
28.770.321.069
10. INVESTMENT
(continued)
IN
SHARES
OF
STOCKS
2011
Nilai Perolehan/
Cost
Penyertaan lainnya
PT Kageo Igar Jaya Tbk.(Kageo Igar)
11.318.955.767
Akumulasi
Laba Belum Direalisasi
atas Kenaikan
Nilai Pasar Investasi/
Accumulated
Unrealized Gain on
Nilai Pasar
Appreciation in Market
Wajar/
Values of Investments Fair Market value
13.618.544.233
24.937.500.000
Other investment
PT Kageo Igar Jaya Tbk.(Kageo Igar)
2010
Nilai Perolehan/
Cost
Investasi pada entitas asosiasi
Orange Kalbe Limited (OKL)
37.403.818.826
Nilai Perolehan/
Cost
Penyertaan lainnya
PT Kageo Igar Jaya Tbk.(Kageo Igar)
Akumulasi Bagian
atas Rugi Neto/
Accumulated Share
in Net Losses
-
Nilai
Tercatat/
Carrying Value
37.403.818.826
Akumulasi
Rugi Belum Direalisasi
atas Penurunan
Nilai Pasar Investasi/
Accumulated
Unrealized Loss on
Nilai Pasar
Decline in Market Values
Wajar/
of Investments
Fair Market value
11.318.955.767
(293.955.767)
11.025.000.000
Other investment
PT Kageo Igar Jaya Tbk.(Kageo Igar)
2009
Nilai Perolehan/
Cost
Investasi pada entitas asosiasi
Orange Kalbe Limited (OKL)
Akumulasi Bagian
atas Rugi Neto/
Accumulated Share
in Net Losses
37.403.818.826
Nilai
Tercatat/
Carrying Value
37.403.818.826
59
Penyertaan lainnya
Other investment
60
Penambahan/
Reklasifikasi/
Additions/
Reclassifications
324.334.253.361
586.533.710.850
17.427.199.763
833.700.229.165
424.794.010.933
209.426.883.695
93.685.167.257
54.922.002.868
34.211.046.710
1.507.685.066
18.212.416.366
48.287.870.820
52.119.537.104
41.260.684.674
739.727.019
3.098.337.017
2.846.522.278
19.139.609.314
23.436.055.975
379.256.256.229
620.744.757.560
18.195.157.810
848.814.308.514
470.235.359.475
242.406.811.485
111.509.795.956
Carrying Value
Direct Ownership
Land and landrights
Buildings and improvements
Leasehold improvements
Machinery and equipment
Office equipment, furniture and fixtures
Vehicles and transportation equipment
Medical equipment
2.489.901.455.024
250.521.243.608
49.260.251.603
2.691.162.447.029
Sub-total
1.496.192.310
216.797.258
1.279.395.052
Sub-total
1.496.192.310
216.797.258
1.279.395.052
Sub-total
195.863.674.823
77.505.375.384
117.206.220.156
183.251.457.674
54.776.978.553
26.779.020.075
258.292.916.426
233.977.812.983
Constructions in Progress
Buildings and improvements
Machinery and equipment
Nilai Tercatat
Pemilikan Langsung
Tanah dan hak atas tanah
Bangunan dan prasarana
Perbaikan kantor disewa
Mesin dan peralatan
Perlengkapan kantor
Kendaraan dan alat transportasi
Peralatan kesehatan
Sub-total
Pengurangan/
Reklasifikasi/
Deductions/
Reclassifications
Saldo Akhir/
Ending
Balance
273.369.050.207
300.457.677.830
81.555.998.628
492.270.729.409
Sub-total
2.764.766.697.541
550.978.921.438
131.033.047.489
3.184.712.571.490
1.212.733.358
199.433.744.739
9.155.203.312
462.226.225.816
302.056.120.264
153.479.099.017
31.341.760.313
35.411.610.780
2.159.793.698
70.939.484.413
52.945.828.034
22.358.106.434
13.409.957.642
739.727.019
1.246.821.787
2.284.313.253
17.356.426.441
10.839.296.258
1.212.733.358
234.845.355.519
10.575.269.991
531.918.888.442
352.717.635.045
158.480.779.010
33.912.421.697
Accumulated Depreciation
Direct Ownership
Land and landrights
Buildings and improvements
Leasehold improvements
Machinery and equipment
Office equipment, furniture and fixtures
Vehicles and transportation equipment
Medical equipment
1.158.904.886.819
197.224.781.001
32.466.584.758
1.323.663.083.062
Sub-total
595.779.624
265.272.364
100.047.292
761.004.696
595.779.624
265.272.364
100.047.292
761.004.696
Sub-total
1.159.500.666.443
197.490.053.365
32.566.632.050
1.324.424.087.758
Nilai Buku
1.605.266.031.098
1.860.288.483.732
61
11. PROPERTY,
(continued)
PLANT
AND
EQUIPMENT
2010
Saldo Awal/
Beginning
Balance
Nilai Tercatat
Pemilikan Langsung
Tanah dan hak atas tanah
Bangunan dan prasarana
Perbaikan kantor disewa
Mesin dan peralatan
Perlengkapan kantor
Kendaraan dan alat transportasi
Peralatan kesehatan
Sub-total
Penambahan/
Reklasifikasi/
Additions/
Reclassifications
Pengurangan/
Reklasifikasi/
Deductions/
Reclassifications
Divestasi
Kageo Igar/
Divestment of
Kageo Igar
Saldo Akhir/
Ending
Balance
265.653.181.322
557.062.978.016
12.753.905.095
919.928.317.603
408.699.222.155
216.347.411.946
61.401.539.457
61.435.167.898
46.300.998.359
4.673.584.668
67.512.943.802
54.821.413.580
27.941.339.437
33.194.391.277
1.101.785.742
1.499.680.000
290.000
27.745.851.062
6.099.142.744
27.819.825.875
910.763.477
1.652.310.117
15.330.585.525
125.995.181.178
32.627.482.058
7.042.041.813
-
324.334.253.361
586.533.710.850
17.427.199.763
833.700.229.165
424.794.010.933
209.426.883.695
93.685.167.257
Carrying Value
Direct Ownership
Land and landrights
Buildings and improvements
Leasehold improvements
Machinery and equipment
Office equipment, furniture and fixtures
Vehicles and transportation equipment
Medical equipment
2.441.846.555.594
295.879.839.021
65.177.338.900
182.647.600.691
2.489.901.455.024
Sub-total
8.500.000.000
1.844.854.000
348.661.690
8.500.000.000
-
1.496.192.310
10.344.854.000
348.661.690
8.500.000.000
1.496.192.310
Sub-total
195.863.674.823
77.505.375.384
Constructions in Progress
Buildings and improvements
Machinery and equipment
61.864.689.182
35.591.391.511
171.132.081.581
90.557.314.167
37.133.095.940
48.643.330.294
97.456.080.693
261.689.395.748
85.776.426.234
273.369.050.207
Sub-total
2.549.647.490.287
557.569.234.769
151.302.426.824
191.147.600.691
2.764.766.697.541
1.117.044.710
181.360.936.219
6.943.616.375
492.477.719.120
281.856.616.318
161.468.423.125
22.837.117.924
95.688.648
25.796.060.972
2.211.606.271
84.533.395.434
52.532.515.550
22.324.428.600
8.803.065.979
425.662.400
19.334
11.167.820.140
4.383.072.934
25.230.864.490
298.423.590
7.297.590.052
103.617.068.598
27.949.938.670
5.082.888.218
-
1.212.733.358
199.433.744.739
9.155.203.312
462.226.225.816
302.056.120.264
153.479.099.017
31.341.760.313
Accumulated Depreciation
Direct Ownership
Land and landrights
Buildings and improvements
Leasehold improvements
Machinery and equipment
Office equipment, furniture and fixtures
Vehicles and transportation equipment
Medical equipment
1.148.061.473.791
196.296.761.454
41.505.862.888
143.947.485.538
1.158.904.886.819
Sub-total
2.921.323.613
536.815.802
705.147.079
299.238.462
240.274.640
3.626.470.692
-
595.779.624
3.458.139.415
1.004.385.541
240.274.640
3.626.470.692
595.779.624
Sub-total
1.151.519.613.206
197.301.146.995
41.746.137.528
147.573.956.230
1.159.500.666.443
Nilai Buku
1.398.127.877.081
1.605.266.031.098
62
11. PROPERTY,
(continued)
PLANT
AND
EQUIPMENT
Penyusutan
Depreciation
2011
Beban pabrikasi
Beban penjualan (Catatan 23)
Beban umum dan administrasi
(Catatan 24)
Beban penelitian dan pengembangan
Total
2010
82.886.336.565
56.560.472.815
82.247.715.007
50.950.855.268
53.783.435.132
4.181.793.664
59.830.238.463
4.032.063.617
Manufacturing overhead
Selling expenses (Note 23)
General and administrative expenses
(Note 24)
Research and development expenses
197.412.038.176
197.060.872.355
Total
2011
Harga jual
Nilai buku
Laba atas penjualan aset tetap
2010
22.069.554.517
16.339.420.167
19.642.293.246
6.559.227.518
Sales proceeds
Net book value
5.730.134.350
13.083.065.728
63
11. PROPERTY,
(continued)
PLANT
AND
EQUIPMENT
2011
2010
354.531.596
397.804.092
432.278.289
864.700.434
752.335.688
(101.969.660)
1.296.978.723
(243.539.217)
650.366.028
1.053.439.506
Total
Bunga yang belum jatuh tempo
Utang sewa pembiayaan
Bagian yang jatuh tempo dalam waktu
satu tahun
Bagian jangka panjang
(285.388.096)
(308.292.399)
364.977.932
745.147.107
Year Due
Within one year
Between one to five years
Total
Amount applicable to interest
Obligations under finance leases
Currently maturing portion
Long-term portion
Construction in progress
Perusahaan
Company
64
11. PROPERTY,
(continued)
PLANT
AND
EQUIPMENT
Entitas Anak
Subsidiaries
EPMT
EPMT
Hexpharm
Hexpharm
KMI
KMI
Hal lain-lain
Other matters
65
11. PROPERTY,
(continued)
PLANT
AND
EQUIPMENT
2010
Biaya perolehan
Goodwill
Merek dagang, hak paten dan formula
Piranti lunak komputer
195.217.373.481
58.761.730.783
45.212.980.952
263.011.258.602
54.542.530.783
43.450.721.450
Cost
Goodwill
Trademarks, patents and formulas
Computer software
Total
299.192.085.216
361.004.510.835
Total
Akumulasi amortisasi
Saldo awal tahun
Goodwill
Merek dagang, hak paten dan formula
Piranti lunak komputer
(29.585.390.180)
(26.067.359.424)
(52.328.030.677)
(26.395.600.347)
(18.961.589.837)
Accumulated amortization
Balance at beginning of year
Goodwill
Trademarks, patents and formulas
Computer software
Sub-total
(55.652.749.604)
(97.685.220.861)
Sub-total
(3.052.483.288)
(7.479.401.761)
(15.465.854.444)
(3.189.789.833)
(7.105.769.587)
Sub-total
(10.531.885.049)
(25.761.413.864)
Sub-total
(66.184.634.653)
(123.446.634.725)
Neto
233.007.450.563
237.557.876.110
66
Net
2010
11.217.596.594
Rupiah
Fixed loan
PT Bank CIMB Niaga Tbk.
Overdrafts
PT Bank Central AsiaTbk.
PT Bank Permata Tbk.
U.S. Dollar
Revolving Credit
The Hong Kong and Shanghai
Banking Corporation Ltd., Jakarta
(US$3,000,000)
Revolving Credit
PT Bank Permata Tbk.
(US$1,750,000)
Singapore Dollar
Fixed loan
DBS Bank Ltd. (SGD1,600,000)
140.056.547.003
24.290.351.153
100.000.000.000
1.079.208.679
555.741.730
8.556.101.153
27.204.000.000
Rupiah
Dolar A.S.
Dolar Singapura
15.734.250.000
2010
9,50% - 10,25%
6,50%
2,00%
10,50% - 12,00%
5,5%
-
Rupiah
U.S. Dollar
Singapore Dollar
67
Perusahaan
Company
68
Perusahaan (lanjutan)
Company (continued)
Saka
Saka
Finusolprima
Finusolprima
69
Innogene
Innogene
Sanghiang
Sanghiang
Bintang Toedjoe
Bintang Toedjoe
Hexpharm
Hexpharm
EPMT
EPMT
70
EPMT (lanjutan)
EPMT (continued)
71
EPMT (lanjutan)
EPMT (continued)
sampai
dengan
tanggal
GCM
GCM
72
GCM (lanjutan)
GCM (continued)
TSJ
TSJ
EMP
EMP
73
EMP (lanjutan)
EMP (continued)
2010
Pihak ketiga
Pemasok lokal
PT Abbott Indonesia
155.558.036.287
PT LOreal Indonesia
66.507.939.041
PT Mead Johnson Indonesia
44.065.756.806
PT Medquest Jaya Global
22.643.729.689
PT Kara Santan Pertama
16.695.413.700
PT Avesta Continental Pack
16.677.828.831
PT Mulya Husada Jaya
13.175.000.000
CV Hentraco
12.812.435.455
PT Mega Andalan Kalasan
11.872.360.995
PT Anta Tirta Kirana
(Rp667.657.299 dan US$1.174.804
pada tahun 2011 dan Rp617.374.771
dan US$684.474 pada tahun 2010)
11.320.779.971
PT Maju Jaya Sarana Grafika
10.082.129.111
Lain-lain (masing-masing
di bawah Rp10 miliar)
326.545.501.459
Sub-total
707.956.911.345
131.295.293.749
35.602.702.206
37.150.175.205
105.427.620
7.997.095.656
12.450.622.223
78.000.000
8.287.144.409
6.771.476.010
7.139.924.305
270.442.593.924
386.025.161.558
Third parties
Local suppliers
PT Abbott Indonesia
PT LOreal Indonesia
PT Mead Johnson Indonesia
PT Medquest Jaya Global
PT Kara Santan Pertama
PT Avesta Continental Pack
PT Mulya Husada Jaya
CV Hentraco
PT Mega Andalan Kalasan
PT Anta Tirta Kirana
(Rp667,657,299 and US$1,174,804
in 2011 and Rp617,374,771 and
US$684,474 in 2010)
PT Maju Jaya Sarana Grafika
Others (each below Rp10 billion)
Sub-total
Foreign suppliers
Biomerieux
(US$5,766,557 in 2011 and
22.185.836.487
US$2,467,561 in 2010)
Morinaga Milk Industry, Co. Ltd., Japan
(185,482,511 in 2011 and
931.910.785
8,450,000 in 2010)
79.097.725.401
102.215.472.673
11.146.177.035
Related party
Foreign supplier
Orange Kalbe Limited
(US$1,229,177)
850.398.382.129
488.240.634.231
74
2010
Lancar
Lewat jatuh tempo:
Lebih 1 bulan sampai 3 bulan
Lebih 3 bulan sampai 6 bulan
Lebih 6 bulan
701.037.284.264
220.194.712.675
139.259.641.594
9.790.060.163
311.396.108
225.196.283.521
42.717.347.345
132.290.690
Current
Overdue:
Over 1 month up to 3 months
Over 3 months up to 6 months
Over 6 months
Total
850.398.382.129
488.240.634.231
Total
2011
2010
Rupiah
Dolar A.S.
(US$22.311.512 pada tahun 2011
dan US$27.166.842 pada tahun 2010)
Mata uang asing lainnya
602.223.618.989
215.230.287.911
202.320.799.882
45.853.963.258
244.257.072.605
28.753.273.715
Rupiah
U.S. Dollar
(US$22,311,512 in 2011 and
US$27,166,842 in 2010)
In other foreign currencies
Total
850.398.382.129
488.240.634.231
Total
2010
Penjualan
Royalti (Catatan 32a, 32e, 32f dan 32g)
Lain-lain (masing-masing
di bawah Rp5 miliar)
208.604.286.273
23.640.993.520
208.914.194.610
19.476.662.553
Selling
Royalty (Notes 32a, 32e, 32f and 32g)
50.892.667.490
73.571.632.969
Total
283.137.947.283
301.962.490.132
Total
75
17. PERPAJAKAN
17. TAXATION
Taxes payable consist of the following:
2010
16.645.842.764
4.791.621.478
28.046.570.654
3.014.869.229
65.114.476.176
36.000.025.269
673.138.532
16.306.020.514
3.368.187.087
19.052.224.890
2.680.693.578
93.512.333.268
54.558.722.381
3.156.762.062
Income taxes:
Article 21
Article 23
Article 25
Article 26
Article 29
Value added tax
Others
154.286.544.102
192.634.943.780
Total
2010
1.987.259.361.668
1.770.434.609.435
8.633.497.757
(1.236.723.993.329)
759.168.866.096
18.665.443.510
(904.442.559.252)
884.657.493.693
Beda temporer:
Penyisihan imbalan kerja
karyawan
9.335.750.984
4.501.040.228
4.007.565.019
111.118.497
524.697.406
(673.344.049)
268.854.553
704.653.054
839.195.971
643.709.740
536.106.689
496.700.172
(98.700.288.226)
(39.615.125.850)
(24.188.188.844)
(24.543.929.518)
6.588.478.752
(18.878.188.256)
465.712.194
716.975.917.185
749.274.961.120
76
2010
716.975.917.000
749.274.961.000
1.269.571.135.000
1.106.063.581.000
Subsidiaries
143.395.183.400
321.488.525.009
149.854.992.200
279.194.469.082
464.883.708.409
429.049.461.282
Entitas Anak
9.821.671.726
681.532.529
349.156.952
132.203.224.212
7.638.801.407
241.522.251
223.691.070
103.181.839.227
Sub-total
143.055.585.419
111.285.853.955
Sub-total
38.296.104.534
3.920.958.315
85.898.346
219.879.020.937
17.703.842.248
2.557.776.577
96.399.590
226.800.707.539
Sub-total
262.181.982.132
247.158.725.954
Sub-total
405.237.567.551
358.444.579.909
Entitas Anak
Pasal 22
Pasal 23
Pasal 24
Pasal 25
Subsidiaries
Article 22
Article 23
Article 24
Article 25
339.597.981
64.774.878.195
38.569.138.245
54.943.195.023
Total
65.114.476.176
93.512.333.268
Total
5.468.335.318
22.907.451.895
Total
5.468.335.318
22.907.451.895
Total
77
Tahun fiskal
2010
2011
Fiscal Year
2011
2010
2009
5.468.335.318
22.907.451.895
7.124.000
22.907.451.895
6.513.925.852
2011
2010
2009
Total
28.382.911.213
29.421.377.747
Total
1.
1.
2.
2.
3.
3.
78
2011
Laba sebelum manfaat (beban) pajak
penghasilan menurut laporan
laba rugi konsolidasian
Ditambah:
Bagian rugi entitas asosiasi
Rugi penjualan saham Entitas Anak
Dikurangi:
Laba Entitas Anak sebelum
manfaat (beban) pajak
penghasilan, neto
Laba Perusahaan sebelum
manfaat (beban) pajak penghasilan
2010
(904.442.559.252)
884.657.493.693
1.987.259.361.668 1.770.434.609.435
8.633.497.757
-
(1.236.723.993.329)
759.168.866.096
79
18.665.443.510
2010
151.833.773.360
176.931.498.739
140.930.611
128.741.948
107.221.338
53.770.911
99.340.034
167.839.194
(7.923.025.170)
(4.837.637.769)
(4.908.785.904)
(3.775.637.651)
1.317.695.749
(19.740.045.645)
93.142.439
1.958.871.662
Total
142.580.452.557
148.870.288.531
Total
321.722.088.819
277.765.352.482
464.302.541.376
426.635.641.013
(196.952.758)
2010
9.804.775.137
(2.559.549.539)
9.896.496.779
(3.466.002.021)
7.245.225.598
6.430.494.758
80
2010
7.245.225.598
6.430.494.758
Entitas Anak
EPMT
Saka
Danfar
Sanghiang
Finusolprima
Hexpharm
Bifarma
PML
AKPI
25.200.511.203
1.681.337.168
1.396.920.235
1.021.446.405
449.495.125
390.748.144
95.160.647
51.547.493
-
23.028.367.185
847.798.903
1.451.871.343
714.808.148
203.486.524
258.731.847
73.162.514
38.536.062
1.726.748.522
Subsidiaries
EPMT
Saka
Danfar
Sanghiang
Finusolprima
Hexpharm
Bifarma
PML
AKPI
30.287.166.420
28.343.511.048
Sub-total Subsidiaries
Total
37.532.392.018
34.774.005.806
Total
5.740.893.677
3.938.351.722
159.575.794
3.806.775.180
3.832.058.100
-
Total
9.838.821.193
7.638.833.280
Total
Entitas Anak
Subsidiaries
Bintang Toedjoe
Bintang Toedjoe
81
Subsidiaries (continued)
Saka
Saka
Danfar
Danfar
82
Subsidiaries (continued)
Finusolprima
Finusolprima
KMI
KMI
83
Subsidiaries (continued)
KMI (lanjutan)
KMI (continued)
GCM
GCM
84
Subsidiaries (continued)
GCM (lanjutan)
GCM (continued)
RTU
RTU
85
Akun ini merupakan hak kepentingan nonpengendali atas aset neto Entitas Anak yang tidak
dimiliki sepenuhnya oleh Grup (Catatan 2b),
dengan rincian sebagai berikut:
2011
2010
1 Januari 2010/
31 Desember 2009/
January 1, 2010/
December 31, 2009
of nonof the
by the
are as
EPMT
KMI
AKPI
Innogene
PML
Kageo Igar
Avesta
Indogravure
201.285.019.748
90.250.419.713
6.704.561.820
2.090.243.984
786.682.243
-
293.024.236.868
92.512.617.467
9.888.931.170
1.825.054.263
881.887.868
-
260.917.913.434
88.360.384.569
2.440.139.718
1.038.642.473
77.694.897.017
30.045.194.919
19.736.793.949
EPMT
KMI
AKPI
Innogene
PML
Kageo Igar
Avesta
Indogravure
Total
301.116.927.508
398.132.727.636
480.233.966.079
Total
of
2011
Pemegang Saham
Jumlah Saham
Ditempatkan
dan Disetor Penuh/
Number of
Shares Issued
and Fully Paid
Persentase
Pemilikan/
Percentage
of
Ownership
4.065.193.405
43,37
203.259.670.250
Sub-total
9.375.024.422
100,00%
468.751.221.100
Sub-total
780.990.000
39.049.500.000
Treasury stock
10.156.014.422
507.800.721.100
Total
Total
10,17%
9,62
9,49
9,47
9,22
8,66
86
47.678.728.850
45.096.468.400
44.479.704.400
44.398.954.400
43.229.529.400
40.608.165.400
Shareholders
Modal treasuri
953.574.577
901.929.368
889.594.088
887.979.088
864.590.588
812.163.308
Jumlah/
Amount
Pemegang Saham
Jumlah Saham
Ditempatkan
dan Disetor Penuh/
Number of
Shares Issued
and Fully Paid
Persentase
Pemilikan/
Percentage
of
Ownership
4.064.356.905
43,36
203.217.845.250
Sub-total
9.375.024.422
100,00%
468.751.221.100
Sub-total
780.990.000
39.049.500.000
Treasury stock
10.156.014.422
507.800.721.100
Total
Total
10,17%
9,62
9,49
9,47
9,22
8,67
47.678.728.850
45.096.468.400
44.479.704.400
44.398.954.400
43.229.529.400
40.649.990.400
Shareholders
Modal treasuri
953.574.577
901.929.368
889.594.088
887.979.088
864.590.588
812.999.808
Jumlah/
Amount
87
88
The original consolidated financial statements included herein are in Indonesian language.
Penjualan neto
Beban pokok penjualan
Laba bruto
Obat Resep/
Prescription
Pharmaceutical
Produk
Kesehatan/
Consumer
Health
Nutrisi/
Nutritionals
2.777.596.650.182
1.841.720.741.978
2.419.829.114.024
947.363.825.205
802.900.008.483
926.229.985.459
2.684.192.987.435
5.360.686.806.582
1.830.232.824.977
1.038.820.733.495
1.493.599.128.565
1.188.520.647.904
5.551.173.334.941
Gross profit
Beban penjualan
Beban umum dan administrasi
Beban penelitian dan pengembangan
Beban bunga dan keuangan
Rugi selisih kurs, neto
Penghasilan bunga
Laba atas penjualan aset tetap
Rupa-rupa, neto
Beban pajak penghasilan, neto
Laba tahun berjalan yang
dapat diatribusikan
kepada kepentingan
non-pengendali
Distribusi dan
Kemasan/
Distribution and
Packaging
Konsolidasian/
Consolidated
3.872.713.635.339 10.911.860.141.523
Net sales
(2.905.465.910.128)
(586.524.605.026)
(91.211.579.687)
(13.172.498.498)
(12.362.082.622)
96.933.578.727
5.730.134.350
(57.841.010.389)
(464.302.541.376)
Selling expense
General and administrative expense
Research and development expense
Interest expense and financial charges
Loss on foreign exchange, net
Interest income
Gain on sale of property and equipment
Miscellaneous, net
Income tax expense, net
(40.719.850.514)
1.482.236.969.778
Total aset
8.274.554.112.840
Total assets
Total liabilitas
1.758.619.054.414
Total liabilities
Penyusutan
197.412.038.176
Depreciation
469.105.400.047
Capital expenditures
89
The original consolidated financial statements included herein are in Indonesian language.
Penjualan neto
Beban pokok penjualan
Laba bruto
Obat Resep/
Prescription
Pharmaceutical
Produk
Kesehatan/
Consumer
Health
Nutrisi/
Nutritionals
2.579.652.644.426
1.700.560.453.456
2.292.639.160.447
848.797.817.525
721.475.517.229
895.771.781.240
2.594.358.505.313
5.060.403.621.307
1.730.854.826.901
979.084.936.227
1.396.867.379.207
1.059.578.442.581
5.166.385.584.916
Gross profit
Beban penjualan
Beban umum dan administrasi
Beban penelitian dan pengembangan
Beban bunga dan keuangan
Rugi selisih kurs, neto
Penghasilan bunga
Laba atas penjualan aset tetap
Rugi penjualan saham
Entitas anak, neto
Rupa-rupa, neto
Beban pajak penghasilan, neto
Laba tahun berjalan yang dapat
diatribusikan
kepada kepentingan
non-pengendali
Distribusi dan
Kemasan/
Distribution and
Packaging
Konsolidasian/
Consolidated
3.653.936.947.894 10.226.789.206.223
(2.699.582.557.897)
(580.973.135.334)
(94.926.170.307)
(20.716.334.764)
(23.397.515.198)
54.977.618.234
13.083.065.728
Net sales
(16.477.053.110)
(27.938.892.833)
(426.635.641.013)
Selling expense
General and administrative expense
Research and development expense
Interest expense and financial charges
Loss on foreign exchange, net
Interest income
Gain on sale of property and equipment
Loss on sale of
shares in Subsidiaries, net
Miscellaneous, net
Income tax expense, net
(57.468.942.410)
1.286.330.026.012
Total aset
7.032.496.663.288
Total assets
Total liabilitas
1.260.361.432.719
Total liabilities
Penyusutan
197.060.872.355
Depreciation
469.775.003.400
Capital expenditures
90
2010
Penjualan neto
Domestik
Ekspor
10.481.124.069.703
430.736.071.820
9.819.344.474.484
407.444.731.739
Net sales
Domestic
Export
Total
10.911.860.141.523 10.226.789.206.223
Total
Aset
Domestik
Pengeluaran untuk barang
modal Domestik
8.004.021.489.612
6.793.789.517.431
Assets
Domestic
451.266.422.387
467.727.842.610
Capital expenditures
Domestic
2010
2.602.527.342.999
1.608.635.364.806
2.397.247.726.559
3.872.713.635.339
2.449.046.394.217
1.448.163.483.421
2.271.742.360.257
3.650.392.236.589
Domestic
Prescription pharmaceutical
Consumer health
Nutritionals
Distribution and packaging
10.481.124.069.703
9.819.344.474.484
Sub-total
Ekspor
Obat resep
Produk kesehatan
Nutrisi
Distribusi dan kemasan
175.069.307.183
233.085.377.172
22.581.387.465
-
130.606.250.209
252.396.970.035
20.896.800.190
3.544.711.305
Export
Prescription pharmaceutical
Consumer health
Nutritionals
Distribution and packaging
Sub-total
430.736.071.820
407.444.731.739
Sub-total
10.911.860.141.523 10.226.789.206.223
Total
Sub-total
Total
91
2010
1.481.122.265.951
92.547.513.092
583.120.373.663
1.520.592.677.908
122.578.262.497
550.609.841.704
2.156.790.152.706
2.193.780.782.109
28.920.080.790
(16.908.445.873)
2.205.792.417.026
428.329.768.202
130.922.023.288
(408.440.883.682)
2.356.603.324.834
783.289.146.961
3.202.090.032.823
769.435.780.341
2.717.653.663.093
Distribution
Finished Goods Inventories
At beginning of year
Purchases
3.985.379.179.784
3.487.089.443.434
(783.289.146.961)
16.908.445.873
(23.312.532.888)
2.150.386.065.691
408.440.883.682
88.585.646.791
(286.805.477.082)
2.360.607.119.082
(985.299.492.284)
3.000.079.687.500
2.703.800.296.473
5.360.686.806.582
5.060.403.621.307
92
2010
913.658.193.578
715.681.452.881
288.011.034.030
190.551.932.679
176.985.044.172
142.293.164.416
87.975.635.903
72.611.195.038
56.560.472.815
55.597.733.043
32.540.890.065
31.127.282.679
29.975.195.298
29.454.312.473
19.515.114.894
15.751.492.222
14.659.481.295
12.203.046.909
10.084.253.105
849.939.173.703
664.618.772.616
255.240.990.209
172.798.324.983
172.695.108.660
143.003.396.850
83.081.968.273
64.807.220.738
50.950.855.268
43.683.401.082
28.313.215.525
30.852.039.668
27.510.779.098
29.416.027.160
16.030.459.675
18.822.854.069
12.808.645.455
11.697.296.412
9.187.518.203
Promotions
Salaries, wages and employee benefits
Market research and development
Travelling, conferences and conventions
Selling supplies
Transportation and delivery
Royalty fees (Notes 32a, 32e, 32f and 32g)
Rental
Depreciation (Note 11)
Representation and entertainment
Equipment and supplies
Postage and telecommunication
Repairs and maintenance
Inventories written-off
Pension costs
Sales of canvassing
Electricity, water and gas
Insurance and taxes
Professional fee
10.228.982.633
14.124.510.250
2.905.465.910.128
2.699.582.557.897
2010
288.748.650.891
53.783.435.132
44.471.771.595
25.608.726.854
20.059.968.789
19.159.228.233
18.652.009.442
17.651.077.787
16.408.875.720
16.307.128.931
15.625.973.295
8.935.062.906
8.616.980.164
7.625.558.005
272.552.202.275
59.830.238.463
29.875.423.824
29.144.673.599
27.548.062.503
19.615.828.399
15.856.577.804
16.114.243.955
22.796.201.800
14.829.956.771
22.073.809.956
11.577.409.048
8.525.199.941
5.427.136.057
24.870.157.282
25.206.170.939
586.524.605.026
93
2010
45.021.927.374
12.224.044.317
8.403.977.713
6.889.291.298
39.032.795.476
13.124.668.474
6.104.696.017
7.741.384.090
18.672.338.985
28.922.626.250
91.211.579.687
94.926.170.307
26. INTEREST
CHARGES
EXPENSE
AND
FINANCIAL
2010
Beban administrasi
Beban bunga dan provisi:
Pinjaman bank dan lain-lain
Utang sewa pembiayaan
Beban keuangan - lain-lain
10.374.954.572
7.928.990.989
2.302.531.148
103.854.774
391.158.004
12.636.739.755
150.604.020
-
Administration charges
Interest expense and provision:
Bank loans and others
Obligations under finance leases
Financial expense - others
Total
13.172.498.498
20.716.334.764
Total
2010
93.196.332.618
3.737.246.109
-
50.304.395.758
4.362.330.645
310.891.831
Total
96.933.578.727
54.977.618.234
Total
94
Tanpa
Pendanaan/
Unfunded
65.149.488.552
(31.961.182.794)
21.226.095.514
(3.679.644.423)
456.576.734
26.007.248.389
8.150.000.346
105.783.904
534.435.400
Total/
Total
129.299.834
129.299.834
51.191.333.583
34.926.767.873
86.118.101.456
Total
95
91.156.736.941
(31.961.182.794)
29.376.095.860
(3.573.860.519)
991.012.134
Tanpa
Pendanaan/
Unfunded
33.147.404.107
(57.626.089.145)
21.961.803.073
(102.004.507)
17.210.092
(2.601.676.380)
Total/
Total
14.235.680.595
8.939.651.021
75.296.309
(3.483.647.308)
47.383.084.702
(57.626.089.145)
30.901.454.094
75.296.309
(3.585.651.815)
776.050.119
793.260.211
20.543.030.736
17.941.354.356
Total
31 Desember 2011/
December 31, 2011
Program
Dana Pensiun/
Pension
Program
Nilai tunai liabilitas
Biaya jasa lalu belum diakui
Keuntungan (kerugian) aktuaria
belum diakui
Nilai wajar aset bersih
Estimasi liabilitas imbalan kerja
karyawan (Selisih lebih liabilitas
aktuaria atas aset bersih
dana pensiun)
Tanpa
Pendanaan/
Unfunded
466.803.512.690
(20.461.793.889)
176.226.737.736
(14.273.820.401)
(139.262.500.618)
(490.644.223.181)
(44.126.190.564)
-
(183.565.004.998)
117.826.726.771
31 Desember 2010/
December 31, 2010
Program
Dana Pensiun/
Pension
Program
Nilai tunai liabilitas
Biaya jasa lalu belum diakui
Keuntungan (kerugian) aktuaria
belum diakui
Nilai wajar aset bersih
Selisih lebih liabilitas imbalan kerja
atas nilai wajar aset program
Estimasi liabilitas imbalan kerja
karyawan (Selisih lebih liabilitas
aktuaria atas aset bersih
dana pensiun)
285.317.163.621
(3.422.824.776)
(9.880.613.922)
(432.007.299.065)
510.969.786
(159.482.604.356)
96
Tanpa
Pendanaan/
Unfunded
110.960.379.800
(11.865.068.622)
212.683.344
105.488.358.666
6.180.364.144
-
31 Desember 2011/
December 31, 2011
Program
Dana Pensiun/
Pension
Program
Tanpa
Pendanaan/
Unfunded
(159.482.604.356)
105.488.358.666
51.191.333.583
34.926.767.873
(75.273.734.225)
(22.588.399.768)
(183.565.004.998)
117.826.726.771
31 Desember 2010/
December 31, 2010
Program
Dana Pensiun/
Pension
Program
Tanpa
Pendanaan/
Unfunded
(91.818.327.580)
108.002.706.839
1.452.359.289
(10.540.974.175)
(2.601.676.380)
20.543.030.736
(66.514.959.685)
-
(12.586.728.274)
70.323.540
(159.482.604.356)
97
105.488.358.666
28. ESTIMATED
SERVICE
(continued)
EMPLOYEES
BENEFITS
LIABILITIES
ENTITLEMENT
2010
7%
8,5%-10%
100% TMI - 99
0,1% TMI - 99
0,5%
55 tahun/years
10%
8,5%-10%
100% TMI - 99
0,1% TMI - 99
1%
55 tahun/years
Discount rate
Annual rate of increase in compensation
Mortality table
Permanent disability rate
Resignation rate
Retirement age
a.
a.
98
c.
Risiko kredit
c.
Credit risk
99
Risiko likuiditas
Liquidity risk
The Group manages its liquidity in financing
its working capital and repayment of matured
loan by providing sufficient cash and cash
equivalents. Therefore, the Group prepares
and evaluates budget or cash flow projection
and its realization on regular basis.
Selain itu, Grup dipersyaratkan oleh UndangUndang Perseroan Terbatas efektif tanggal
16 Agustus 2007 untuk mengkontribusikan sampai
dengan 20% dari modal saham ditempatkan dan
disetor penuh ke dalam dana cadangan yang tidak
boleh didistribusikan. Persyaratan permodalan
eksternal tersebut dipertimbangkan oleh Grup pada
Rapat Umum Pemegang Saham.
Grup
mengelola struktur permodalan dan
melakukan penyesuaian terhadap perubahan
kondisi
ekonomi.
Untuk
memelihara
dan
menyesuaikan struktur permodalan, Grup dapat
menyesuaikan
pembayaran
dividen
kepada
pemegang saham, menerbitkan saham baru atau
mengusahakan pendanaan melalui pinjaman. Tidak
ada perubahan atas tujuan, kebijakan maupun
proses pada tanggal 31 Desember 2011 dan 2010.
100
2010
Nilai wajar/
Fair
values
Nilai tercatat/
Carrying
values
Nilai wajar/
Fair
values
Aset Keuangan
Kas dan setara kas
Investasi jangka pendek
Piutang usaha, neto
Piutang lain-lain
Penyertaan saham
2.291.335.810.101
113.871.418.384
1.529.991.628.590
105.319.628.145
24.937.500.000
2.291.335.810.101
113.871.418.384
1.529.991.628.590
105.319.628.145
24.937.500.000
1.901.871.765.050
5.315.920.203
1.262.710.670.671
101.246.432.140
11.025.000.000
1.901.871.765.050
5.315.920.203
1.262.710.670.671
101.246.432.140
11.025.000.000
Financial Assets
Cash and cash equivalents
Short-term investments
Trade receivable, net
Other receivables
Investment in shares of stocks
Total
4.065.455.985.220
4.065.455.985.220
3.282.169.788.064
3.282.169.788.064
Total
140.056.547.003
850.398.382.129
202.423.719.905
283.137.947.283
650.366.028
140.056.547.003
850.398.382.129
202.423.719.905
283.137.947.283
650.366.028
24.290.351.153
488.240.634.231
139.052.381.971
301.962.490.132
1.053.439.506
24.290.351.153
488.240.634.231
139.052.381.971
301.962.490.132
1.053.439.506
Financial Liabilities
Short-term loans
Trade payables
Other payables
Accrued expenses
Obligations under finance leases
1.476.666.962.348
1.476.666.962.348
954.599.296.993
954.599.296.993
Total
Liabilitas Keuangan
Pinjaman jangka pendek
Utang usaha
Utang lain-lain
Biaya masih harus dibayar
Utang sewa pembiayaan
Total
32. PERJANJIAN
KONTINJENSI
PENTING,
KOMITMEN
DAN
Pihak Ketiga
Third Parties
Perusahaan
Company
a.
101
KOMITMEN
DAN
Perusahaan (lanjutan)
Company (continued)
102
KOMITMEN
DAN
Perusahaan (lanjutan)
Company (continued)
c.
c.
.
Pada bulan Januari 2009, melalui surat
keterbukaan informasi Perusahaan kepada
Bursa Efek Indonesia No. 004/CSEC-KF/I-09
tanggal 16 Januari 2009, Perusahaan
melaporkan bahwa JP Morgan Chase Bank,
N.A., London (JP Morgan) telah mengajukan
klaim sejumlah US$19.194.206 yang menurut
JP Morgan diakibatkan atas pelanggaran
pasal tertentu 2002 ISDA Master Agreement
mengenai transaksi derivatif. Perusahaan
menolak klaim tersebut karena Perusahaan
belum
pernah
menyetujui
maupun
menandatangani dokumen tersebut.
103
KOMITMEN
DAN
Perusahaan (lanjutan)
Company (continued)
104
KOMITMEN
DAN
Perusahaan (lanjutan)
Company (continued)
Subsequently, on March 8, 2012, the Company
received the decision notification from Supreme
Court of Republic of Indonesia on JP Morgan
Chase against the Company and the
official
copy
of
Supreme
Court
Decision
No.
2681K/Pdt/2010
Jo.
No.
89/Pdt.G/2009/PN.Jkt.Pst.
In
such
decision, Supreme Court of Republic of
Indonesia accepted the Companys exception
and denied the claim of JP Morgan (Note 35).
KI
d.
105
KOMITMEN
DAN
Sanghiang
Sanghiang
e.
Pada
bulan
April
2003,
Sanghiang
mengadakan perjanjian lisensi dan pengadaan
persediaan dengan Martek Biosciences
Corporation, perusahaan Delaware USA
(Martek), yang berlaku efektif hingga dua
puluh lima (25) tahun sejak pertama kali
penjualan komersial (bulan September 2003).
Berdasarkan perjanjian ini, Sanghiang akan
memperoleh lisensi non-eksklusif dari Martek
untuk
menggunakan,
memasarkan,
mengimpor, mengekspor, mendistribusikan,
melakukan penawaran penjualan dan/atau
menjual setiap produk Sanghiang yang
berisikan produk Martek.
Sebagai
kompensasinya,
Sanghiang
membayar biaya royalti sesuai dengan
persyaratan dan kondisi yang terdapat di
dalam
perjanjian.
Biaya
royalti
yang
dibebankan pada operasi disajikan sebagai
bagian dari Beban Penjualan (Catatan 23).
f.
f.
106
KOMITMEN
DAN
Sanghiang (lanjutan)
Sanghiang (continued)
g.
h.
Bintang Toedjoe
Bintang Toedjoe
i.
i.
107
KOMITMEN
DAN
j.
Hexpharm
Hexpharm
k.
l.
l.
108
KOMITMEN
DAN
Hexpharm (lanjutan)
Hexpharm (continued)
n.
Saka
Saka
p.
q.
109
KOMITMEN
DAN
Fima
Fima
r.
s.
EPMT
EPMT
t.
t.
u.
110
Rata-rata
Tertimbang Saham/
Weighted Average
Number of Share
Laba per
Saham/
Earnings
per Share
1.482.236.969.778
9.375.024.422
158
1.286.330.026.012
9.374.329.227
137
Total dalam
Mata Uang Asing/
Amount in
Foreign
Currency
FOREIGN
Dalam Rupiah/
In Rupiah
71.526.736
13.424.870
525.000
648.604.442.048
121.736.721.160
4.760.700.000
770.143
9.040.708.677
37.706.963.833
Current Assets
In U.S. Dollar
Cash and cash equivalents
Accounts receivables
Short-term investments
In Euro
Cash and cash equivalents
In other foreign currencies
821.849.535.718
IN
Aset Lancar
Dalam Dolar A.S.
Kas dan setara kas
Piutang
Investasi jangka pendek
Dalam Euro
Kas dan setara kas
Dalam mata uang asing lainnya
LIABILITIES
22.311.513
3.000.000
840.100
376.822
202.320.799.884
27.204.000.000
7.618.026.800
3.417.021.896
324.882
3.813.789.798
95.077.011.642
Current Liabilities
In U.S. Dollar
Accounts payables
Short-term loan
Accrued expenses
Other Liabilities
In Euro
Accounts payables
In other foreign currencies
339.450.650.020
534.542.014.628
5.226.918.879
(57.370.047.809)
Aset Neto
482.398.885.698
111
Euro (EUR1)
Dolar A.S. (US$1)
Yen Jepang (JP100)
Dolar Singapura (SGD1)
Ringgit Malaysia (MYR1)
Rand Afrika Selatan (ZAR1)
9 Maret 2012/
March 9, 2012
31 Desember 2011/
December 31, 2011
12.119
9.133
11.171
7.297
3.040
1.208
11.739
9.068
11.680
6.974
2.852
1.210
Foreign Currency
Euro (EUR1)
U.S. Dollar (US$1)
Japanese Yen (JP100)
Singapore Dollar (SGD1)
Malaysian Ringgit (MYR1)
South African Rand (ZAR1)
FOREIGN
IN
TANGGAL
Perusahaan
Company
EPMT
EPMT
Berdasarkan
pernyataan
keputusan
para
pemegang saham MDI tanpa mengadakan rapat
umum pemegang saham yang ditandatangani pada
tanggal 23 Desember 2011 dan diaktakan dalam
Akta Notaris George Handojo Hermawi, S.H.,
No. 23 tanggal 30 Desember 2011, para pemegang
saham MDI telah menyetujui peningkatan modal
ditempatkan dan disetor sebesar Rp6.000.000.000
(terdiri dari 60.000 lembar saham dengan nilai
nomimal per saham Rp100.000) yang seluruhnya
diambil bagian dan telah disetor penuh oleh EPMT.
Perubahan tersebut telah disahkan oleh Menteri
Hukum dan Hak Asasi Manusia Republik Indonesia
melalui
Surat
Penerimaan
Pemberitahuan
Perubahan Anggaran Dasar No. AHU-AH.01.1003967 tanggal 6 Februari 2012.
112
Dilaporkan
Saat Ini/
As Currently
Reported
Reklasifikasi/
Reclassifications
5.210.236.155
(10.935.191.377)
37.403.818.826
(21.888.646.997)
(9.790.216.607)
5.210.236.155
186.234.901.247
37.403.818.826
4.648.423.080
20.252.412.300
480.233.966.079
(480.233.966.079)
EKUITAS
Selisih transaksi dengan pihak
non-pengendali
Laba belum direalisasi atas
kenaikan nilai pasar
investasi, neto
Kepentingan non-pengendali
(7.067.833.816)
102.392.500
-
(182.829.714)
EQUITY
Differences arising from transaction
with non-controlling interest
Unrealized gains on
appreciation in market values of
investments, net
Non-controlling interest
(7.250.663.530)
182.829.714
480.233.966.079
285.222.214
480.233.966.079
31 Desember 2010
ASET
Pajak pertambahan nilai
dibayar dimuka
Aset lancar lainnya
Penyertaan saham
Uang muka pembelian aset tetap
Aset tidak lancar lainnya
215.296.212.071
11.025.000.000
30.067.758.568
47.114.793.988
11.115.707.317
(16.840.662.539)
37.403.818.826
(21.888.646.997)
(9.790.216.607)
11.115.707.317
198.455.549.532
48.428.818.826
8.179.111.571
37.324.577.381
398.132.727.636
(398.132.727.636)
EKUITAS
Selisih transaksi dengan pihak
non-pengendali
Laba belum direalisasi atas
kenaikan nilai pasar
investasi, neto
Kepentingan non-pengendali
(1.106.981.876)
(210.124.293)
-
(171.418.729)
CASH
FLOW
Non-cash transactions:
2011
(38.705.564)
398.132.727.636
37. SUPPLEMENTARY
INFORMATION
Transaksi non-kas:
(1.278.400.605)
171.418.729
398.132.727.636
EQUITY
Differences arising from transaction
with non-controlling interest
Unrealized gains on
appreciation in market values of
investments, net
Non-controlling interest
2010
81.555.998.628
85.776.426.234
Reclassification of constructions
in progress
100.725.505
4.172.462.319
113
38. PERNYATAAN
STANDAR
AKUNTANSI
KEUANGAN YANG TELAH DIKELUARKAN TAPI
BELUM BERLAKU EFEKTIF
a.
a.
b.
b.
c.
c.
d.
d.
e.
e.
114
f.
f.
g.
g.
h.
PSAK
50
(Revisi
2010),
Instrumen
Keuangan: Penyajian, menetapkan prinsip
penyajian instrumen keuangan sebagai
liabilitas atau ekuitas dan saling hapus aset
keuangan dan liabilitas keuangan menetapkan
prinsip penyajian instrumen keuangan sebagai
liabilitas atau ekuitas dan saling hapus aset
keuangan dan liabilitas keuangan.
h.
i.
PSAK
55
(Revisi
2011),
Instrumen
Keuangan: Pengakuan dan Pengukuran,
mengatur prinsip-prinsip dasar pengakuan
dan pengukuran aset keuangan, liabilitas
keuangan, dan kontrak pembelian atau
penjualan item non-keuangan. Persyaratan
penyajian informasi instrumen keuangan
diatur dalam PSAK 50 (revisi 2010): Instrumen
Keuangan:
Penyajian.
Persyaratan
pengungkapan informasi instrumen keuangan
diatur dalam PSAK 60: Instrumen Keuangan:
Pengungkapan.
i.
j.
j.
115
k.
PSAK
60,
Instrumen
Keuangan:
Pengungkapan,
mensyaratkan
pengungkapan dalam laporan keuangan yang
memungkinkan
para
pengguna
untuk
mengevaluasi
signifikansi
instrumen
keuangan
terhadap posisi dan kinerja
keuangan; dan sifat dan luas risiko yang
timbul dari instrumen keuangan yang mana
entitas terekspos selama periode dan pada
akhir periode pelaporan, dan bagaimana
entitas mengelola risiko tersebut.
k.
PSAK
60,
Financial
Instruments:
Disclosures, requires disclosures in financial
statements that enable users to evaluate the
significance of financial instruments for
financial position and performance; and the
nature and extent of risks arising from
financial instruments to which the entity is
exposed during the period and at the end of
the reporting period, and how the entity
manages those risks.
l.
l.
n.
n.
o.
o.
p.
p.
q.
q.
39. PENYELESAIAN
KONSOLIDASI
LAPORAN
KEUANGAN
CONSOLIDATED
116
No
Halaman
Page
8-9
10-11
11
Laporan Dewan Komisaris dan Direksi / Report of the Board of Commissioners and Directors
1
Laporan Direksi
Memuat Hal-Hal Sebagai Berikut:
1. Analisis Atas Kinerja Perusahaan Misalnya Kebijakan Strategis,
Perbandingan Antara Hasil Yang Dicapai Dengan Yang
Ditargetkan, Dan Kendala-Kendala Yang Dihadapi Perusahaan.
2. Prospek Usaha
3. Penerapan Tata Kelola Perusahaan Yang Baik Yang Telah
Dilaksanakan Oleh Perusahaan
4. Perubahan Komposisi Dewan Direksi (Jika Ada).
14-23
24-37
38-39
No.
Halaman
Page
Bidang usaha
Uraian mengenai antara lain:
1. Bidang usaha yang dijalankan sesuai dengan anggaran dasar
yang telah ditetapkan; dan
2. Penjelasan mengenai produk dan atau jasa yang dihasilkan
Business activity
To include description of:
1. Company business activity in pursuant to the articles of
association; and
2. Product and services description
Struktur organisasi
Dalam bentuk bagan, meliputi nama dan jabatan
Organization structure
In chart include names and positions
54-55
62-77
Shareholders composition
Includes:
1. Shareholders name with 5% or more shares
2. Name of Directors and Commissioners with shares ownership
3. Public shareholders with the ownership of less than 5%, its
percentage
42
44
46-47
48
50-51
52-53
78-79
No
11
12
13
14
15
Halaman
Page
84-85
Nama dan alamat entitas anak dan atau kantor cabang atau kantor
perwakilan (jika ada)
80-81
79
11
43
100-123
142-162
154, 159
159-160
No
5
10
11
12
13
Halaman
Page
165-166
100-123
163
Not
Applicable
145
162
164
164
165
15
16
Halaman
Page
165
166-167
167-171
Uraian Direksi
Uraian memuat antara lain:
1. Ruang lingkup pekerjaan dan tanggung jawab masing-masing
anggota Direksi.
2. Frekuensi pertemuan
3. Tingkat kehadiran anggota Direksi dalam pertemuan
4. Program pelatihan dalam rangka meningkatkan kompetensi
Direksi
Komite Audit
Mencakup antara lain:
1. Nama dan jabatan anggota komite audit
2. Kualifikasi pendidikan dan pengalaman kerja anggota komite audit
3. Independensi anggota komite audit
4. Uraian tugas dan tanggung jawab
5. Laporan singkat pelaksanaan kegiatan komite audit
6. Frekuensi pertemuan dan tingkat kehadiran komite audit
Audit Committee
Includes:
1. Name and position of audit committee
2. Education qualification and work experience of audit committee
members
3. Independence of audit committee members
4. Duties and responsibilty
5. Brief report on the implementation of audit committee activity
6. Meeting frequency and total attendance
183-188
188-196
195
194
196-199
No
6
10
11
12
13
14
Halaman
Page
Komite Nominasi
Mencakup antara lain:
1. Nama, jabatan, dan riwayat hidup singkat anggota komite
nominasi
2. Independensi anggota komite nominasi
3. Uraian tugas dan tanggung jawab
4. Uraian pelaksanaan kegiatan komite nominasi
5. F
rekuensi pertemuan dan tingkat kehadiran komite nominasi
Nomination Committee
Includes:
1. Name and position of nomination committee
2. Independence of nomination committee members
3. Duties and responsibilty
4. Implementation activity of nomination committee
5. Meeting frequency and total attendance
Komite Remunerasi
Mencakup antara lain:
1. Nama, jabatan, dan riwayat hidup singkat anggota komite
remunerasi
2. Independensi anggota komite remunerasi
3. Uraian tugas dan tanggung jawab
4. Uraian pelaksanaan kegiatan komite remunerasi
5. F
rekuensi pertemuan dan tingkat kehadiran komite remunerasi
Remuneration Committee
Includes:
1. Name and position of remuneration committee
2. Independence of remuneration committee members
3. Duties and responsibilty
4. Implementation activity of remuneration committee
5. Meeting frequency and total attendance
215-221
204-208
Akuntan Perseroan
Informasi memuat antara lain:
1. J
umlah periode akuntan telah melakukan audit laporan keuangan
tahunan perusahaan
2. J
umlah periode Kantor Akuntan Publik telah melakukan audit
laporan keuangan tahunan perusahaan
3. B
esarnya fee audit dan jasa atestasi lainnya (dalam hal akuntan
memberikan jasa atestasi lainnya bersamaan dengan audit)
4. J
asa lain yang diberikan akuntan selain jasa financial audit
208-209
209-214
199-200
200-201
201-203
204
250-254
16
17
18
19
20
21
249-250
224-225
221
Informasi Keuangan
Financial Statements
1
Halaman
Page
248-249
240-249
227-229
229-230
Factory
Gedung KALBE
Jl. Let.Jend. Suprapto Kav. 4
Cempaka Putih, Jakarta 10510
Indonesia
Tel. (62-21) 4287 3888 - 89
Fax. (62-21) 4287 3678
Email: cor.comm@kalbe.co.id
www.kalbe.co.id